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Abstract 
Natural Health Products (NHPs) are regulated and require safety and efficacy information 
for their approval into the Canadian market. Flaxseed lignans are NHPs with putative health 
benefits in a number of chronic diseases. In the flaxseed the principal lignan is 
secoisolariciresinol diglucoside (SDG). After oral consumption SDG is converted into its 
aglycone secoisolarisiresinol (SECO) and subsequently into mammalian lignans (enterodiol (ED) 
and enterolactone (EL)) in the presence of gastrointestinal microflora. In my Ph.D. research, I 
conducted a series of in vitro and in vivo PK studies to enable the design of prospective safety 
and efficacy studies of lignans. In vitro PK studies in the Caco-2 cell monolayer suggest that 
SDG has poor intestinal permeation and intestinal conjugation characteristics (glucuronidation 
and sulphation); however, SECO, ED and EL undergo passive permeation and extensive 
conjugation (SECO<ED<EL) by Caco-2 cells. Single oral and intravenous dose 
pharmacokinetics in male Wistar rats showed that these lignans exhibit high volumes of 
distribution, high systemic clearance values, and short half-lives. EL was fatal to the rats at the 
given intravenous and oral doses while SDG was not orally bioavailable and may not likely be 
the bioactive lignan form. I investigated the effect of acute SDG and chronic BeneFlax oral 
administration in blunting the postprandial hyperglycemia in healthy and streptozotocin induced 
male Wistar type II diabetic rats, respectively; however, my pilot study failed to show any 
change in postprandial blood glucose levels. Further, I conducted selective cytotoxicity 
evaluations in prostate and breast cancer cell lines. Only EL caused selective cytotoxicity of 
breast and prostate cancer cells with IC50 values that may be physiologically achievable.  To 
elucidate the mechanism of action, I tested concentration and time dependent effects of EL on 
various enzymes and transcription factors of fatty acid metabolism at mRNA and protein levels 
in cancer (PC-3) and normal (RWPE-1) prostate cell lines. mRNA and protein expression 
analysis showed a concentration and time dependent inhibition of fatty acid synthase (FAS) and 
suggested that EL may inhibit FAS to show anti-proliferative effect on prostate cancer. The 
pharmacokinetic characteristics and pharmacodynamics properties of flaxseed lignans warrant 
their further investigation. 
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CHAPTER 1 
 
Literature Review 
1.1 Introduction 
Flaxseed consumption is known to have several health benefits. Centuries of flaxseed 
consumption and long-term intervention studies suggest these benefits are associated with the 
flaxseed lignans (1, 2). This literature review on flaxseed lignans is divided into four sections. 
The first section deals with the health benefits of flaxseed lignans. This section discusses several 
clinical and important preclinical studies that demonstrated health benefits of flaxseed lignans. 
The second section deals with the pharmacokinetics (PK) of flaxseed lignans. The 
pharmacokinetics (absorption, distribution, metabolism and excretion) data on flaxseed lignans is 
limited, but I use the PK data on structurally similar natural compounds to understand the 
pharmacokinetics of flaxseed lignans. The third section deals with the pharmacodynamics of 
flaxseed lignans with special emphasis on the possible role in fatty acid metabolism. This section 
discusses the importance of fatty acid metabolism in cancer cells and some of the therapeutic 
agents that act via modulation of fatty acid metabolism. The fourth and last section discusses the 
status and future prospect of flaxseed lignan within the Canadian regulatory framework. This 
section gives the broad overview of Canadian regulations over the marketing of Natural Health 
Products (NHPs) and discusses the various options available for marketing of flax lignans in 
Canada.  
 
1.2 Flaxseed lignans and their health benefits 
Flaxseed is a major economic crop of Saskatchewan, Canada (3) and is being widely 
studied due to its putative health benefits (4, 5). Given its widespread usage and health benefits, 
flaxseed has garnered significant interest in recent times.  
 
1.2.1 Flax  
Flax (Linum usitatissimum), also known as linseed, a native of eastern Mediterranean to 
India, has a long history of traditional use in making linen, dye, paper, hair gels since 6000 BC 
(6). Previously, flaxseed was recognised as a good source of industrial oil and fibre; however, in 
the 1980’s flaxseed gained major interest as a nutritional supplement or functional food (7).  The 
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major reason for this shift in interest was the identification of various chemical constituents, 
which were associated to have health benefits in a number of diseases (8).  
Whole flaxseed contains 41% oils, 28% dietary fibre (soluble and insoluble), 21% proteins, 
lignans and minerals along with vitamins, carbohydrates and minor amounts of cyanogenic 
glycosides, flavonol herbacetin glycosides, and other compounds. (9). Flaxseed lignans are 
suggested to be the bioactive constituents that exhibit various putative health benefits in 
cardiovascular diseases (4, 10), cancer (11, 12) and diabetes (13). The major form of lignan 
present in flaxseed is secoisolariciresinol diglucoside (SDG). In addition to SDG, flaxseed also 
contains small amounts of other lignans such as pinoresinol, isolarisiresinol and metairesinol and 
represents less than 1% of the amount of secoisolarisiresinol (SECO) (14, 15).   
 
1.2.2 Flaxseed lignans 
Plant lignans are polyphenolic phytoestrogens along with flavonoids and stilbenes, 
consisting of the dibenzyl butane scaffold (16, 17). The major sources of plant lignans are 
flaxseed followed by sesame and rye bran (18). Along with sesame and rye bran lignans, 
flaxseed lignans have demonstrated several health benefits in cancer, cardiovascular disease and 
diabetes (19-22).   
SDG was first isolated from flaxseed in 1956 by Bakke and Klosterman (23), but scientific 
interest grew in the early 1970s when two new lignan molecules were identified in female urine 
samples and later named as enterodiol (ED) and enterolactone (EL), collectively called 
mammalian lignans (24, 25). These mammalian lignans were later correlated to ingestion of 
dietary lignans and intestinal bacteria were suggested for the conversion of the dietary lignans to 
mammalian lignans (26, 27). In 1982, Axelson et al identified SDG as a precursor for the 
conversion to mammalian lignans in flaxseed (28) and Setchell observed that administration of 
flaxseed bread leads to high levels of mammalian lignans in a patient with celiac disease (3). 
These two major studies led to an important research outcome that flaxseed or food containing 
flaxseed rich in SDG are important precursors to the mammalian lignans, which was later 
confirmed by different research groups (28, 29). 
SDG is the diglycosidic form of an aglycone, secoisolarisiresinol (SECO). SDG is present 
in the plant as an oligomeric polymer complexed with hydroxy-methylglutaric acid (HMGA) 
(30), and the hydroxycinnamic acids, p-coumeric acid, ferulic acid glucosides and herbacetin 
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diglucoside (31). SDG is linked to this complex through an ester bond between the glucose of 
SDG and the HMGA (Figure 1.1) (30, 32) and the hydroxycinnamic acids are also linked 
directly to the glycosyl moiety of SDG by an ester bond (31). This complex is a straight chain 
oligomeric complex with an average molecular weight of 4000 (33) and the average chain length 
of the complex is three SDG moieties with coumeric and ferulic acids at each of the terminal 
positions (34).  
This complex undergoes a series of transformations in the gastrointestinal tract (GIT) to 
generate other flaxseed lignans which are subsequently biotransformed into mammalian lignans. 
The SDG-HMG complex undergoes hydrolysis to its monomer units, 3HMG and SDG (23). β-
Glucosidase/β-glucuronidase enzymes (35, 36) and bacterial fermentation are suggested to 
cleave glucose moieties from SDG and convert it to its aglycone form, secoisolarisiresinol 
(SECO). Many bacterial species e.g. Clostridium sp. and Peptostreptococcus productus, present 
in the GIT deglycosylate SDG to form SECO (37, 38). SECO can undergo further metabolism to 
form the mammalian lignans in the colon, enterodiol (ED) and enterolactone (EL) (28, 39, 40). 
This conversion is a result of demethylation and/or dehydroxylation to ED and subsequent 
conversion into EL, respectively (41, 42). EL can also be produced from other lignans such as 
matairesinol, pinoresinol and pinoresinol diglycoside (38). A consortium of bacteria including 
Peptostreptococcis sp. and Eubacterium sp are responsible for the biotransformation of 
matairesinol into EL (43). 
 
1.2.3 Variation in the content and method of hydrolysis of SDG 
The various efficacy and pharmacokinetic studies on flaxseed lignans use a variety of 
sources of flaxseed and require careful assessments while making inferences. Several studies 
administer whole flaxseed or crushed flaxseed and calculate the equivalent amount of SDG 
based on literature values without determining the actual content in the flaxseed lignan in the 
administered flaxseed (12, 44). The high degree of variability in flaxseed lignan content and 
experimentally induced errors such as inappropriate choice of extraction technique or 
inappropriate analytical methods should be carefully considered during interpretation of different 
studies. Changes in climatic conditions and methods of cultivation may influence the percent 
content of active ingredients (45, 46) and extrapolation of content of active ingredient between  
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Figure 1.1: Pathways for the conversion of plant lignan SDG-HMG polymer to mammalian 
lignan (EL). The SDG-HMG complex undergoes hydrolysis into its monomer units, 3-HMG and 
SDG and intestinal β-glycosidase/β-glucuronidase enzymes cleave the glucose moieties from 
SDG to convert it to its aglycone form, secoisolariciresinol (SECO). SECO can undergo further 
metabolism to the Enterodiol (ED), Matairesinol (MAT) and Lariciresinol (LAR) and to 
Enterolactone (EL) by intestinal microflora (29, 36, 38). 
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two different batches may be erroneous. The variability in flaxseed lignans may not affect the 
interpretation of a study if same flaxseed batch is used; however, the use of different batches 
without appropriate normalization such as percent active content may lead to erroneous 
comparison between studies.  The other source of variability may be inappropriate analytical 
methodology including inappropriate choices of extraction techniques (bacterial, chemical or 
enzymatic hydrolysis) and analytical techniques.  
The SDG content by enzymatic and bacterial hydrolysis was 1-4 mg of SDG/g of whole 
flaxseed, while chemical hydrolysis determined it as 4.2 to 25.9 mg/g of whole flaxseed (29, 32). 
Enzymatic and bacterial hydrolysis of flaxseed complex to isolate SDG resembles more the in 
vivo transformations; however, several factors may still confound the inference. The 
commercially available enzymes used to hydrolyze SDG-HMG complex are not from bacterial 
or human intestinal origin; rather the enzymes are an isolate from Helix pomatia, a snail. The 
differences in specificity and activity between enzymes from Helix pomatia and human gut or 
human gut flora are not well understood and often results from the Helix pomatia enzyme are 
treated as surrogate to the human intestinal enzymes, which may be erroneous. Some of the 
analytical techniques are highly sensitive, specific and require less cumbersome sample 
processing while other methods may have poor sensitivity, lack of selectivity and may require 
complex sample processing steps such as chemical derivatization of analytes. Additionally, the 
inter-analyst and inter-laboratory variability of the analytical methods remain unestablished and, 
therefore, extrapolation of analytical methodology from one to other laboratory without 
validation may add inaccuracies in the inferences. Ideally, the lignan content in each batch of 
flaxseed products should be determined in order to make comparative evaluations of different 
studies. Muir, A.D. has discussed the influence of different analytical methods on the 
interpretation of flaxseed studies in detail (32). Many studies seldom consider these confounding 
factors during their design of the experiments and, thus, these studies require careful 
interpretation.  
 
1.2.4 Therapeutic benefits of flaxseed lignans 
Flaxseed lignans are associated with number of health benefits in chronic diseases such as 
cancer (11, 12), cardiovascular disease (5) and diabetes (47, 48). Various research studies 
showed these health benefits when flaxseed or flaxseed lignans were administered in vivo/in 
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vitro in different preclinical and clinical studies (49, 50). However, interpretation of these 
research outcomes and assessment of the health benefits of flaxseed lignans is a challenging task 
due to multiple reasons described below (51). 
First, most studies administer whole flaxseed, flaxseed meal and defatted flaxseed (52, 53) 
rather than purified lignan due to ease of availability of the products and less stringent regulatory 
requirements for approval of clinical studies. Although the method of extraction of flaxseed 
lignan was known since 1956, lignans became commercially available only recently. This last 
decade purified or semipurified SDG or other lignan forms have become commercially available 
and are being used in different efficacy studies (54). Therefore, earlier studies, which associated 
the health benefits after consumption of flaxseed with flaxseed lignans, may be making an 
erroneous inference and other components of the flaxseed could also be responsible for these 
health benefits.  
The second problem is overemphasis on mammalian lignan, EL. Since incubation of SDG 
with fecal microflora formed EL, some studies suggested that EL is responsible for all the 
benefits of flaxseed lignans (55, 56); however, the conversion of SDG into EL does not prove 
unambiguously that the EL is the only form responsible for health benefits of flaxseed. Seven 
different metabolites of SDG including ED and EL were identified upon incubation with human 
fecal suspension suggesting that other metabolites can also be absorbed rather than just getting 
converted to ED and EL (43).  Most of the studies only tested the EL and ED and did not 
evaluate the other lignans such as SECO, MAT, or LAR. For example, Makela et al synthesized 
the precursors for EL and ED, which inhibited aromatase activity (57). Additionally, 
Nordihydroguaiaretic acid (NDGA) and dihydorxy-EL were also found to be potent aromatase 
inhibitors (58). Dibenzyl butanediol (DBB), another lignan, inhibited human breast cancer cell 
line ZR-75-1 (59) growth more effectively than ED and EL. Besides ED and EL, NDGA also 
caused dose dependent inhibitory effects on steroid hormone binding globulin (SHBG) binding 
along with flavonoids (51, 60). 
Thirdly, flaxseed lignans have been associated with multiple health benefits; however, their 
modes of actions are unknown. Role of the various plant and/or mammalian lignans may be 
different in these health benefits (51). Various research groups believe that mammalian lignans 
(ED and EL) are ultimately responsible for these health benefits; however, the in vivo 
ineffectiveness of SDG and SECO has not been proven so far. Unless purified lignans are tested 
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directly for the benefits in these disease conditions, identification of the active form of lignans is 
difficult. 
Lastly, the selection of biomarkers as a measure of efficacy in different studies is another 
source of perplexity of flaxseed lignans. Most of the preclinical and clinical research studies 
evaluated the modulation of different biomarkers in different diseases because these biomarkers 
are well correlated with the pathogenesis and treatment of various diseases. However, the 
modulations of different biomarkers were not consistent in all studies and all tested biomarkers 
did not change favourably. For example, the serum levels of total cholesterol (TC) and low 
density lipoprotein (LDL) decreased after SDG administration in rabbits but had no impact on 
the levels of high density lipoproteins (HDL) (2, 49, 61). Similar contradictory results have been 
observed in prostate cancer and breast cancer and have been discussed in ensuing sections.  
 
1.2.4.1 Cancer 
A number of dietary constituents exhibit chemopreventive action against cancer (62). 
Phytoestrogen containing nutritional supplements such as flavonoids and lignans show potential 
benefits in a number of cancers such as breast, prostate, colon and skin cancers. Flaxseed lignans 
might have use in cancer prevention due to their estrogenic and/or antiestrogenic activities, anti-
oxidative effects, antiaromatase activity and antiproliferative activity (63, 64). 
 
1.2.4.1.1 Breast cancer 
Consumption of flaxseed, defatted flaxseed, flaxseed meal or purified lignans has shown 
benefits in breast cancer. Administration of flaxseed lignans and associated mammalian lignans 
to various animal breast cancer models suggested their inhibitory effects at different stages of 
breast cancer. Administration of SDG (1.5 mg/day) at the initiation stage for 20 weeks to rats 
caused 37% reduction in number of tumours per tumour-bearing rat and 47% reduction in 
number of tumours per number of rats in the group (65). The same research group conducted 
another study where SDG (1.5 mg/day) was administered at early progression stage (13 weeks 
after the cancer production). SDG administration caused reduction in tumour volume by 54% 
and tumour incidence by 27%, suggesting inhibitory effect of SDG at different stages of tumour 
(44). Surface area of subcutaneously xenografted MDA-MB-231 breast tumours and the number 
of intumescent lymph nodes in MDA-MB-231 xenografted nude mice were decreased with SDG 
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consumption (66). These studies show that per oral administration of SDG will reduce the 
occurrence and progression of tumour; however, the conclusion that SDG is responsible for 
anticancer activity cannot be drawn because the concentrations of SDG and its metabolites were 
not measured. SDG or its metabolites may be responsible for anticancer activity. In in vitro 
cytotoxicity studies, SECO inhibited the growth of MCF-7 and MDA-MB-231 breast cancer 
cells at 50 and 100 µM concentrations, respectively (67). Hydroxymetairesinol, a precursor of 
EL, at a dose of 4.7 mg/kg/body weight and 15 mg/kg/body weight was reported as an anticancer 
agent for mammary gland tumors in rats (68, 69). Similarly, EL inhibited breast cancer cell 
growth at a dose more than 50 µM (70).  
Most clinical trials administered flaxseed or ground flaxseed but none of the trials 
administered purified flaxseed lignan in breast cancer patients. In 2005, Thompson et al 
conducted a double blind randomized controlled clinical trial in post menopausal women with 
breast cancer (Appendix I), where consumption of muffins containing 25 g of ground flaxseed 
reduced tumour growth (1). Breast cancer reduction biomarkers were assessed and benefits were 
mostly attributed to flaxseed lignans rather than other constituents based on large body of 
research data from studies in animal models. McCann et al suggest the association of dietary 
intake of lignans and reduction in breast cancer in postmenopausal women (Appendix I). This 
association was based on monitoring of dietary intake of lignans and serum levels of lignans over 
5 years. However, large variation in the content of lignans in various food items may also have 
affected study outcomes (71). Haggans et al conducted a clinical study in 28 postmenopausal 
women and suggested that flaxseed intake (5-10 g of flaxseed /day) caused reduction in levels of 
16-α hydroxyestrone (a marker for increased cancer risk) (72). These clinical studies suggest the 
association of flaxseed/flaxseed lignan intake and breast cancer reduction; however, 
administration of purified lignans would be interesting in future. 
Flaxseed lignans and associated mammalian lignans may exhibit their benefits in breast 
cancer via several different mechanisms. First, these lignans act via alteration of different stages 
of breast cancer (73). ED and EL interfere with cell adhesion, invasion and migration of MDA-
MB-231 and MDA-MB-435 tumour in nude mice by down regulation of insulin like growth 
factor–I (IGF-I) and epidermal growth receptor (74, 75). Second, these lignans decrease pro-
inflammatory cytokine IL-1β secretion through IL-1 receptor antagonism (IL-1Ra) (76). Third, 
these lignans inhibit tumour angiogenesis via reduction of vascular endothelial growth factor 
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(VEGF). ED and EL decreased VEGF in MCF-7 cells and in subcutaneously xenografted MCF-7 
tumours in nude mice (64, 77). Fourth, inhibition of aromatase enzyme, a cytochrome P450 
enzyme that converts testosterone and androsterone into estrogens (17β-estradiol and estrone), 
and therefore, decreases the production of estrogen (78). This proposed mechanism of action 
originates from the epidemiological association of vulnerability to breast cancer with high 
estrogen activity. 
. 
1.2.4.1.2 Prostate cancer 
Prostate cancer is one of the leading causes of cancer-related deaths. Dietary intake and 
nutritional supplements such as flaxseed have been shown to alleviate the initiation and 
progression of prostate cancer. Prevalence of prostate cancer is higher in the western population 
than that in Asian and Mediterranean population. Dietary intake of phytoestrogens such as 
flavonoids and lignans exhibits chemopreventive activity in prostate cancer (79). 
Flaxseed lignans show cytotoxicity against prostate cancer cell lines. EL inhibits the 
growth of PC-3, DU-145 and LNCaP cell lines while ED inhibited only PC-3 and LNCaP cell 
lines (80) at 10-100 µM concentration. EL (IC50=57 µM) was more potent than ED (IC50=100 
µM). The antiproliferative activity of SECO and its glycoside (SDG) against prostate cancer cell 
lines have not been reported so far. 
The chronic administration of flaxseed and flaxseed extract demonstrates chemopreventive 
activity against prostate cancer; however, the association of these benefits with lignans is not 
proven unambiguously. Zhang et al administered BeneFlax (flaxseed lignan extract containing  
~33% SDG ) at the dose equivalent to 300 and 600 mg/day of SDG to the patients with benign 
prostate hyperplasia (BPH) (Appendix I) and observed significant reduction in lower urinary 
tract syndrome (LUTS), a frequently observed symptom in prostate hyperplagic patient (81). The 
author associated these benefits to SDG content present in the BeneFlax; however, the author 
ignored the probability that other constituents of BeneFlax that were not present in control diet 
may also be responsible for this anti-prostate cancer activity. One of the main reasons of this 
extrapolation of clinical result to lignans is the epidemiological association of EL concentration 
with the occurrences of prostate cancer established by Morton et al (82).  
Demark-Wahnefried  et al showed that chronic administration of flaxseed (30 g/day) with 
fat restricted diet in prostate cancer patients caused significant reduction in prostate cancer 
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tumour progression metrics such as concentration of testosterone in blood, total serum 
cholesterol, free androgen index (the ratio of total testosterone concentration and concentration 
of SHBG) and prostate specific antigen (PSA) index (83, 84). In subsequent clinical trials, the 
flaxseed treated groups showed lower number of Ki-67 positive cells than control group or low 
fat diet group (83). Interestingly, in another clinical trial, the cytokines and angiogenic factors 
were modulated with low fat diet and no difference was observed between flaxseed fed low fat 
diet group and low fat diet group, which contradicted earlier outcomes (85). This difference in 
activity raises the issue of selection of appropriate biomarker and their association with clinical 
outcomes, which in itself is very challenging (Appendix I).  
Even in preclinical studies, no study has tested the efficacy of purified lignans in prostate 
cancer. Only one study administered purified hydroxyl metairesinol (HMR), a precursor of 
enterolignan, at the dose level of 0.15% and 0.30% of the diet to LNCaP xenografted athymic 
mice for 9 weeks and observed low tumour incidence rate and decreased tumour volume (86).  
Based on these studies we cannot clearly delineate that flaxseed lignan administration is 
helpful to alleviate prostate cancer and the clinical efficacy of flaxseed lignan remains to be 
proven. Further investigation is required to prove the efficacy of flaxseed lignans and identify the 
active moiety responsible.  
 
1.2.4.2 Cardiovascular benefits 
Cardiovascular disease (CVD) is one of the major causes of morbidity and mortality 
throughout the world (87). CVD is a group of diseases including coronary artery disease (CAD), 
atherosclerosis, thrombosis, stroke, hypertension, hypercholesterolemia and obesity. Major 
factors responsible for pathogenesis of CVD include smoking, diet and inflammation (88). 
Dietary intervention with phytoestrogens containing natural products, such as flaxseed lignan, is 
associated with decreased prevalence of CVD (89). 
Two different schools of thoughts on the active constituent responsible for cardiovascular 
effects of flaxseed exist. Some of the literature support flaxseed oil as the responsible component 
for cardiovascular effects of flaxseed (90-92). Flaxseed oil is one of the richest sources of α-
linolenic acid (ALA), which has known cardioprotective effects. Basett et al summarized all the 
clinical studies involving flaxseed, defatted flaxseed and flaxseed oil (5). Most of the clinical 
studies involving flaxseed oil did not measure the change in the levels of total cholesterol (TC), 
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low-density lipoprotein (LDL-C), triglycerides (TG) and high-density lipoprotein (HDL-C), but 
some studies that measured CVD biomarkers did not observe any significant change (the 
decrease in triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol 
(LDL-C) and increase in high-density lipoprotein cholesterol (HDL-C) exhibits cardioprotective 
activity) (5). On the other hand, most of the clinical studies administering flaxseed, defatted 
flaxseed or flaxseed lignan (SDG) observed decreases in the total cholesterol (TC) and low-
density lipoprotein (LDL-C) while the levels of triglycerides (TG) and high-density lipoprotein 
(HDL-C) remained unaltered. Administration of SDG (300 and 600 mg/g) as a lignan extract to 
hypercholestremic patients significantly decreased TC and LDL-C along with dose dependent 
reduction in serum cholesterol (93). Similarly, administration of SDG (100 mg/d) to moderately 
hypercholestremic men for 12 weeks caused significant reduction in the ratio of LDL-C/HDL-C 
and TC (94). Therefore, the second school of thought associates cardioprotective activity to 
flaxseed lignans. Additionally, administration of lignan complex equivalent to SDG (500 
mg/day) to healthy postmenopausal women was found to be safe as it did not alter the levels of 
CVD biomarkers such as TG, TC, LDL-C and HDL-C (95). 
In rabbits, the administration of flaxseed and flaxseed lignans shows antiatherogenic 
activity. Prasad reported in a series of experiments using flaxseed, CDC-flaxseed and SDG that 
flaxseed lignans are responsible for antiatherogenic activity of flaxseed, but not flaxseed oil. 
SDG (15 mg/kg) administration for 8 weeks in hypercholestremic rabbits reduced 
hypercholestremic atherosclerosis by 73% (2, 49, 54). Similarly, administration of flaxseed 
(contains 55-60% of ALA as flaxseed oil) at 7.5 g/kg/day dose to hypercholestremic rabbits for 8 
weeks resulted in 46% reduction in hypercholestremic atherogenic plaques (49). Furthermore, 
administration of CDC-flaxseed (similar to normal flaxseed with 2-3% ALA) at the same dose 
(7.5 g/kg/day) in rabbits demonstrated 69% reduction in the development of hypercholestremic 
atherosclerosis, which led to the conclusion that flaxseed lignans are mainly responsible for 
antiatherogenic effects but not ALA (2). However, the direct comparison of these two studies is 
difficult because both treatments were not included in the same study and the evaluated CVD 
biomarkers were different. Administration at two different occasions brings in several sources of 
variability including variability in different lot of animals, different lot of SDG, environmental 
factors and other unknown sources of residual variability. Additionally, opposing effects on 
some biomarkers make it more difficult to compare. For example, TC increased with flaxseed 
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administration (49) but decreased with CDC flaxseed administration (2). In contrast to the result 
of these studies by Prasad K., the decrease in atherogenic plaques was insignificant after 
administration of ground flaxseed for four weeks (96). This study also reported a similar change 
in levels of CVD biomarkers and observed decrease in LDL-C but no change in HDL-C, but the 
authors attributed the lack of effect on atherogenic plaques to the shorter duration and design of 
the study. In the studies that Prasad has published the biomarkers showed plateau effect at four 
weeks and the change in the levels of CVD biomarkers between 4 and 8 weeks were minimal. 
Interestingly, 8 weeks administration resulted in decrease in antiatherogenic plaques despite 
exhibiting plateau effect on CVD biomarkers (49).  
Flaxseed lignan administration favourably modulates cardiovascular disease biomarkers in 
rodents. Chronic administration of SDG and SECO to hyperlipidemic rats resulted in dose 
dependent reductions in the body weight gain, total cholesterol (TC) and low-density lipoprotein-
cholesterol (LDL-C) (97). The administration of SDG into high fat fed rats reduced serum TG, 
TC and LDL-C by 39%, 33% and 45%, respectively, and increased HDL-C by 22% (98).  
Administration of SDG demonstrates dose dependent reduction in systolic, diastolic and 
mean arterial pressure in rats under anaesthesia (99). The hypotensive effect fades after 20 mins 
but mean arterial pressure remains lower in comparison to normal rats. Inhibition of cholesterol 
absorption and transcriptional regulation of different genes involved in hepatic lipid homeostasis 
may influence therapeutic outcomes in laboratory animals and humans (97). Hypotensive activity 
may be mediated through soluble guanylate cyclase (99). Nitric oxide (NO) activates soluble 
guanylate cyclase (sGC) to produce cGMP, which produces protein kinase G (PKG). PKG 
cascade leads to vasodilation and thus hypotension. Specific and nonspecific inhibition of sGC 
by oxadiazolo quinoxalin  and methylene blue, respectively, removed SDG induced hyptension 
in Sprague Dawley rats indicating that SDG mediates its activity via sGC (99).  
 
1.2.4.3 Diabetes mellitus 
Diabetes mellitus (DM) is a major metabolic disorder characterised by a perturbance in the 
insulin-glucose homeostasis (100). Type I diabetes is diagnosed by the inability to produce 
insulin due to the loss of insulin producing β-cells in the islets of langerhans (101). Type II DM 
is due to the reduced production of insulin or the impaired insulin signalling (102, 103). In 
addition to decreased insulin production, increased hepatic glucose production, decreased uptake 
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of glucose in muscle and liver that causes type II DM, and increased lipolysis may also lead to 
pathogenesis of diabetes (104). An elevated serum free fatty acid level results in the development 
of insulin resistance in muscle and liver and impairs insulin secretion. Insulin resistance of the 
liver impairs the feedback loop that controls hepatic glucose production and increases basal 
hepatic glucose production rate. Additionally, insulin resistance of adipocytes results in impaired 
release of adipokines and causes insulin resistance in muscle and liver (105). 
Chronic administration of flaxseed modulates some of the biomarkers associated with 
diabetes; however, the beneficial role of flaxseed lignans in diabetes mellitus is ambiguous. 
Administration of  SDG (20%) containing capsules at the dose equivalent to 360 mg/day of SDG 
for 12 weeks to type II DM patients reduced glycosylated hemoglobin (HbA1c) without 
reduction in the levels of glucose and insulin resistance (106) (Appendix I). The clinical 
importance of this finding remains unrecognized and requires further investigation. In another 
clinical study the administration of same capsule with same dosing regimen suppressed the 
increase in C-reactive protein (CRP) in post-menopausal women without any alteration in the 
levels of fasting glucose, lipids, interleukin-6 (IL-6) and retinol binding protein 4 (RBP4); 
elevated CRP, IL-6 and RBP4 are biomarkers associated with type II diabetes mellitus (13) 
(Appendix I). In another study, administration of SDG at 600 mg/day as BeneFlax to 
hypercholesterolaemic patients for 6 and 8 weeks reduced fasting blood glucose levels by almost 
25% in high risk diabetic patients (>5·83 mmol/L) but the decrease in levels of blood glucose 
was insignificant at 300 mg/day (93) (Appendix I). This study suggests that higher dose of 
BeneFlax may reduce blood glucose concentrations. All these three studies did not administer 
purified SDG and, therefore, the role of flaxseed lignans in diabetes cannot be ascertained 
clinically. Some studies in preclinical animals suggest such benefits. SDG administration to 
ZDF/gmi-fa/fa female rats (a type II diabetic model) delayed onset of type II DM and reduced 
serum and pancreatic malondialdehyde (MDA) levels (48). Administration of SDG to the BBdp 
rat (Bio-Breed diabetic prone rat, a genetic model of diabetes) reduced serum glucose levels, 
serum and pancreatic malondialdehyde (MDA) levels, pancreatic–chemiluminescence (anti-
oxidant reserve of pancreas) and WBC-chemiluminescence (reactive oxygen species producing 
ability of WBCs) (47, 54, 107).  
Flaxseed lignans are believed to show antidiabetic effects via different mechanisms. First, 
flaxseed lignans may act as anti-oxidants and reduce reactive oxygen species (ROS) levels to 
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avoid diabetic complications (108). Second, the effect on the modulation of lipid profile is likely 
to be partially responsible for antidiabetic effect. Third, the inhibitory effect of flaxseed lignans 
on phosphoenolpyruvate carboxykinase (PEPCK), an important enzyme of gluconeogenesis, 
may result in their antidiabetic effects (109).  
1.2.4.4 Metabolic syndrome 
Metabolic syndrome is a set of disorders comprising visceral obesity, dyslipidemia, 
hyperglycemia and hypertension (100). Metabolic syndrome is a risk factor for cardiovascular 
disease. Various dietary interventions and lifestyle changes along with therapeutic agents can 
prevent and/or decrease the risk of developing metabolic disorders (110).  
Flaxseed lignans might potentiate positive outcomes in diabetes, obesity, 
hypercholesterimea (54, 111), hyperlipidemia and inflammation. Earlier sections already 
identified different clinical investigations of SDG administration on lipid profile, glucose levels 
in hypercholestremic patients. Investigations in pre-clinical animals also have shown the 
beneficial effect of flaxseed lignan in these diseases. Development of diet induced obesity was 
assessed in C57BL/6 mice, consuming high fat diet or high fat diet along with SDG (0.5% or 
1%). In the SDG consuming group, levels of visceral fat gain were significantly reduced along 
with liver TG, serum TG, total cholesterol, insulin and leptin concentration (112). Administration 
of SDG (40 mg/kg/d) to female rats delayed the onset of diabetes by 80% (glucosuria) at age of 
72 days (48). 
In a clinical study, administration of flaxseed lignan complex containing 543 mg SDG/day 
for 6 months caused a decrease in the metabolic syndrome composite score in a randomised 
double blind placebo control human clinical trial (113) (Appendix I). The flaxseed lignan 
consuming group had a significant decrease in diastolic blood pressure compared to placebo 
group. Flaxseed lignans caused reduction in diastolic blood pressure and triglyceride (TG) levels. 
Daily administration of 100 mg of SDG to hypercholesterolemic men reduced blood cholesterol 
and liver disease risk factors (94).  
 
1.2.5 Safety evaluations on flaxseed lignans 
Flaxseed has been consumed for centuries in different parts of the world without any 
known adverse effect; however, the required safety evaluations of lignans are incomplete. A few 
studies identified some adverse reactions as a part of nutritional intervention studies where 
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purified forms of lignans were not used (114, 115). Earlier preclinical/clinical studies provide 
supportive evidence to prohibit use of flaxseed lignans in pregnant and breast feeding population 
while later studies provide contradictory evidence (115, 116). Administration of 5% and 10% of 
flaxseed as a part of the diet or equivalent flaxseed lignan SDG (1.5 mg) dose orally in rats 
resulted in dose dependent harmone related effects, especially low birth pups at 10% flaxseed 
group (114). Given the lignans were found to pass into neonatal rats through milk, these effects 
were suggested due to the lignans (114). In a human clinical study, Hutchins et al demonstrated 
reduction in estrone sulphate and 17β-estradiol and an increase in prolactin levels in post 
menopausal women due to flaxseed consumption (115). Such hormonal changes in 
postmenopausal women have been associated with osteoporosis or breast cancer. On the 
contrary, Collins et al showed that consumption of flaxseed (flaxseed 40% and flaxseed meal 
26%) by rats during and after pregnancy as a part of their diet to rats showed no changes on 
ferterlity and fetal development (116). In our own laboratory, daily oral administration of SDG 
(4.4 μmol/kg body weight) for 4 weeks to female Wistar rats did not show any apparent change 
in behaviour, hematology and blood parameters (36). Our results were consistent with another 
study, which showed no clinical significant daily activity and haematological changes when 10 
% flaxseed chow diet was administered to Fisher 344 rats (117, 118). Similarly in healthy human 
subjects, daily consumption of flaxseed (32 g) did not cause any clinical significant change in 
various haematological parameters. Studies in healthy geriatric patients showed that 
administration of BeneFlax (~ 33% SDG) is not likely to cause hypoglycaemia or hypotension in 
healthy older adults over 65 years of age (119). These differences in the outcomes may be due to 
different experimental designs and conditions; however, further systematic investigations are 
required to consolidate these studies and determine the safety of flaxseed lignans in human 
subjects, including at risk subpopulations such as post-menopausal, pregnant and lactating 
women.  
Flaxseed lignans did not show any hepatotoxicity and genotoxicity. Administration of 
flaxseed to rats did not alter serum levels of alanine aminotransferase and γ-
glutamyltranspeptidase, which are marker enzymes for hepatic functions. Additionally, glucose 
homeostasis remained unaltered (117). Absence of genotoxicity was evident by unaltered 
micronuclei or absence of gene mutation in Chinese hamsters after SDG administration in the 
standard micronucleus test of genotoxicity (120). 
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Flaxseed contains minute amounts of cyanide containing substances. The literature 
suggests administration of large quantities of uncooked flaxseed could result in toxicity due to 
the cyanogenic content above 50 mg of inorganic cyanide, however; baking flaxseeds is 
suggested to eliminate this risk (121). 
Most of the nutritional intervention studies suggest flaxseed lignans are safe to use, 
however; none of the studies evaluated safety of purified flaxseed lignans other than SDG. The 
toxicity pattern of pure form of lignans is likely to be different than the administration as various 
complex forms and most studies do not aim to investigate the toxicity of purified lignans. 
Therefore, extensive safety and toxicity evaluations are required using purified flaxseed lignans. 
 
1.3 Pharmacokinetics of flaxseed lignans and associated polyphenols 
The pharmacokinetics of flaxseed lignans is largely uncharacterized and the results are 
very contradictory because most of the pharmacokinetic information is not derived from 
systematic pharmacokinetic investigations. Other structurally similar group of compounds, 
flavonoids, are better characterized than lignans. Given that flavonoids and lignans belong to the 
same chemical class called polyphenols and share a similar molecular scaffold, these compounds 
are expected to show similarities in their interactions with the physiological system. Thus, to 
better understand the pharmacokinetics this section will provide examples of pharmacokinetic 
studies of various structurally related polyphenols. 
 
1.3.1 Absorption 
Lignans and structurally related polyphenols mostly exist as glycosides in the plant (122). 
While earlier experiments suggested that glycosides are absorbed through the intestine (123), 
subsequent experiments suggested that aglycone forms of glycosides are the bioavailable forms 
(124, 125). In 1995, Hollman et al observed that about 52 % of quercetin glycoside was absorbed 
in ileostomy volunteers while the absorption of aglycone form was only about 24% (123). 
However, this study design precluded an unequivocal conclusion that the glycosides were 
absorbed in their original form in the intestine. Five years later, Walle et al found that quercetin 
glycosides were completely hydrolyzed into aglycone forms in ileostomy patients before being 
absorbed (126). Similarly, pharmacokinetic studies on soy isoflavones and other phenolic 
compounds such as resveratrol suggest that the rate and extent of absorption of the aglycone 
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forms is higher than the corresponding glycosides. In the case of flaxseed lignans, no study has 
compared the absorption of SDG with their aglycone forms in human to suggest that the 
aglycone is the primarily absorbable form of lignans; however, indirect evidence suggests that 
the aglycone form is being absorbed. Most of the lignan metabolites (not SDG) were found in 
their conjugated (glucuronide and sulfate) form in the portal vein after oral administration of 
flaxseed in rats (27). SDG must undergo deglucosylation either in the gut or enterocytes before 
conjugation in the enterocytes. Further, in vitro incubation of SDG with fecal slurries (38) found 
different forms of aglycones, which suggested that the intestinal microflora has the capability to 
convert SDG into other aglycone forms. Therefore, it can be hypothesized that SDG is converted 
into aglycone forms of lignans in the intestine before being absorbed.  
Caco-2 permeability of glycosides of lignans and other polyphenols are poorer than their 
corresponding aglycones. Since it is difficult to determine permeability in human intestine in 
vivo, Caco-2 monolayer permeability model is a gold standard for in vitro permeability 
assessments due to its morphological and physiological similarity with the small intestine (127). 
After 21 days of differentiation, Caco-2 cells become a polarized epithelial monolayer with villi 
like structures when grown in a Transwell® system (Figure 1.2). The formation of villi like 
structures, formation of tight junctions and expression of different intestinal influx/efflux 
transporters makes it very similar to the small intestine (127). The permeability of many drugs 
often correlates well with their bioavailability in human subjects. Therefore, the Caco-2 model 
has been used in several studies to determine the fate of polyphenols in the intestine (128-130). 
While the comparative evaluation of Caco-2 permeability of all flaxseed lignans has not been 
reported yet, the Caco-2 permeability assay on other structurally related polyphenols suggest that 
the glycosides are not likely to be absorbed into the systemic circulation (131, 132). Quercetin 
exhibits significantly higher permeability than its glycosides. The apparent permeability of 
quercetin (58 nm/sec) was several times higher than quercetin-4’-O-glucoside (<0.2 nm/sec), 
quercetin-3,4’-O-glucoside (0.9 nm/sec), quercetin-3-O-glucoside (0.6 nm/sec) and quercetin-3-
O-galactoside (1.4 nm/sec) in a Caco-2 monolayer model. Similar to quercetin glycosides, 
sesaminol triglycoside also exhibits poor permeability in Caco-2 (10.7 nm/sec) which increased 
modestly after submicrosizing due to increase in the surface area (133).  Soy flavones, genestein 
and diadzein were highly permeable while genestin and diadzin were barely permeable (134, 
135). All these examples suggest that the aglycone forms of lignans are likely to get absorbed. 
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SDG undergoes four sequential biochemical transformations into different aglycone forms and 
the reactions are catalyzed by different species of bacteria present in the intestine (40, 136-138). 
Microflora from Bacteroides and Clostridium genera can O-deglycosylate SDG to form 
secoisolariciresinol (SECO). In a second and third step, SECO undergoes O-demethylation and 
dehydroxylation catalyzed by Ruminococcus productus and Eggerthella lenta, respectively, to 
form enterodiol (ED). In the fourth and last step, ED is dehydrogenated by Lactonifactor 
longoviformis to generate enterolactone (EL). Anhydro SECO, an acid degradation product of 
SECO, also is converted to ED and EL; however, the rate and extent of conversion is different 
(139). Alternatively, the activities of bacterial flora on other lignans such as pinoreciresinol, 
lariciresinol and matairesinol may also form mammalian lignans in the intestine (140). Figure 1.3 
illustrates the various interconnected pathways and bacteria involved in the interconversion of 
lignans in the gut. The elucidation of the interconversion pathways further supports that the 
lignans are absorbed in its aglycone form rather than glucosidic forms (137). 
 
 
 
Figure 1.2: Diagrammatic representation of Transwell® system and Caco-2 cell monolayer. 
Caco-2 cell monolayers are cultured on a semipermeable membrane for 21 days to form tight cell 
junctions. The inner well that contains the cells and the cell culture media is called the apical 
compartment, whereas the outer well that contains only cell culture media is called the 
basolateral compartment.  
Apical  
Porous 
b
Basolateral Tissue culture  
Transwell  Insert 
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Since the microflora of intestine such as Lactobacillus (141-143), Enterococcus (141), 
Bacteroids (144) and Clostridium (145, 146), contain β-glucosidase/β-glucuronidase enzymes 
(35, 36), the biochemical transformations of polyphenols were proposed (43). However, the 
subsequent pharmacokinetic studies refute the exclusive involvement of gut microflora based on 
several arguments. Firstly, the microflora reside in the colon of human and orally ingested 
products need at least a few hours of transit time before it can reach the distal ileum. Thus, the 
conversion of glycosides into aglycone exclusively by gut microflora cannot explain the early 
Cmax of many polyphenols. For example, about 2% of the ingested dose of pinoresinol and 
lariciresinol were present after 1 h of oral intake of sesame seeds. This suggests that a small 
fraction of the administered dose is absorbed before it reaches the colon where these polyphenols 
undergo deglucosylation. In another study in the gnotobiotic rats, SECO was detected in cecum 
contents, colon contents and feces after oral ingestion of a flaxseed rich diet (147). The small 
percent of free SECO in flaxseed is unlikely to explain the concentration of SECO in the cecum 
and suggests that the sugar moiety of SDG is removed prior to reaching the cecum. Similar to 
SDG, Lu et al detected diadzein and genistein in female urine within 1-2 h of soya milk ingestion 
(148). In rats, a large amount of intact diadzein and genistein were detected in the urine of 
gnotobiotic rats after their oral consumption (149, 150), which cannot be explained with a very 
small amount of free aglycone in the soy isoflavone diet.  The possibility of hydrolysis of the 
sugar moiety due to acidic conditions of the stomach or basic conditions of the small intestine is 
rejected because SDG is difficult to hydrolyze at physiological conditions. In vitro incubation of 
SDG in simulated gastric fluid for 3 h did not yield aglycones (137, 151). 
Similarly, SDG was found to be stable in simulated intestinal fluid (137). Although some 
flavonoid glycosides are converted into their aglycones in saliva, which may explain early 
detection of flavones in the plasma, no information is available on lignan glycosides (152). The 
counter argument to the hypothesis of salivary metabolism is that during oral administration the 
glycosides are swallowed and thus, salivary hydrolysis is less likely to account for the early 
absorption. Early detection of aglycones in rats may be explained by the ability of rats to harbour 
bacteria in the stomach but the observations in gnotobiotic rats and human, who do not harbour 
bacteria in stomach, are difficult to explain. More plausible explanation could be the 
deglucosylation in the small intestine. Since β-glucosidase/β-glucuronidase enzymes (35, 36) 
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activity is present in the brush boarder of the intestine (153), the enterocyte may also be 
mediating the deglucosylation of polyphenol glycosides. Several studies identified the ß-
glucosidase activity in rat and human enterocytes with deglucosylation activity and the critical 
role of deglucosylation in the enterocytes (154). Some of the recent studies favour the hypothesis 
of deglucosylation in the enterocytes but its involvement has not been proven unambiguously 
(154). 
The enterolignans are systemically available with delayed appearance in the plasma. Oral 
administration of 25 g of ground flax to healthy young women increased the plasma 
concentration of enterolignans from its baseline value of 29.35 ± 3.69 nmol/L to 65.94 ± 11.38 
nmol/L. The plasma concentration achieved a plateau phase (97.14 ± 27.06 nmol/L) after 8 days 
of administration (155). Similarly, Mazur et al reported an increase in plasma enterolignan 
concentration from 10.3 nmol/L to 20.6 nmol/L after a single dose administration of strawberries 
(500 g) to healthy volunteers (156).The Cmax of ED and EL in healthy volunteers after oral 
administration of a single dose of 1.31 µmol/kg SDG were 73 ± 40 and 56 ± 30 nmol/L, 
respectively (157). These studies indicate that the enterolignans are systemically available. 
Contrary to other polyphenols and flavonoids, the appearances of enterolignans in plasma are 
delayed and remain high even after 24 h of flaxseed administration. The Tmax of ED and EL after 
1.31 µmol/kg dose in healthy volunteers were 14.8 ± 5.1 and 19.7 ± 6.2 h, respectively (157). In 
another study, the highest plasma concentrations of ED (46.3±9.3 nmol/L) and EL (19.7±6.5 
nmol/L) in healthy women occurred 24 h after the administration of 25 g of raw flaxseed (155). 
Understandably, these delayed appearances of enterolignans are likely due to the conversion of 
plant lignans into enterolignans.  
Although our understanding of the processes involved in the absorption of lignans has 
improved in the years, several contentious issues exist that needs investigation for better 
understanding of the absorptive processes. 
 
1.3.2 Distribution 
The tissue distribution of flaxseed lignans and associated mammalian lignans is not well 
understood and several issues remain unstudied. Firstly, the tissue distribution of different 
structurally related polyphenols suggest significant variability in their affinity towards different 
organs. Secondly, the tissue distributions of most of the compounds have been investigated in 
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rodents and, thus, interspecies extrapolation of the distribution pattern to humans is difficult. 
Lastly, most of these polyphenols act as phytoestrogens and, therefore, the pharmacokinetics and 
tissue distribution may be influenced by sex hormones and their concentrations. Studies on these 
factors influencing the tissue distribution of lignans and their impact on pharmacodynamics may 
be helpful in the future to understand the high variability in lignan PK. However, some of the 
general trends observed in the tissue distribution studies on most of the polyphenols will be 
discussed in ensuing paragraphs.  
 Flaxseed and associated lignans accumulate predominantly in liver, prostate, kidney and 
intestine. The tissue distribution of enterolignans, ED and EL, is inconsistent at different doses in 
nutritional intervention studies (158). The concentration of ED was highest in the liver at 15 
mg/kg per oral dose of SDG while the concentration was highest in prostate at 60 mg/kg (158). 
The concentrations of ED in liver, testes, prostate and lung were 386, 58, 258 and 14 pmol/g at 
15 mg/kg dose, respectively, and increased to 1844, 114, 1899 and 54 pmol/g at 60 mg/kg, 
respectively (158). The concentrations of ED and EL in testes and prostate of rats significantly 
increased after oral ingestion of SDG (159). The other major organs in which the polyphenols 
significantly distribute include lung, kidney and heart. Upon oral administration of SDG (15 
mg/kg) in rats, the concentrations of ED and EL in the lung were 14 and 8 pmol/g, respectively 
(158). Enterolignans were detected in the tissue of colon, liver, breast and brain at a much higher 
level with rye than with wheat when high fibre rye and wheat bread was administered to pigs for 
58-67 days (160). 
Chronic administration of flaxseed lignans caused 1-3 fold increase in tissue accumulation 
than acute administration. Liver radioactivity and adipose tissue accumulation of SDG 
metabolites was increased by 50-80 % and 1-3 fold, respectively, when 1.5 mg unlabeled SDG/d 
was administered orally to rats for 10 days in comparison to 3H-SDG (3.7 kBq/g body weight) 
administration as a single dose (161). The same research group reported that serum lignan 
concentration increased 4-fold with chronic oral administration of unlabelled SDG (5.3 µg/g 
body weight) for 7 days to SD rats in comparison to single dose administration of 3H-SDG (3.7 
kBq/g body weight). Most of the lignan metabolites accumulated in the liver (48-56%) after 
acute and chronic administration (159).   
The plasma protein binding data of flaxseed lignans are not available in the literature; 
however, binding affinities of SECO, ED and EL are reported with steroid hormone binding 
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globulins (SHBG). SECO and EL seem to have higher binding affinity than ED. SECO and EL 
could displace 60 ± 7% and 55 ± 7% of 3H-dihydrotestosterone (DHT) from the binding site, 
respectively, while ED displaced only 16 ± 6% (162, 163). 
 
1.3.3 Metabolism 
Intestinal metabolism has a very vital role in the metabolism of lignan and other 
polyphenols (165). The conversion of SDG into SECO and subsequently into ED and EL by gut 
microflora was discussed in section 2.2. The role of gut microflora in the interconversion of 
lignans is indisputable. No ED and EL was detected in the cecum of gnotobiotic rats after oral 
administration of SDG while significant amounts of ED and EL were detected in the rats 
harbouring lignan activating bacteria (Clostridium saccharogumia, Eggerthella lenta, Blautia 
product and Lactonifactor longoviformis) (39). Additionally, no EL was detected in the urine of 
gnotobiotic rats while ED was present in rats with gut microflora (166). Similarly, Setchell et al 
found the exclusive involvement of human intestinal bacterial flora in the conversion of soy 
isoflavones into S-equol (167). Enterolignans are the major metabolite of sesame lignans in 
humans (168). These results demonstrated the involvement of intestinal microflora in the lignan 
metabolism.  
Most of the polyphenols including lignans undergo significant first pass metabolism. 
Primarily, these compounds undergo glucuronidation and sulfation in enterocytes and liver. Most 
of the ED and EL detected in the portal vein of rats were in conjugated form (27). A primary site 
of glucuronidation of lignans is enterocytes. Enterocytes take up the various aglycone forms 
generated by gut microflora and these aglycone forms undergo conjugation in enterocytes (169, 
170). UDP-Glucuronosyltransfersase (UGTs) of enterocytes mediates glucuronidation reactions 
of many xenobiotics. About 45% of flavonols were present as the glucuronide in the jejunum 
perfusate (171) suggesting that flavanols are glucuronidated in enterocytes. Similarly, reservatrol 
and ezetimibe also undergo glucuronidation in the enterocytes (172-174). In the pig ileum, most 
of the rye bran lignans are found as conjugates (175). The lignans were primarily found as 
glucuronides and sulfate conjugates in the portal vein blood in rats collected after oral 
administration of SDG (27) . Glucuronide (ED and EL) and sulfate (EL) conjugates have been 
identified in in vitro HT-29 and Caco-2 colon epithelial cells and this conjugation is suggested to 
take place during their uptake into colon cells (176). In urine the majority of these lignans are  
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excreted as glucuronides. About 91.7 and 74.9% of ED and EL were found as glucuronides in 
the rat urine, respectively (41). 
While the majority of metabolites are glucuronides and sulfate conjugates, a minor percent 
of phase I metabolites were also detected in different systems. Aromatic hydroxylated 
metabolites of enterodiol and enterolactone was detected in rat, pig, rhesus monkey and human 
microsomes (56). Some of these hydroxylated metabolites were also detected in human and rat 
serum or urine along with their sulfate and glucuronide conjugates (Table 1.1). These results 
suggest that some of the aglycone forms that reach to the liver are hydroxylated and further 
glucuronidated. The enzymes involved in the phase I metabolism are not identified but their 
inhibitory effects on several CYPs have been documented. In our own lab, high concentrations of 
EL and Nordihydroguaiaretic acid (NDGA) showed reversible inhibition of a combination of 
CYP3A, CYP2B/2C11 and CYP1A2 enzymes (177). SECO and EL activate pregnane X receptor 
(PXR), which is a nuclear receptor that mediates the induction of metabolic enzymes (178). This 
activation would likely affect those drugs which are primarily metabolized by CYPs. Another 
lignan, sesamin, also inhibited CYP mediated metabolism of tocopherol and elevated systemic 
and tissue concentrations (179). Gomicin C was more potent than ketoconazole in the inhibition 
of CYP3A4 (180). In general, at high concentrations the lignans seem to have inhibitory capacity 
to CYPs.  
The pharmacological importance of these glucuronide conjugates is still unknown. 
Traditionally, glucuronidation is considered a process of inactivation and results in the loss of 
pharmacological activity of xenobiotics. However, recent evidence of pharmacological activity 
of morphine-O-glucuronide and ezetimibe glucuronide provides important examples of 
glucuronide conjugates that exhibit pharmacological activity (181). Given the high 
concentrations of glucuronides of lignans and polyphenols, it would be interesting to study the 
pharmacological activity of lignan glucuronides.  
Flaxseed lignans undergo enterohepatic recirculation, a process that increases the systemic 
exposure and the mean residence times of the lignans and other polyphenols. The mean residence 
times of ED and EL was 20.6±5.9 and 35.8±10.6 h, respectively, in healthy volunteers (N=12) 
after per oral administration of 1.31 µmol/kg of purified SDG. The high residence time of EL 
was due to biomodal plasma-concentration profiles, which usually results from enterohepatic 
recirculation (157). Additionally, the presence of significant amounts of glucuronide metabolites 
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in the bile supports the hypothesis of enterohepatic recirculation of lignans. Lignans are 
conjugated in enterocytes, which is evident by the fact that lignans were primarily found as 
glucuronides and sulfate conjugates in the portal vein blood in rats collected after oral 
administration of SDG. About 20-50% of glucuronide and sulfate conjugates of lignans are 
excreted in the bile (160) and about 80% of the biliary excreted conjugates are deconjugated in 
the intestinal lumen by β-glucuronidase of intestinal microflora (182). Given the significant 
amount of ß-glucuronidase activity in Lactobacillus and Enterococcus isolates from human 
intestine, these glucuronides are likely to be hydrolyzed into their aglycone forms and 
reabsorbed. Due to enterohepatic recirculation, only about 10% the lignans are excreted in feces 
in their aglycone forms (27).  
 
Table 1.1: Various metabolites of enterodiol (ED) and enterolactone (EL) detected in different 
species: 
Enterolignan  Metabolism Metabolic study system Reference 
OH
CH2OH
CH2OH
OH
1
2
3
4
5
6
1
2
3
4
5
6
A
B
1'
 
ED 
Hydroxylation at 
 2/4/6C in 
ring B 
 2/4/5C in 
ring A 
 1’C 
Detected in 
 Human urine 
 Rat, pig and human 
liver microsomes 
 Rat bile and urine 
 Monkey 
hepatocytes 
 (183-186) 
 
Glucuronidation 
and sulphation at 
 3C in ring 
A 
Detected in  
 Human serum and 
urine 
(187) 
OH
O
O
OH
1
2
3
4
5
6
1
2
3
4
5
6
B
A
1'
 
EL 
Hydroxylation at 
 2/5/6C in 
ring B  
 2/4/5/6C in 
ring A 
 1’C 
 
Detected in 
 Human urine 
 Rat, pig and human 
liver microsomes 
 Rat bile and urine 
 Monkey 
hepatocytes 
 
(183-186) 
Glucuronidation 
and sulphation at 
 3C in ring 
A,B 
 
Detected in  
 Human serum and 
urine 
 Monkey 
hepatocytes 
 
(183, 187) 
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Enterohepatic recirculation also favours the metabolism of SECO and ED into EL. 
Conjugated ED that is excreted in the bile is deconjugated and a fraction of deconjugated ED is 
converted into EL. Therefore, in most of the studies and in a stable dose environment, urinary 
and fecal excretion of EL is higher than ED (27, 188). 
1.3.4 Excretion 
Fecal excretion is one of the major routes of excretion of lignan metabolites in different 
species. Flaxseed consumption increased the fecal excretion of lignans as conjugates in humans, 
which supports that the fecal lignans originate from flaxseed. The fecal excretions of ED, EL and 
matairesinol conjugates in pre-menopausal women on normal diets were 80, 640 and 7.33 
nmol/day, which increased with flaxseed consumption to 2560, 10300 and 11.9 nmol/day, 
respectively (189). In terms of percent, fecal excretion of enterolignans in humans accounts for 
46% of the administered dose of total lignans (188). Other species such as pigs and rats also 
excrete substantial amounts of lignans in feces. While the urinary excretion of enterolignan in 
pig feces is only about 34-35% (190, 191) more than 50% of administered SDG was recovered in 
the feces of rats (161). The high fecal excretion of enterolignans may be due to incomplete 
absorption or enterohepatic circulation. Lignan glucuronides are excreted in bile and 
subsequently undergo deglucuronidation by bacterial β-glucuronidase activity. Intraduodenal 
administration of 14C-labelled genestein in rats resulted in 70-75% recovery of radioactivity in 
the bile (192).  
The urinary route of excretion is one of the primary routes of excretion of lignan 
metabolites. The major amount of lignan is excreted as enterolignan glucuronide in urine while a 
minor amount is excreted as sulfates and aglycones (193). A very small percent of plant lignans 
are excreted in the urine (194). About 73-94% of EL conjugates excreted in urine are 
monoglucuronides and sulfoglucuronides while only 1-17% are excreted as sulfate conjugates 
(195). Urinary excretion of various conjugates of EL is higher than ED in different populations 
on a normal traditional diet. The urinary excretion of EL conjugates was 1.4 µmol/day while the 
urinary excretion of ED conjugates was only 0.7 µmol/day in Japanese women on a traditional 
Japanese diet (196). Similarly, volunteers on a western diet excreted 3.64, 1.25 and 0.98 
µmol/day of EL, ED and matairesinol, respectively (197). In Finnish men, the urinary excretions 
of EL, ED and matairesinol were 3.20, 0.55 and 0.05 µmoles/day, respectively (198). All these 
studies indicate that EL is the preferentially excreted lignan in the urine. The higher excretion of 
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these lignans may be partly explained by the higher systemic concentrations of EL than ED 
(157). Adlecruetz et al observed good correlation between the plasma concentrations and the 
urinary excretions of various lignans and isoflavonoids (191, 193).  
After nutritional intervention with a lignan rich diet, a dose-dependent increase in the 
excretion of ED and EL was observed (199). The consumption of a flaxseed diet increased the 
concentration of EL from 4.55 µmol/day (flaxseed free diet) to 24.42 µmol/day in the follicular 
phase of menstrual cycle in pre-menopausal women. The urinary concentrations of ED in pre-
menopausal women increased about 14-15 times from the baseline concentration after flaxseed 
diet consumption (200). While the urinary excretion of ED and EL increased upon consumption 
of flaxseed diet, the urinary excretion of other lignans and isoflavones including metairesinol, 
daidzein and genestein did not change significantly. In postmenopausal women, a dose-
dependent increase of urinary excretion of lignans was observed (199).  
High variability in the excretion of lignans is observed due to several factors such as sex, 
age, disease condition and diet. Vegetarian diets result in a higher excretion of lignans in 
comparison to an omnivorous diet. Vegetarians had higher matairesinol, EL, ED, daidzein and 
genistein concentrations in feces than omnivorous subjects (190). Additionally, Knudsen et al 
demonstrated that 24% of the ingested enterolignan were excreted in urine when pigs were fed 
with low lignan wheat diet but the percent urinary excretion decreased to 14% with high lignan 
diets (188). The second factor is gender as women tend to eliminate lignans more rapidly than 
men. The mean residence time of EL and ED in women was 28.4 and 17.3 h, respectively, while 
the mean residence time in men was 43.2 and 23.9 h, respectively (157). Lastly, the disease 
condition may also influence the excretion of lignans. Interestingly, the urinary excretion of 
enterolignan was lower in postmenopausal women with breast cancer than normal omnivorous or 
vegetarian postmenopausal women (201).  
 
1.3.5 Variability in lignan pharmacokinetics 
High degree of inter-individual variability in the blood levels of the enterolignans exists in 
different cohorts of nutritional intervention studies due to a variety of factors including diet, 
microflora, gender and age. Firstly, dietary flaxseed lignans may alter the blood levels of 
mammalian lignans in the systemic circulation (140). A number of human studies report (Table 
1.2) baseline blood levels of these lignans (mostly EL) between 5.4 to 30 nmol/L and after 
28 
 
dietary intervention; levels are as high as 820 nmol/L (51). In most of the studies, different 
dietary source of lignan have been used which can affect the blood lignan concentrations. 
Additionally, these studies measured the concentrations of enterolignans and ignored the 
presence of other plant lignans, which might have roles in various health benefits. 
 
Table 1.2: Variability of lignans measured in various clinical studies after flaxseed/flaxseed 
lignans administration 
Administration Measured 
Lignan 
Baseline 
Concentration 
(nmol/L)  
Treated 
Concentration 
(nmol/L) 
Reference 
Flaxseed (25 g) ED and EL 16 744 (mean) 
(highest as 820) 
(202) 
Raw flaxseed (25 g) for 7 
days 
ED and EL 22.45, 6.90 72.69, 24.45 
(ED levels are 
higher that EL) 
(155) 
Crushed flaxseed (25 g) for 3 
days 
ED and EL - 7.0 and 39.2  (203) 
 
Flaxseed (20 g/day) for 8 
weeks 
ED and EL 1.9 and 45 11 and 111 
(large variation) 
(42) 
 
Ground flaxseed (0.3 g/kg/d) 
for 10 days 
ED and EL 1.9 and 9.5 103 and 167 (204) 
SDG (60 mg) o.d. ED and EL  - 73 and 56 (157) 
SDG (500 mg) as lignan 
complex extract for 6 weeks 
EL 46 385 (95) 
SDG (600 mg) as lignan 
complex 
ED, EL and 
SECO 
28.6,77.5,67 561, 1334, 500 (93) 
 
Secondly, high inter-individual variability in the microflora population inhabiting the gut 
may explain the variability in systemic concentrations (205). Since the microflora plays an 
important role in the rate and extent of absorption of lignans and other polyphenols, the 
interindividual differences in gastrointestinal microflora may influence the systemic blood 
concentrations of enterolignans. Thirdly, gender also influences the systemic concentration of 
enterolignans (206). Since females have a higher population of enterolignan producing bacteria 
in the gut, they are likely to extensively metabolize the lignans. Additionally, the levels of sex 
hormones have correlated with enterolignan bioavailability (207). Eighteen women consumed 
flaxseed (10 g/d) for three menstrual cycle period and enterolignan excretion varied from 3-285 
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folds (200). Lastly, the age of subjects also affects the absorption of lignans. The ß-glucosidase 
activity of Enterococcus, bacteria present in the human gut, was higher in a population below 30 
years (0.013-0.17 mM p-nitrophenyl/h/mg of protein) of age than a population between the ages 
of 30-80 years (0.006-0.010 mM p-nitrophenyl/h/mg of protein) (141). 
Among different species, urinary excretion of lignans in human is higher than other animal 
species. Rats excreted 28-32 % of ingested tritium labelled SDG in the urine within 48 h of 
administration (161). About 12% of the ingested lignans is excreted in the urine of pigs after oral 
consumption of high lignan rye diet. In a separate study, about 15.74 % of ingested dose of SDG 
was excreted as ED, EL and SECO in rats (208). In humans, about 40% of the ingested purified 
SDG (1.31 µmol/kg body weight) was excreted as conjugates via urinary excretion and EL alone 
constitutes about 58% of urinary excreted lignan (157). Administration of 5, 15 and 25 g raw and 
processed flaxseed for 7 days to healthy young women leads to higher urinary enterolignan 
conjugate excretion after 7 days suggesting enterolignan excretion is time- and dose-dependent 
(155). The lower excretion of lignans may be explained with lower glomerular filtration rate in 
rats; however, the exact mechanism of urinary excretion should be elucidated to explain 
interspecies variability. Given the correlation between urinary excretion and systemic 
concentration of enterolignans (191), the variability in urinary excretion may cause variability in 
efficacy and safety among species and makes interspecies extrapolation difficult.   
 
1.4 Pharmacodynamics of flaxseed lignans: mechanism(s) of action 
This section will focus on the pharmacodynamics of flaxseed lignan with emphasis on fatty 
acid metabolism pathway. This section discusses fatty acid metabolism as an alternate source of 
energy in cancer cells, the biochemical pathways of fatty acid metabolism, important enzymes 
and transcription factors regulating fatty acid metabolism pathways and the possible role of 
lignans in fatty acid metabolism.  
Several mechanisms have been suggested for the pharmacological activity of flaxseed 
lignans. First, SDG, HMR, ED and EL exhibit antioxidant properties (209). These lignans are 
believed to decrease oxidative stress and reactive oxygen species in the body which underlies the 
pathophysiology of various metabolic diseases and cancer. Second, flaxseed lignans may 
decrease levels of extracellular VEGF, a key factor for the angiogenesis of cancer cells and thus 
act as antiangiogenic agent mainly in breast and prostate cancer (77). Third, these lignans are 
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suggested to downregulate the expression of IGF-I and epidermal growth factor receptor (75). 
Serum levels of these factors are strongly associated with mammary cancer risk.  Fourth, these 
lignans are suggested to have estrogenic and/or antiestrogenic potential especially in breast 
cancer, with the exact mechanism varing with concentration of these lignans (70). Last, these 
lignans are suggested to inhibit the estrogen biosynthesis by inhibiting the key enzyme of 
synthesis, aromatase, and thus inhibit breast cancer growth (58, 210). Higher estrogen levels are 
positively associated with breast cancer growth.  
Although the effect of flaxseed lignans on fatty acid metabolism has not been investigated 
so far, other lignans such as sesame lignans alter fatty acid metabolism in the body (211). Fatty 
acid metabolism (synthesis and oxidation) is the key pathway to regulate the lipids in the body. 
Lipids play a central regulatory role in many metabolic diseases and cancer (212). Therefore, 
alteration in lipids via fatty acid metabolic pathways may be one of the major mechanisms to 
exhibit the putative health benefits in number of diseases.  
 
1.4.1 Fatty acid metabolism: an alternate source of energy  
Normal cells produce pyruvate in aerobic conditions and lactate in anaerobic condition 
while cancerous cells mostly (95%) produce lactate in the presence or absence of oxygen (called 
Warburg effect) (213, 214). Aerobic glycolysis via formation of pyruvate produces 36 ATPs 
while formation of lactate produces only 2 ATPs. This seems paradoxical because cancer cells 
need more energy for rapid division but choose a less efficient mechanism for ATP production. 
The exact reasons for this effect is unknown but have been explained in several ways. These 
explanations have been discussed elsewhere in detail (215).  
One of the explanations of Warburg effect is that cancer cells optimize their bioenergetics 
and biosynthetics by conversion of glucose to lactate during aerobic glycolysis. Cancer cells 
divide at higher rate and require not only higher energy (ATP) but also larger biomass including 
nucleotides, proteins and lipids to cater the need of rapid mitosis. Higher energy requirement is 
compensated by higher glycolytic flux. Higher glycolytic flux coerces the less efficient biomass 
synthetic pathway to work at their maximum efficiency. For the large biomass requirements, 
cancer cells largely depend upon de novo synthesis rather than depending on external sources. 
By synthesizing biomass from glucose, a most abundant nutrient source, cancer cells optimize 
their biosynthetics and bioenergetics (214, 216).  
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The lipid requirement of cancer cell is met by de novo synthesis of fatty acids and their 
inhibition results in apoptosis of cancer cells (216). Mitochondria use pyruvate to synthesize 
citrate, which is subsequently converted into fatty acids (Figure 1.4). Lactate dehydrogenase can 
convert lactate generated during aerobic glycolysis in cancer cells into pyruvate. The pyruvate is 
taken up by TCA cycle to synthesize other intermediates (216). Inhibition of fatty acid synthase 
(FAS), an enzyme responsible for fatty acid synthesis, induces apoptosis in breast and prostate 
cancer, which indicates the reliance of tumor survival on FAS (217-219). In breast and prostate 
cancer patients, higher levels of FAS are associated with an increase in the risk of patient death 
and higher Gleason grade (a metric of severity of prostate cancer) in prostate cancer patients. 
Recently, higher levels of FAS have been associated with HER2 expression in breast cancer 
(220). This association clearly suggests the dependence of these cancer cells on fatty acid 
metabolism for growth and survival.  
Prostate cancer cells do not show high glycolytic flux and depends on beta-oxidation of 
fatty acid as their main source of energy (221). The mRNA of glucose transporter 1 (GLUT1) 
transporter, which is responsible for uptake of glucose by cancerous cells, is weakly expressed in 
prostate cancer cells (222). Glucose deprivation did not inhibit the growth of LNCaP prostate 
cancer cell lines (223). These results suggest that slow growing prostate cancer does not depend 
upon glucose as their primary source of energy and may depend upon β-oxidation of fatty acid as 
an alternate source of energy. Normal prostate cells produce and accumulate high level of citrate 
but cancerous prostate cells have low levels of citrate indicating that cells are using it for some 
purpose (224, 225). As per Costello and Franklin’s ‘bioenergetic theory of prostate malignancy’, 
normal citrate producing prostate epithelial cells transforms itself into malignant cells which 
oxidize citrate (226).  
 
1.4.2 Fatty acid metabolism: biochemical pathways 
The balance of fatty acid synthesis and oxidation plays an important role in the 
maintenance of cellular structure and regulation of various cellular functions (227). Since fatty 
acids are integral components of phospholipids and glycolipids in cellular substructures, the 
regulation of its synthesis and oxidation is important to cell survival. Fatty acid synthesis 
provides an important reserve of fatty acids and lipids in the body and fatty acid oxidation via β-
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oxidation breaks down fatty acids to provide energy required for biochemical processes in the 
cells (228, 229).  
 
1.4.2.1 Fatty acid synthesis 
Fatty acid synthesis occurs by a series of steps primarily in liver and adipose tissues (230). 
Under normal physiological conditions, the glycolytic pathway converts glucose into pyruvate, 
which is subsequently converted into acetyl CoA. Then, mitochondria use acetyl CoA and 
oxaloacetate to synthesize citrate, which is a main precursor for cytosolic acetyl CoA. Fatty acid 
synthesis begins by conversion of acetyl CoA into malonyl CoA by acetyl CoA carboxylase 
(ACC) enzyme. Fatty acid synthase (FAS), another vital enzyme, converts acetyl CoA and 
malonyl CoA into palmitate in the presence of NADPH. These two major steps are catalyzed by 
various enzyme activities (Figure 1.4). Enzymes of the fatty acid synthesis pathway are regulated 
by transcription factors such as sterol regulatory element binding proteins (SREBPs) (231).  
 
1.4.2.2 Fatty acid oxidation 
Fatty acid oxidation is a process that provides energy to the cells and requires the 
activation of fatty acids in the cytoplasm. The activation of fatty acid is achieved by conversion 
of fatty acid into fatty acyl CoA, which is then subsequently transported into mitochondria (232), 
where fatty acyl CoA is converted into acetyl CoA. These acetyl CoA enters into tri-carboxylic 
acid cycle and electron transport system to generate energy (232). However, the transport of fatty 
acyl CoA into mitochondria occurs as an acylcarnitine intermediate, which is generated by the 
addition of carnitine to fatty acyl CoA. The carnitine palmitoyltransferase system is comprised of 
CPT-I and CPT-II (233). Carnitine palmitoyltransferase-I (CPT-I) catalyzes the addition of 
carnitine to fatty acyl-CoA to form acylcarnitine intermediate, which is translocated into 
mitochondria by another enzyme called carnitine acylcarnitine translocase (CACT). Carnitine 
palmitoyl transferase-II (CPT-II), an enzyme present in the inner membrane of mitochondria, 
breaks the translocated acyl carnitine intermediate within the mitochondria to initiate β-oxidation 
of fatty acyl-CoA (Figure 1.5) (234). Given the roles of CPT-I and -II in the transport of fatty 
acyl-CoA into the mitochondria where the oxidation occurs, their regulation (inhibition and 
induction) is likely to impact fatty acid oxidation. 
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Figure 1.4: Schematic diagram of fatty acid synthesis pathway in humans. Citrate is a main 
precursor for fatty acid synthesis in cytosol. Citrate is converted to acetyl-CoA by ATP citrate 
lyase. Acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2) converts acetyl-CoA to malonyl-
CoA. Malonyl-CoA is converted to palmitate by fatty acid synthase (FAS). Activities of ACC1, 
ACC2 and FAS are the key steps for fatty acid synthesis (saturated and unsaturated) from 
palmitate (Adapted from 
http://www.mitosciences.com/fatty_acid_synthesis_pathway_diagram.html) (236).  
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Malonyl-CoA is a regulator of fatty acid oxidation and synthesis. Malonyl-CoA inhibits 
CPT-I (235) and thus prevents the fatty acid oxidation and degradation in mitochondria. 
Additionally, malonyl-CoA acts as a regulatory molecule in the fatty acid synthesis pathway. 
 
1.4.3 Important enzymes and transcription factors in fatty acid metabolism 
1.4.3.1 Acetyl CoA carboxylase (ACC)  
ACC plays a pivotal role in fatty acid metabolism. ACC is a multi subunit enzyme, present 
in the endoplasmic reticulum of eukaryotes, having two active sites, biotin carboxylase (BC) and 
carboxyltransferase (CT). The two different isoforms of ACCs, ACC1 and ACC2, differ in tissue 
distribution and function (237). ACC1 is found in cytoplasm of all cells and is enriched in 
lipogenic tissues such as adipose and mammary gland. ACC2 is found in skeletal muscles and 
heart, whereas in liver both ACC1 and ACC2 are present (237). ACC catalyses the carboxylation 
of acetyl-CoA to form malonyl-CoA, a rate limiting step of fatty acid synthesis, in the liver, 
adipose tissue and mammary gland. Malonyl-CoA acts as a precursor of fatty acid synthesis and 
regulates β-oxidation of fatty acids using carnitine palmitoyl-CoA transferase shuttle system 
(232).  
 
1.4.3.2 Fatty acid synthase (FAS) 
Fatty acid synthase is an enzymatic system, which catalyzes the terminal step of fatty acid 
synthesis. Mammalian fatty acid synthase (FAS) has two identical multifunctional polypeptides. 
The polypeptide has three catalytic domains in the N-terminal section and is separated by a core 
region of 600 residues from four C-terminal domains (238). FAS catalyzes the condensation of 
acetyl-CoA and malonyl-CoA to produce saturated fatty acid palmitate. The genetic expression 
of FAS is regulated by the transcription factor, SREBP-1c, in response to glucose/insulin system 
(239, 240) .  
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Figure 1.5: Schematic diagram of transport of fatty acids from the cytoplasm into mitochondria for 
β-oxidation. See text for explanation (234). 
 
 
1.4.3.3 Sterol regulatory element binding proteins (SREBPs) 
SREBPs are transcriptional factors regulating the expression of fatty acid synthase to 
regulate fatty acid metabolism. SREBPs bind to the sterol regulatory element specific DNA 
sequence. When sterol levels are low in cells, SREBP is cleaved to a water-soluble N-terminal 
domain that is translocated to the nucleus (241). This translocation upregulates the expression of 
various enzymes involved in sterol biosynthesis (241). However, when sterol levels are high in 
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cells, feedback mechanism regulates SREBP activities (242). The mammalian genome has two 
separate SREBP genes – SREBP-1 and SREBP-2. SREBP-1 is present in two different isoforms, 
SREBP-1a and SREBP-1c. These isoforms differ in their first exons owing to the use of different 
transcriptional start sites for the SREBP-1 gene. SREBP-1a and SREBP-1c are more selective for 
fatty acid synthesis regulation whereas SREBP-2 regulates genes involved in cholesterol 
metabolism (243). 
 
1.4.3.4 Carnitine palmitoyl transferase (CPT)  
CPT-I, a mitochondrial enzyme, belongs to the carnitine acyl transferase family and plays 
an important role in the transport of activated fatty acid into the mitochondria. The two known 
isoforms of CPT-I are CPT-Iα and Iβ. CPT-Iα is located mostly in liver whereas CPT-Iβ is 
mostly located in skeletal muscle and thus the isoforms are referred to as “liver” and “skeletal” 
isoforms, respectively (233). CPT-I mediates the essential step of β-oxidation. CPT-I catalyses 
rate limiting step of carnitine palmitoyl transferase shuttle system (244).  
CPT-I is regulated by hormones and dietary constituents. High insulin concentration causes 
inhibitory effects on CPT-I, which are mediated via malonyl-CoA. Another isoform CPT-II, a 
nuclear protein located in mitochondrial inner membrane, breaks down the translocated acyl 
carnitine intermediate which leads to β-oxidation (234). 
 
1.4.4 Therapeutic agents and lignans influencing fatty acid metabolism pathways 
Alterations in fatty acid synthesis and fatty acid oxidation modify the availability of triacyl 
glycerol synthesis and low density lipoprotein production in the liver and thus influence the lipid 
metabolism – a central link to metabolic diseases and cancer. Therefore, inhibitors of essential 
proteins involved in fatty acid metabolism including ACC, FAS, CPT-I along with lignans and 
various NHPs are suggested to be therapeutic agents against different metabolic diseases and 
cancer (237, 245, 246). Hyperphagic (fed with fat rich diet) ACC deficient mice exhibit reduced 
levels of malonyl-CoA, increased fatty acid oxidation, reduced body fat mass and reduced body 
weight. These observations suggest the vital role of ACC in the pathogenesis of obesity (237). 
No incidence of metabolic syndrome was observed in these hyperphagic ACC deficient mice. 
Inhibition of SREBP by betulin decreases biosynthesis of cholesterol and fatty acids and 
decreases the formation of atherosclerosis plaques (247). Clomoxir, 2-tertadecyglycidic acid and 
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etomoxir inhibit CPT-I, which is elevated in type II diabetes and, therefore, these agents may 
undergo development as novel anti-diabetic drugs (248). Similarly, FAS inhibitors such as 
orlistat are a promising anti prostate and anti breast cancer agent (246). Along with these above 
mentioned therapeutic agents, various lignans and related NHPs are also involved in fatty acid 
metabolism. 
Sesame lignans and various flavonoids affect fatty acid synthesis and fatty acid oxidation 
pathways. Three sesame lignans, sesamin, episesamin and sesamolin, decreased the activity and 
mRNA abundance of various enzymes involved in fatty acid metabolism. These lignans are 
equally effective in lowering the levels of fatty acid synthase and SREBP-1c, two important 
enzymes that regulate the fatty acid synthesis pathway (249); however, a dose-dependent effect 
is not yet clear. Sesamolin shows higher induction of fatty acid oxidation enzymes in comparison 
to sesamin (212, 250). This difference is suggested due to the greater bioavailability of sesamolin 
than sesamin. Tissue and serum levels of sesamolin were much greater that sesamin when equal 
amounts of these lignans were fed to the rats (250). Furthermore, affinity and ability to activate 
PPARα may explain the differences in these two lignans (250). Different flavonoids such as 
luteolin, quercetin, kaempferol, apigenin, and taxifolin inhibited fatty acid synthase and this 
inhibition is well correlated with their cancer preventive actions (251). 
 
1.5 Natural Products under Canadian regulations 
The ultimate goal of any product development is regulatory approval and benefit to 
consumers. Different countries may regulate flaxseed lignans differently, but our focus is in to 
the development of flaxseed lignans for Canadian market. In the following section, I will discuss 
the current status and prospects of flaxseed lignans in the Canadian market. 
The Canadian regulations governing natural products are complex and dynamic in nature. 
Under the Food and Drugs Act, the Natural Health Products Directorate (NHPD), Food 
Directorate (FD) and Therapeutic Products Directorate (TPD) govern the approval and marketing 
of natural products under different classifications including natural health products, foods, 
functional foods, nutraceuticals and drugs. The definitions and classification are discussed in this 
section; however, the boundaries between these classes are sometimes unclear and regulatory 
bodies (NHPD, FD and TPD) decide on the classification of these products and fix the regulatory 
requirements  
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1.5.1 Natural Health Products  
Health Canada defines Natural Health Product (NHP) as “a substance set out in Schedule 1 
(Schedule 1 includes a list of NHP substances) or a combination of substances in which all the 
medicinal ingredients are substances set out in Schedule 1, a homeopathic medicine or a 
traditional medicine that is manufactured, sold or represented for use in (a) the diagnosis, 
treatment, mitigation or prevention of a disease, disorder or abnormal physical state or its 
symptoms in humans; (b) restoring or correcting organic functions in humans; or (c) modifying 
organic functions in humans, such as modifying those functions in a manner that maintains or 
promotes health” (252).  
In general, NHPs are used for maintenance of good health, reduction of various health risks 
and chemoprevention of an acute or a chronic illness including cancer, multiple sclerosis, 
asthma, rheumatological conditions, depression, gastroenterological problems and other 
disorders (253). Various health care therapies such as homeopathic medicines, traditional 
Chinese, Ayurvedic medicine and probiotics incorporate NHPs in various formulations as 
tablets, capsules, solutions, tinctures and inhalations (254). In addition, NHPs are also used by 
specific population groups, such as the elderly (255), pregnant or breast-feeding women (256), 
and children (257). The World Health Organisation (WHO) estimates that 65-80% of world’s 
population (258) and about 71% of Canadians use NHPs such as vitamins, minerals and 
homeopathic medicines as a part of their healthy living styles (259).  
There are several reasons for the increased consumption of NHPs. A national survey of 
“Consumer use of Dietary Supplements” was conducted by telephone interviews to a population 
sample of 2000 individuals of continental United States. According to this survey, 43% of the 
individuals preferred NHPs over conventional medicines due to dissatisfaction with conventional 
medicines, 21% people believed that NHPs are safe and without side effects, 14% suggested that 
NHPs are more effective, 11% people had the desire for self treatment, 8% people found NHPs 
are cost effective and 6% thought that NHPs are gentle and mild (260). Therefore, belief of 
NHPs being safe and without side effects plays a significant role in their increased use. This 
belief gives an advantage to NHPs over conventional medicines, many of which have some 
associated side effects; however, our increasing scientific knowledge about NHPs indicates that 
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inappropriate administration of NHPs is also associated with various potential risks as with the 
conventional medicines.  
 
1.5.2 Foods, functional foods and nutraceuticals 
Under the Canadian Food and Drugs Act, Food is defined as “any article manufactured, 
sold or represented for use as food or drink for human beings, chewing gum, and any ingredient 
that may be mixed with food for any purpose whatever” (252). Health Canada considers a food 
as functional food if it is “similar in appearance to conventional food or may be a conventional 
food, is consumed as part of a usual diet, and is demonstrated to have physiological benefits 
and/or reduce the risk of chronic disease beyond basic nutritional functions” (261). Functional 
foods have effects on specific physiological functions in the body besides their normal functions 
of nutrition and nourishment. Some of the examples of functional foods may include insoluble 
fibers in wheat bran and omega-3 fatty acids in fish oil (262). These are likely to reduce the risk 
of colon cancer and cardiovascular diseases, respectively (262).  
Another class of natural products, nutraceutical, is defined as “a product isolated or 
purified from food that is generally sold in medicinal forms and not usually associated with food. 
A nutraceutical is demonstrated to have a physiological benefit or provide protection against 
chronic disease” (261). Currently, Health Canada considers nutraceuticals as NHPs (263). 
 
1.5.3 Classification of Natural Products 
Health Canada uses various criteria to determine class of a natural product such as food, 
functional food and NHPs. Classification of some natural products such as energy drinks and 
protein supplements may be difficult if only active constituent is used as a criterion for 
classification (264). Alternatively, many of the natural products containing same active 
ingredients (e.g. phytosterols, lignans and flavonoids) can be consumed as a component of food 
as well as NHPs. To avoid such situations, Health Canada uses different criteria that include 
product composition, product representation, product format, public perception and history of 
use (261, 264). Although these criteria are for the guidance purposes, regulatory bodies make 
their decision based on the specific natural product. 
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1.5.4 Flaxseed lignans in Canadian regulatory framework 
Health claims made by a natural product largely determines the classification of natural 
products. Flaxseed lignans may be categorized into different classes based on health claims and 
format. Flaxseed given in regular foods such as muffin, pasta and bread will be considered food 
if it does not claim any health benefits. However, the same food may be considered a functional 
food if it claims health benefits (nutritional claims, general health claims and restricted risk 
reduction claims) due to presence of lignans. Unlike other functional foods that make claims 
such as “good source of” or “a rich source of”, flaxseed containing food may not be able to make 
such claims because the daily recommended dose of lignan is not established (51). To claim a 
“good source of” or “a rich source of” a product must contain more than 5% of recommened 
daily intake (RDI) of nutrients. As yet, sufficient safety and epidemiological data does not exist 
for lignans to determine an RDI value.  
Flaxseed lignans isolated from flaxseed or chemically synthesized may be marketed as an 
NHP if the health claims are chemopreventive in nature; however, the treatment claims 
complicates the classification (252). The flaxseed lignans with therapeutic claims will be 
assigned a DIN and will be regulated by TPD but will still be considered as a NHP. Flaxseed 
lignans may be approved as a NHP for various disease risk reduction claims especially in case of 
cardiovascular diseases (CVD) and cancer (51). Risk reduction claims depend significantly on 
well designed clinical studies along with epidemiological evidences against risk reduction of a 
particular disease. The literature supports the reduction of various CVD biomarkers in clinical 
studies and may further be investigated; however, conducting a clinical study for cancer risk 
reduction claims is difficult and probably impossible due to ethical reasons. Thus, it is likely that 
flaxseed lignans may be marketed as NHP for cardiovascular disease but less likely to be 
approved for cancer. Alternatively, several studies indicate treatment potential of flaxseed lignan 
in breast and prostate cancer, but the treatment claims will require rigorous safety and efficacy 
studies to corroborate the claims. Marketing lignans as anticancer agents will depend on the 
therapeutic or safety edge that lignans will offer over existing anticancer agents, which may 
attract the pharmaceutical industry to develop lignan products. Clinical studies comparing the 
efficacy of lignans with leading anticancer agents for the treatment of breast cancers and prostate 
cancers will be interesting.  
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1.5.5 Natural Health Products (NHPs) regulation in Canada: Historical perspective and 
current status 
Historically, NHPs were regulated as either food or drugs under Food and Drugs Act in 
Canada. Food and Drugs Act first passed in 1920, incorporated drug, food, cosmetic and medical 
devices; however, dietary supplements, NHPs and functional food remained undefined. As a 
consequence, most of the NHPs were treated as drugs for various health claims under the 
Canadian Food and Drugs act; therefore, NHP manufacturers had to provide safety, efficacy and 
quality data in a new drug submission (NDS). Subsequently, the product used to be assigned a 
Drug Identification Number (DIN) if approved (265). Since other regulatory agencies including 
US had relaxed requirements for NHPs, manufacturers did not prefer to invest in proving 
Canadian requirements of safety and efficacy, which in itself is very challenging due to the 
complexity of NHPs. Even until now, testing of traditional Chinese, Ayurvedic, and other 
traditional medicines that would meet the standards of evidence required by the traditional drug 
approval system is very expensive and probably impossible. As a result of such stringent 
requirements for approval, Canadian population had fewer choices to select NHPs in the 
Canadian market. 
In late 1990’s Canadian politicians were under immense pressure to avoid a situation in 
which only fewer choices of NHPs/traditional medicines would be available in the market due to 
the strict drug regulatory system in Canada. Criticism from the public and the press coerced 
Health Canada to relax the laws for NHPs marketing and resulted in the introduction of a policy 
called “Interim DIN Enforcement Directive” in 1998 (266). According to this directive, some of 
the NHPs came into a special category called “Products Subject to Special Measures (PSSMs)” 
that included traditional medicines such as Chinese and Ayurvedic medicines, Aboriginal, 
Homeopathic medicines, vitamins and minerals. These NHPs could obtain a DIN number if they 
met the specifications given in their monographs that eased their marketing approval. For 
previously marketed NHPs without a DIN number, manufacturers were notified by a letter to 
have a DIN number; however, no other enforcement actions were taken. This raised the question 
of the legal status of the Interim DIN Enforcement Directive. Therefore, Interim DIN 
Enforcement Directive was followed by various consultations and concerns regarding the 
regulation of NHPs in Canada, which finally ended up in the establishment of Natural Health 
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Products Directorate (NHPD) in 2000, which works separately from the Therapeutic Products 
Directorate (TPD) within Health Canada (266).  
NHPD was implemented on January 1st, 2004 and defined NHPs in Canadian regulations. 
In 2008, NHPD allowed advertisement of NHPs for a chemopreventive use in disease conditions 
identified in schedule A, which was earlier prohibited. Currently, NHPD and Natural Health 
Product Regulations lead to set out that the NHPs (new and available in the market) must be 
licensed by NHPD prior to sale in Canada. The major regulatory framework of NHPD 
incorporates product licensing, site licensing, good manufacturing practices (GMPs), labelling 
and packaging provisions and adverse reaction reporting. NHPD provides the specific Natural 
Product Number (NPN) and DIN-HM (for homeopathic medicines) after the approval of various 
NHPs. It also provides Exemption Number (EN) to the various NHPs whose preliminary positive 
safety testing led to their availability in the market. In this way, NHPD increases the availability 
of a variety of NHPs to Canadian population for various chemopreventive health claims while 
ensuring their safety and quality (265, 267).  
Implementation of NHPD to regulate NHPs is comparatively new in Canada. The NHPs 
regulatory system under NHPD is still evolving and various guidelines are continuously being 
amended based on the feedbacks from various regulatory, academic and industrial bodies. NHPD 
requires submission of phase-III clinical trial data for any chemopreventive health claim of a 
NHP or non-prescription drug against schedule A diseases. These data incorporate at least two 
randomised phase-III clinical trials along with various epidemiological studies, safety data and 
background information including in vitro experiments and animal studies and literature 
outcomes in support of the chemopreventive claim requested (252). NHPs with therapeutic 
claims get a DIN number from TPD and require the results of various preclinical and clinical 
studies including drug safety, effectiveness and quality. TPD also requires details regarding the 
production of the drug, packaging and labelling details, and information regarding therapeutic 
claims and side effects as new drug submission (NDS) (259, 265). For example, flaxseed lignans 
will be assigned a DIN if claims to cure cancer while the same product will receive a NPN if it 
claims to prevent occurrences of cancer. 
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1.5.6 Safety issues in NHPs 
Frequently, people concurrently consume more than one or more products of these 
different classes of natural products and some of the pharmacokinetic and pharmacodynamic 
interactions (drug, food or NHP) between the active ingredients of these products may be 
significant and may pose risks of side and adverse effects (Figure 1.6). The side and adverse 
effects related to NHPs may arise due to a variety of reasons including overdosing and 
interactions with conventional medicines, food, functional food and other NHPs (268, 269). 
Patients tend to overdose themselves due to the impression of NHPs being safe at any dosage and 
desire to overcome the disease symptoms over a short period of time, which may pose a potential 
risk of adverse effects. As well, a small change in the percentage of active constituent may result 
in pharmacodynamic ineffectiveness or toxicity (270). For example, the extract of Ginkgo biloba 
may induce allergic reactions if the content of ginkgolic acid in the extract exceeds 5 parts per 
million (271).  
Various kinds of possible interactions (Figure 1.6) between drugs, NHPs, food and 
functional food may cause adverse reactions (268). A number of clinically significant drug-NHP 
or NHP-NHP interactions are well-known. St. John’s Wort, a NHP, may interact with 633 drugs 
(272). In a recently published report, St. John’s Wort decreased the systemic concentrations of 
indinavir (anti-HIV drug) and deteriorated HIV patient’s health condition. St. John’s Wort 
induces CYP3A4, which is the primary metabolic enzyme responsible for the metabolism of 
indinavir, and decreases the systemic concentration (273). As well, high doses of vitamin C may 
decrease the urinary excretion of acetaminophen and increase its blood levels, which may 
increase the adverse effects associated with acetaminophen (274). Since Vitamin C is present in 
citrus fruits, this interaction may also result in food-drug interactions. Furthermore, co-
administration of vitamin B3 and ginseng leads to blood sugar alterations and may increase the 
risk of bleeding. Similarly, co-administration of eucalyptus and ginger may lower the blood 
sugar levels (275, 276).  
A clinically significant food-drug interaction is that of grapefruit juice with several drugs 
that are CYP3A4 substrates (e.g. cyclosporine) (277). Alternatively, co-administration of 
functional food with drugs may modulate absorption of various drugs. Fish oil may exhibit a 
pharmacodynamic interaction with antihypertensive drugs. It decreases blood pressure (278) and 
therefore, co-administration of fish oil with antihypertensive drugs may potentiate the 
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antihypertensive effect and render patient hypotensive. Such interactions speak to a need for a 
better understanding of possible interactions and their mechanisms to aid in the design of better 
therapeutic strategies.  
 
 
Figure 1.6: Diagrammatic representation of various types of interactions possible between drugs, 
NHPs, food and functional food.  
 
Therapeutic claims of NHPs emphasize complete safety and efficacy studies (preclinical as 
well as clinical data) for any new chemical entity, which includes pharmacokinetic, 
pharmacodynamic, toxicological and drug-drug interaction assessments (279). Given the 
correlation between systemic exposure and safety and efficacy of a molecule, a pharmacokinetic 
understanding facilitates an understanding of the pharmacodynamics or potential for toxic effects 
of the molecule. In order to exhibit a pharmacodynamic effect the active constituent of the 
molecule must undergo the pharmacokinetic processes of absorption and distribution to gain 
access to the biophase (effect site of the drug). These pharmacokinetic processes in addition to 
the elimination processes of metabolism and excretion regulate the concentration at the biophase. 
Consequently, a complete understanding of pharmacokinetic processes is necessary to aid in the 
evaluation of safety and efficacy and determination of an effective dose and dosing schedule for 
a drug molecule (280).   
Understandably, identification of active constituents, determination of optimum dose, 
pharmacokinetics, efficacy and identification of mechanism of action of active constituents are 
often conducted retrospectively. For example, garlic (both food (in food format) and natural 
health product (in dosage format)) has been used for centuries as a food and may possess various  
health benefits such as anti-bacterial, anti-viral, anti-fungal, anti-hypertensive, blood-glucose-
lowering, anti-thrombotic, anti-mutagenic and anti-platelet activities (281). The active 
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constituents responsible for these activities were identified as Allicin and Allin. Along with 
various health benefits, excessive consumption of garlic has been associated with breath and 
body odour, allergic reactions, nausea, heartburn and flatulence (282). Various pharmacokinetic 
and pharmacodynamic studies on garlic identified that the optimum dose of 0.5 to 12 g/day of 
garlic bulb in adults (equivalent to maximum dose of 12 mg/day of allicin and 27 mg/day of 
allin) is required to avoid the abovementioned side effects while remaining effective (283,284).  
Additionally, pharmacodynamic studies are necessary to rationalize the usage of NHPs against 
any indication. Of the several studies that tested the chemopreventive efficacy of garlic against 
various indications (285), only the serum cholesterol lowering, lipid lowering and anti-infective 
effects were reproducible and conclusive. Uses against other indications need further 
investigations. 
Similarly, NHPs containing phytoestrogens such as flaxseed have been associated with 
various health benefits in cancer, cardiovascular disease and diabetes and have long history of 
safe use as a food through the ages (286); however, limited information on the bioactive 
constituents, the mechanisms of actions and pharmacokinetic behavior exist. One of the putative 
active constituents of flaxseed is flaxseed lignans. Role of flaxseed lignans in potential health 
benefits is a new and growing area (4). These health benefits can be promoted to the consumer 
through various health claims as discussed earlier. In addition to health promotion and risk 
reduction claims, various therapeutic claims of flaxseed lignans will require complete preclinical 
and clinical testing along with quality and safety evaluations as that of a drug molecule. With 
respect to preclinical and clinical testing, most of the pharmacokinetic and pharmacodynamic 
studies on these lignans were conducted as a part of nutritional studies and, thus, a complete 
characterization of the pharmacokinetics of flaxseed lignans is required.  
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1.6 Premise of the current study 
Flaxseed, one of the natural products that have been consumed for centuries, finds 
epidemiological association with the lower prevalence of several life style-related diseases such 
as diabetes, obesity, cardiovascular diseases and cancer. Flaxseed lignans may exhibit various 
health benefits; however, the active lignan form remains unknown. Our lab aims to identify the 
active form of the lignan and promote flaxseed lignans as a therapeutic measure to modulate 
common risk factors of chronic disease such as diabetes, cancer, and CVD to treat or prevent 
such diseases.  
The flaxseed lignans act via a variety of mechanisms to exhibit their anticancer effects. 
Prostate cancer cells are known to use fatty acids as an alternate source of energy and inhibition 
of the fatty acid metabolism results in death of these cancer cells. Given the beneficial effects of 
flaxseed lignans in breast, prostate cancers and diabetes, the flaxseed lignans may modulate fatty 
acid metabolism, which is central to the pathology of all these diseases. This is true of the 
sesame lignans such as sesamin, episesamin or sesamolin, which presumably mediates its 
anticancer effect via regulation of these targets. Since flaxseed lignans share structural similarity 
with the sesame lignans and exhibit similar health benefits to sesame lignans, we expect the 
flaxseed lignans to exhibit a similar effect on fatty acid metabolism. In my current work I study 
the effect of flaxseed lignans and associated mammalian lignans on fatty acid metabolism in 
breast and prostate cancer cells. Specifically, I selected one of the lignans, enterolactone (EL), to 
determine its effect on the regulation of various fatty acid metabolism targets. Vital proteins and 
enzymes in fatty acid metabolism including fatty acid synthase, sterol regulatory element binding 
protein (SREBP)-1C and acetyl Co-A carboxylase (ACC) are over-expressed in prostate and 
breast cancers and play an important role in overall lipid metabolism. Therefore, these vital 
proteins may be useful targets for chemotherapeutic agents. 
Additionally, I elucidate the pharmacokinetics of flaxseed lignans in rats in order to better 
understand the safety and efficacy of purified lignans. The determination of oral bioavailabilities 
of purified flaxseed lignans is critical to explain their biological activity and to understand 
pharmacokinetic-pharmacodynamic relationships, which determines the safety or efficacy. We 
determined oral bioavailability and other pharmacokinetic parameters of purified lignans in rats 
and explained the observed biaovailabilities of purified lignans with in vitro permeability and 
metabolism studies.  
47 
 
 
1.7 Hypothesis 
1. Flaxseed and mammalian lignans demonstrate favourable permeability characteristics, 
which will allow their further pharmacokinetic evaluation.  
2. Flaxseed and mammalian lignans alter fatty acid synthesis and/or oxidation pathways. 
  
1. 8 Objectives 
1. To develop and validate a HPLC bioanalytical method for the analysis of flaxseed and 
mammalian lignans and its application in pharmacokinetics studies.  
2. To determine the apparent permeability and phase-II metabolism of flaxseed and 
mammalian lignans using the Caco-2 cell system.  
3. Pharmacokinetic characterization of flaxseed and mammalian lignans using rat as a 
model.  
4. Evaluation of the effect of enterolactone (EL) on fatty acid synthesis and/or oxidation in 
cancer and normal immortalized cell lines.  
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CHAPTER 2 
 
HPLC Method with Fluorescence Detection for the Quantitative 
Determination of Flaxseed Lignans 
 
2.1 Abstract 
We report a rapid and simple HPLC method with fluorescence detection for the quantification of 
the major flaxseed lignan, secoisolarisiresinol diglucoside (SDG) and its major metabolites.  The 
method is specific for SDG, secoisolarisiresinol (SECO), enterodiol (ED) and entrolactone (EL) 
in rat serum. The assay procedure involves chromatographic separation using a Waters 
Symmetry C18 reversed-phase column (4.6 ×150 mm, 5µ) and mobile phase gradient conditions 
consisting of acetonitrile (0.1 percent formic acid) and water (0.1 percent formic acid). SDG 
extraction from serum requires the use of Centrifuge filters while SECO, ED and EL are 
extracted with diethyl ether. The organic layer is evaporated and reconstituted in 100 µl of 
mobile phase and 50 µl of reconstituted sample or filtrate is injected onto the column. Total run 
time is 25 min. Calibration curves are linear (r2 ≥ 0.997) from 0.05-10 μg/mL for SDG and EL 
and 0.01-10 μg/mL for SECO and ED. Precision and accuracy are within USFDA specified 
specified limits. The stability of all lignans is established in auto-injector, bench-top, freeze-thaw 
and long term stability at -80°C for 30 days. The method’s reasonable sensitivity and reliance on 
more widely available HPLC technology should allow for its straightforward application to 
pharmacokinetic evaluations of lignans in animal model systems such as the rat.  
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2.2 Introduction 
  Lignans are a class of diphenolic compounds widely distributed in the plant kingdom 
(287). Flaxseed is one of the richest sources of lignans with secoisolarisiresinol diglucoside 
(SDG) (Figure 2.1A) as the principal lignan form. Flaxseed also contains minor amounts of the 
aglycone form, secoisolariciresinol (SECO) (Figure 2.1B), and other lignans such as metaresinol 
and larisiresinol (288, 289). In the mammalian gastrointestinal tract SDG is hydrolysed to its 
aglycone, SECO, possibly through β-glucosidase and β-glucuronidase activity (290).  SECO is 
further converted to the mammalian lignans, enterodiol (ED) (Figure 2.1C) and enterolactone 
(EL) (Figure 2.1D) in the presence of colonic gut microflora (40, 291). 
At present, research principally attributes the health effects of the flaxseed lignans to their 
antioxidant activity (292, 293) estrogenic activity (294), or to their role as the principle precursor 
lignans to the mammalian lignans, ED and EL (295). Uncertainty exists as to whether the plant 
lignans (i.e. SDG or SECO) and/or the mammalian lignans (i.e. EL and ED) mediate the putative 
health benefits associated with flaxseed lignan consumption (296). A complete pharmacokinetic 
characterization of flaxseed lignans would contribute vital information on lignan effects in vivo. 
As flaxseed lignans receive increasing attention in the treatment of cardiovascular disease and 
cancer (297), their promotion will require an improved understanding of lignan absorption and 
disposition characteristics. Such a pharmacokinetic evaluation will require a simple and rapid 
analytical method for the quantitative determination of lignans in biological matrices. 
We found only a few analytical methods for the quantitation of lignans in the mammalian 
system. These methods involved the use of HPLC with fluoroimmunoassay (298), gas 
chromatography (GC) (299), UV detection or liquid chromatography-mass spectrophotometry 
(LCMS) techniques (187, 300-302). LCMS is not universally available and the reported HPLC 
methods suffer from various disadvantages including lack of analytical sensitivity and failure to 
report procedures for the simultaneous determination of all major lignan metabolites of SDG. To 
the best of our knowledge, the use of fluorescence detection for the quantification of flaxseed 
lignans in biological matrices has not been demonstrated. Fluorescence detection often improves 
analytical sensitivity as compared to UV detection methods. Therefore, we developed a HPLC 
fluorescence detection method for the determination of SDG, SECO, ED and EL in a rodent 
model system (the rat) commonly used for preliminary pharmacokinetic evaluations of new 
chemical entities and bioactive components of plants.  
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Figure 2.1: Structural representation of Secoisolarisiresinol diglucoside (SDG) (A), 
Secoisolarisiresinol (SECO) (B), Enterodiol (ED) (C), and Enterolactone (EL) (D). 
2.3 Materials and Methods 
2.3.1 Chemicals and reagents 
SDG and SECO (>95 percent purity) were kind gifts from Agriculture and Agri-Food 
Canada, (Dr. Alister Muir). ED and EL were purchased from Sigma-Aldrich Canada Ltd 
(Oakville, ON). Umbelliferone (7-Hydroxycoumarin) and riboflavin were purchased from 
Sigma-Aldrich Canada Ltd (Oakville, ON). HPLC grade acetonitrile was purchased from Fisher 
Scientific Canada (Ottawa, ON). Diethyl ether was purchased from EMD Chemicals Limited 
(Gibbstown, NJ). Methanol was purchased from Caledon Laboratories (Georgetown, ON). A 
MilliQ Synthesis (Millipore, Bedford, MA) Water Purification system provided purified 
deionized water. All other chemicals used were analytical grade. 
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2. 3.2 Instrumentation and chromatographic conditions  
The HPLC (Agilent Technologies, Mississauga, ON) system consisted of a Series 1200 
quaternary pump (G1311A) with online degasser (G1322A), autosampler (G1329A), and 
fluorescence detector (G1321A). Processed samples (50 µL) were injected onto a Waters 
Symmetry C18 column (4.6 × 150 mm, 5 µm). The analytes were eluted under gradient mode 
with mobile phase consisting of water with 0.1 percent formic acid (component A) and 
acetonitrile with 0.1 percent formic acid (component B) in different ratios delivered at a flow rate 
of 1 mL/min.  Excitation wavelength was set at 277 nm and emission wavelength at 617 nm. The 
mobile phase was filtered through a 0.22 µm Nylon filter (Pall Scientific, Mississauga, ON) and 
degassed in an ultrasonic bath for 30 min prior to use. The column was maintained at room 
temperature (22°C) and washed with water:methanol (50:50) after every use. The potential for 
autosampler carry over was reduced by injection of blank mobile phase after the highest 
calibration curve concentration.For SDG the mobile phase gradient conditions consisted of an 
initial isocratic condition of 85:15 component A:component B from 0 – 12 min, an increasing 
gradient from 15 percent to 50 percent of component B from 12 – 14 min and then 50 to 90 
percent from 14 – 16 min, a decreasing gradient from 90 percent to 15 percent component B 
from 16 – 23 min, and a return to 85:15 component A:component B between 23-25 min. For 
SECO, ED and EL the gradient consisted of 85:15 component A:component B from 0 – 12, an 
increasing gradient from 15 percent to 50 percent component B and from 50 percent to 90 
percent between 12 – 14 min and then 90 percent between 14 –18 min, with a decreasing 
gradient from 90 percent – 15 percent component B from 18 – 20 min and a return to 85:15 
component A:component B between 20 – 25 min.  
 
2.3.3 Preparation of stock and working standard solutions 
Stock solutions (1 mg/mL) of the lignans and internal standards (umbelliferone and 
riboflavin) were prepared by initial dissolution in methanol followed by dilution with mobile 
phase (70 percent component A:30 percent component B for SECO, ED, EL and umbelliferone; 
80 percent component A:20 percent component B for SDG and riboflavin). Working solutions of 
the lignans (0.1 µg/mL – 100 µg/mL) were prepared by serial dilution of the stock solution with 
mobile phase while working solutions of the internal standard were prepared by a single dilution 
of the stock solution to a concentration of 100 µg/mL. Quality control samples were prepared in 
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a similar manner by a different analyst to achieve working stock solutions (as per USFDA 
guidelines) at the low quality control (LQC) (3-fold the lower limit of quantification (LLOQ)), 
middle quality control (MQC) and high quality control (HQC) (80 percent of the upper limit of 
quantification). These stocks were stored at -20±5°C, and used to prepare standard curve samples 
on the day of analysis. The stock solutions were stable up to 30 days (data not shown).  
    
2.3.4 Preparation of calibration curve samples and quality control (QC) samples 
Calibration curve samples were prepared on each day of analysis by adding 10 µL of 
individual working solutions to 90 µL of pooled rat blank serum (see section 2.7) with vortex-
mixing for 30 seconds. For the quality control samples a separate analyst added the appropriate 
volume of working solutions into pooled rat serum in bulk on the first analysis day and these 
samples were then individually aliquoted into polypropylene microcentrifuge tubes (disposable 
conical economy micro tubes with snap caps, 2 mL volume, Catalog No. 14231-064, VWR 
Mississauga, ON) and stored at -80±5°C in the dark until analysis.  
 
2.3.5 Sample preparation 
For SECO, ED and EL, 10 µL of umbelliferone (internal standard) solution (100 µg/mL) 
was added to 100 µL of calibration standards, QC samples, or rat serum samples and vortex-
mixed for 10 sec. To all samples, 4 mL of diethyl ether was added, vortex-mixed for 10 minutes, 
and centrifuged at 4°C at 780 × g in an Eppendorf microcentrifuge (Model 5804A, Brinkmann 
Instruments, Westbury, NY). The aqueous layer was snap frozen using liquid nitrogen and the 
organic layer was transferred to glass tubes and evaporated to dryness under vacuum at 40°C in 
an evaporator (Centrivap Concentrator, Labconco Corporation, Kansas, MO). The residue was 
reconstituted in 100 µL of mobile phase, vortex-mixed for 2 minutes, transferred to HPLC vials 
and 50 µL was injected onto the column. 
For SDG, 10 µL of riboflavin (internal standard) solution (25 µg/mL) was added to 100 µL 
of calibration standards, QC samples, or rat serum samples and briefly vortex-mixed. Samples 
were transferred to centrifuge filters (Modified PES 10K, 500 µL, VWR International, 
Mississauga, ON) and centrifuged at 13,300 × g in a microcentrifuge (Accuspin Micro17 
centrifuge, Fisher Scientific Canada, Ottawa, ON) for 30 min. The filtrate was transferred to 
HPLC vials and 50 µL of sample was injected onto the column.  
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Recovery was determined at LQC, MQC and HQC. The peak areas of post-extracted or 
post-filtered serum samples were compared with those obtained from unextracted LQC, MQC 
and HQC samples prepared in mobile phase. 
 
2.3.6 Validation procedures  
A complete validation for the assay of SDG, SECO, ED and EL in rat serum was 
performed in accordance with USFDA guidelines (303). Specificity was assessed by analysis of 
serum from six different rats to determine the absence of endogenous substances with similar 
retention times to the lignans and internal standards.  
The limit of detection (LOD) was the lowest detectable concentration with a signal-to-
noise ratio of 3. Lowest Limit of quantification (LLOQ) was determined at the lowest 
concentration that gave precision and accuracy values within 20% of the mean and nominal 
values, respectively. The LOQ was the lowest concentration on the calibration curve and the 
linearity from LLOQ to 10,000 ng/mL was assessed by processing a ten-point calibration curve 
on several different days. The ratio of peak areas of the analytes and internal standards were 
plotted against the nominal concentrations of the calibration curve samples. A linear least-
squares regression analysis, using 1/X2 as weighting factor, was conducted to determine slope, 
intercept and coefficient of determination (r2) to demonstrate linearity of the method. Calculated 
concentrations of the calibration curve samples had no more than ±15 percent deviation from 
nominal concentration, except at LLOQ which was less than ±20 percent. 
The intra- and inter-day precision and accuracy of the method was determined by 
analyzing six replicates at each of LLOQ, LQC, MQC, and HQC on three different days. 
Precision was expressed as percent relative standard deviation (RSD) with acceptance criteria of 
RSD ±15 percent at each concentration except at LLOQ, which was allowed RSD±20 percent. 
Accuracy (percent) was expressed as [(calculated amount/predicted amount) x100] with 
acceptance set at ±15 percent of the nominal concentrations of QC samples except at LLOQ, 
where it was set at ±20 percent.  
Stability studies included freeze/thaw stability, bench top stability, and long-term stability, 
which were performed at LQC, MQC, and HQC, and autosampler stability was tested at these 
concentrations but also included LLOQ. Freeze/thaw stability was tested after three freeze/thaw 
cycles space at least 24 hours apart with sample storage at -80 °C between each thaw. Bench top 
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stability was established at room temperature for SDG and on ice for SECO, ED and EL for 6 
hours. To determine autosampler stability, processed samples were maintained in the 
autosampler for at least 24 hours prior to injection. Predicted concentrations were calculated 
using fresh calibration curve standards. Long-term stability was assessed after 30 days of storage 
at -80±5°C. 
 
2.3.7 Application to a pharmacokinetic study in rat 
An in vivo intravenous pharmacokinetic study was performed in male Wistar rats (N = 4, 
weight range 250–300 g and age range 7-9 weeks) obtained from the Animal Resources Centre 
(ARC), University of Saskatchewan, Canada to demonstrate the applicability of the validated 
bioanalytical method. SECO was administered intravenously at a dose of 20 mg/kg in a 
parenteral formulation consisting of PEG 300, Tween 80, benzyl alcohol, and ethanol in a 
65:8:3:24 (v/v) mixture. Femoral and jugular veins were surgically cannulated under isoflurane 
anaesthesia for administration of SECO and for blood sampling, respectively, 24 hours prior to 
SECO dosing. Blood samples (250 µL) were collected into polypropylene microcentrifuge tubes 
(disposable conical economy micro tubes with snap caps, 2 mL volume, Catalog No. 14231-064, 
VWR Mississauga, ON) at 0-12 h post-dosing. Blood was allowed to clot at room temperature 
for 30 min and serum was collected following centrifugation at 5000 × g for 10 min at 4°C and 
stored frozen at –80 ± 5°C until analysis. Rat serum (100 µL) samples were spiked with 
umbelliferone and processed as described above, and the analysis run was accepted based on the 
performance of QC samples. The criteria for acceptance of the analytical runs encompassed the 
following: (i) not more than 33percent of the QC samples were greater than ±15 percent of the 
nominal concentration (ii) not less than 50 percent at each QC concentration level must meet the 
acceptance criteria. The animal protocol for the pharmacokinetic analysis of SECO was 
conducted in accordance with Canadian Council of Animal Care (CCAC) guidelines and 
approved by University Committee on Animal Care and Supply at the University of 
Saskatchewan. 
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2.3.8 Data and statistical analysis 
A Student t-test was used to determine whether slopes and intercepts of the calibration 
curves were significantly different from zero using Prism 4.0 (GraphPad Prism, San Diego, CA, 
USA). The level of significance was set at P<0.05. Noncompartmental pharmacokinetic (PK) 
analysis for SECO was performed using WinNonLin 4.1 (Pharsight Inc, Mountain View, CA). 
 
2.4 Results and discussion 
This HPLC method with fluorescence detection represents a relatively simple and rapid 
bioanalytical technique for the major plant lignan, SDG, and its major metabolites SECO, ED 
and EL, using a widely available pharmaceutical analysis technology. Although the advantage of 
analytical sensitivity afforded by LC-MS analysis is indisputable, its lack of widespread 
availability limits pertinent evaluations of lignan pharmacology in mammalian systems. Our 
relatively straightforward and reasonably sensitive HPLC method for the analysis of lignans 
derived from flaxseed offers significant advantages in terms of sensitivity and ease of selectivity, 
sample preparation, and lower volume of sample requirements as compared to previously 
reported HPLC methods (187, 301), which should allow for enhanced investigations into lignan 
pharmacology.  
Many of the reported methods describe quantification of flaxseed lignans from flaxseed 
(300, 304, 305) or flax products (304, 306, 307). A fewer number report methods for lignan 
quantification in human or rat biological matrices (187, 308). Some of these methods use the less 
widely available LC-MS technology for quantification of ED and EL (187).These methods do 
not describe the quantification of SDG or SECO, thereby limiting their application for 
assessments of the major lignan form of flaxseed (SDG) and its relevant metabolites (SECO, EL, 
ED). Nurmi et al. achieved very sensitive detection limits for the quantification of 
secoisolariciresinol, enterodiol and enterolactone in human plasma using coulometric electrode 
array detection, but the accuracy of the method was only 69% for ED and SDG was not included 
in the analysis (309). Gamache et. al. used HPLC with coulometric assay to quantify ED and EL 
in rat plasma and human urine with a low LOD, but SDG and SECO was not included in the 
analysis (310). In general, the reported methods for quantification of lignans in biological 
matrices fail to allow the simultaneous estimation of all major metabolites of SDG produced in 
vivo. Our current method simultaneously quantifies all major metabolites of SDG in rat serum 
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using low sample volumes (0.1 mL), which is necessary to permit serial blood sampling and the 
pharmacokinetic characterization of lignans in rat. Our method also quantifies SDG using 
slightly different extraction methods and mobile phase conditions.  
Given the widely divergent physicochemical properties of the lignans, the use of two 
different extraction procedures and elution conditions was inevitable. With the two glucose 
moieties, SDG is a highly polar compound compared to its aglycone form, SECO, and the 
mammalian lignans, ED and EL. Although we attempted to establish a consistent mobile phase 
gradient condition and extraction method suitable for all relevant lignans derived from flaxseed, 
unacceptable run times, interfering endogenous peaks and poor extraction efficiencies thwarted 
these efforts. Hence, SDG requires analysis separate from SECO, ED and EL. Despite this 
disadvantage, though, our method does offer a suitably sensitive analytical alternative to LC-MS 
methods. 
 
2.4.1 Method validation  
Figure 2.2 presents representative HPLC chromatograms of lignans and their respective 
internal standards spiked into rat serum. The chromatograms demonstrate that The method is 
specific with the absence of endogenous peaks that co-elute with the lignans and internal 
standards. The chromatographic conditions used for the analysis gave retention times for 
riboflavin (internal standard) and SDG of 4.3 min and 6.8 min respectively, while retention times 
for umbelliferone (internal standard), SECO, ED, and EL, retention times were 7.0, 7.9, 9.4 and 
12.3, respectively. Absolute recovery of SDG was 83.4±10.7, 99.0±1.9 and 95.3±1.1 percent at 
LQC, MQC and HQC, respectively, and recovery for riboflavin at 2.5 µg/mL was 85.0±3.0 
percent. The absolute recovery of SECO was 87.7±9.4, 91.6±9.3 and 93.7±3.3 percent at LQC, 
MQC and HQC, respectively. The recovery of ED was 91.2±5.8, 95.6±5.2 and 90.2±7.0 percent 
at LQC, MQC and HQC, respectively, and the recovery of EL was 88.2±12.8, 84.7±5.8 and 
80.2±13.0 percent at LQC, MQC and HQC, respectively. The recovery of umbelliferone at 10 
µg/mL from rat serum was 94.0 ± 6.0 percent. 
The limit of detection (LOD) for SDG, SECO, ED and EL was 16.6, 3.3, 3.3 and 16.6 
ng/mL respectively, and the lowest limit of quantification (LLOQ) was 50, 10, 10, and 50 
ng/mL, respectively. The method was linear over a concentration range of 10 – 10,000 ng/mL for 
SECO and ED, and 50 – 10,000 ng/mL for SDG and EL with coefficient of determination values 
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greater than 0.997 for all calibration curves. The relevant slope values and coefficients were 
statistically different from zero (p < 0.05). The average percent accuracy across different 
standard concentration levels varied from 93.6-104.6 for SDG and 93.4-109.6 for SECO, ED and 
EL, while average percent coefficient of variation (CV) ranged from 1.21-3.93 for SDG and 
from 0.18-13.04 for SECO, ED and EL (data not shown).  
Tables 2.1 and 2.2 summarize the intra- and interday precision and accuracy data. Overall 
intraday and interday precision evaluations gave CV values of less than 13.3 percent and 
accuracy was within 10 percent of the nominal values. This data suggest the method is both 
accurate and precise in rat serum. 
Table 2.1:Intraday assay precision and accuracy for SDG, SECO, ED and EL in rat serum (N = 
6) 
QC 
Levels* Precision
a Accuracyb 
 SDG SECO ED EL SDG SECO ED EL 
LLOQ         
  (Day-1) 6.5 8.0 11.6 7.4 91.1 96.8 87.4 94.1 
  (Day-2) 3.5 9.6 5.7 5.8 86.2 91.5 84.9 93.6 
  (Day-3) 13.3 4.5 6.1 7.4 101.4 99.9 99.6 89.9 
LQC         
  (Day-1) 2.4 5.6 2.0 2.9 96.8 104.3 89.0 100.0 
  (Day-2) 3.7 5.3 3.2 5.3 90.2 95.8 89.8 101.8 
  (Day-3) 4.6 8.6 4.4 5.7 100.9 100.6 97.3 89.5 
MQC         
  (Day-1) 2.5 4.2 3.9 4.2 100.0 107.2 101.3 105.0 
  (Day-2) 3.6 4.5 3.6 3.9 98.4 93.3 100.7 102.8 
  (Day-3) 5.1 5.5 5.3 4.4 98.7 95.8 104.2 89.5 
HQC         
  (Day-1) 3.4 1.4 1.3 1.1 100.5 104.3 89.9 94.8 
  (Day-2) 4.8 1.6 1.6 1.3 104.2 90.8 90.4 97.2 
  (Day-3) 3.9 4.0 4.6 4.7 98.8 103.9 103.2 88.5 
aExpressed as percent R.S.D. ( (S.D./mean) × 100 % ). 
bCalculated as (mean determined concentration/nominal concentration) × 100%. 
*LLOQ for SDG and EL 50ng/mL and for SECO and ED is 10 ng/mL; LQC for SDG and EL is 
150 ng/mL and for SECO and ED is 30 ng/mL; MQC is 4000 ng/mL and HQC is 8000 ng/mL 
for all four lignans. 
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Figure 2.2: Representative HPLC chromatograms of rat blank serum for SECO (10 µg/mL), ED 
(10 µg/mL) and EL (10 µg/mL) (A), rat serum spiked with Umbelliferone (10 µg/mL), SECO, 
ED and EL (B), rat blank serum for SDG (C), and rat serum spiked with Riboflavin (2.5 µg/mL) 
(IS) and SDG (10 µg/mL) (D).  
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Table 2.2: Interday assay precision and accuracy for SDG, SECO, ED and EL in rat serum (N = 
6). 
QC 
Levels* Precision
a Accuracyb 
 SDG SECO ED EL SDG SECO ED EL 
LLOQ 9.6 8.0 10.6 7.3 87.3 96.1 90.6 92.7 
LQC 5.9 7.2 5.3 6.3 96.0 100.2 92.1 96.6 
MQC 3.7 7.7 4.4 8.6 99.1 98.7 102.3 99.8 
HQC 4.5 7.0 7.4 4.1 101.1 99.7 94.4 92.7 
aExpressed as % R.S.D.  ((S.D./mean) × 100 %). 
bCalculated as (mean determined concentration/nominal concentration) × 100 %. 
*LLOQ for SDG and EL 50ng/mL and for SECO and ED is 10 ng/mL; LQC for SDG and EL is 
150 ng/mL and for SECO and ED is 30 ng/mL; MQC is 4000 ng/mL and HQC is 8000 ng/mL 
for all four lignans. 
 
 The stability of lignans derived from flaxseed was established in rat serum under 
different storage conditions that included bench top (6 hour) and autosampler (24 hour) stability 
at room temperature freeze/thaw (3 cycles) stability, and 30 day storage at -80°C stability. These 
were assessed at three different quality control levels and our data suggest that the lignans were 
stable in the auto-injector for 24 h, up to three freeze-thaw cycles, on the bench top for 6 hours at 
room temperature for SDG and on ice for SECO, ED and EL, and for 30 days with storage at -
80±5°C. SECO, ED and EL were not stable on the bench top for 6 hours. 
 
2.4.2 SECO pharmacokinetics following intravenous bolus injection  
To demonstrate applicability of this method, a pharmacokinetic analysis of SECO was 
performed following a bolus intravenous injection. All QC samples met the acceptance criteria 
(data not shown). The mean serum SECO concentration versus time profile is shown in Figure 
2.3. Systemic clearance (Cls) for SECO was 8.0 ± 1.9  L/hkg, elimination rate constant (k) was 
0.20 ± 0.10 h-1and half life (t1/2) was 4.1 ± 1.5 h. Volume of distribution (Vd) for SECO was 45.0 
± 11.7 L/Kg and area under curve (AUC0-∞) was 2.6 ± 0.6 h*µg/mL.  The sensitivity and 
specificity of the assay were found to be sufficient for accurately characterizing the 
pharmacokinetics of SECO following an intravenous bolus injection. The single ED 
determination was likely due to enterohepatic recirculation as SECO becomes conjugated in the 
liver to glucuronide and sulfate metabolites, which are subsequently excreted into the 
gastrointestinal lumen (290). Deconjugated and unabsorbed SECO, which becomes available in 
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the colon, undergoes bacterial metabolism to the mammalian lignans, which are subsequently 
absorbed and also undergo extensive conjugation by the gastrointestinal mucosa and liver (28).  
Treatment of serum samples with b-glucuronidase/sulfatase would likely result in the 
quantification of much higher levels of SECO, ED and EL as the glucuronic acid and sulfate 
moieties become removed making the parent form available for analysis. The highly polar nature 
of the glucuronic acid and sulfate conjugates would result in their rapid elution during 
chromatographic separation under the mobile phase conditions required for SECO, ED and EL 
analysis. 
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Figure 2.3: Log Mean ± SD serum concentration versus time profile of secoisolariciresinol 
(SECO) (•) and enterodiol (ED) ( ) following an intravenous bolus administration of SECO (20 
mg/kg) to male Wistar rats (N = 4). 
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2.5 Conclusion 
With the growing interest in flaxseed lignans and their association with a variety of health 
benefits, including prevention of cancer, cardiovascular diseases and hyperlipidemia, availability 
of a more widely accessible analytical method is necessary to improve our understanding of 
lignan pharmacology. The currently available HPLC methods tend to lack analytical sensitivity 
or accuracy, may require large sample volumes, or fail to report the simultaneous determination 
of all SDG metabolites, while the existing LC-MS analytical methods have more restricted 
accessibility to research laboratories. Our HPLC-fluorescence detection method is relatively 
simple and provides reasonable analytical sensitivity for the simultaneous quantification of the 
major metabolites of SDG, the principal lignan of flax. This method should be suitable for a 
complete pharmacokinetic analysis of lignans in suitable animal model species with possible 
extension to human clinical trial evaluations.  
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Relation of this manuscript to the thesis: 
Intestinal permeability and metabolism are major factors in the intestinal absorption and 
bioavailability of drugs. Caco-2 is one of the widely used in vitro systems for the determination 
of permeability and intestinal metabolism due its similarity with human intestine. This 
manuscript discusses the extent of permeability and conjugative metabolism of flaxseed lignans 
which helped us to understand the absorption of flaxseed lignans.   
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CHAPTER 3 
 
Permeability and Conjugative Metabolism of Flaxseed Lignans by Caco-2 
Human Intestinal Cells 
 
3.1 Abstract 
To enhance our understanding of the oral absorption of flaxseed lignans we evaluated intestinal 
permeation and phase II metabolism of lignans using Caco-2 cells grown on Transwell® 
supports. For permeation studies, lignans (100 µM) were added to acceptor or donor 
compartments and samples were taken at 2 hours. For metabolism studies, lignans (100 µM) 
were incubated in Caco-2 for maximum 48 hours. Cell lysates and media were treated with β-
glucuronidase/sulphatase and lignan concentrations determined using HPLC. Apical-to-basal 
permeability coefficients for secoisolariciresinol (SECO), enterodiol (ED), and enterolactone 
(EL) were 8.0±0.4, 7.7±0.2 and 13.7±0.2 (×10-6) cm/s, respectively, whereas efflux ratios were 
0.8-1.2 consistent with passive diffusion. Secoisolariciresinol diglucoside (SDG) permeation was 
not detected. Extent conjugation after 48 h was <3%, 94.6%, 90% and >99% for SDG, SECO, 
ED and EL, respectively. These data suggest SDG metabolites, SECO, ED and EL, but not SDG 
undergoes passive permeation and conjugative metabolism by intestinal cells. 
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3.2 Introduction  
Plant polyphenolic compounds continue to receive prominent attention for their positive 
health benefits in a number of chronic disease states (311). Such attention has intensified 
research to confirm efficacy and to elucidate the mechanisms underlying their bioactivity in 
chronic disease. Lignans, a class of diphenolic compounds widely distributed in the plant 
kingdom (287), have generated particular interest due to their ability to favourably modulate 
biological risk factors of cardiovascular disease and cancer (1, 312). Flaxseed is a rich source of 
the lignan secoisolarisiresinol diglucoside (SDG) (288), and human clinical trials and animal 
model studies have reported important beneficial cardiovascular effects of flaxseed lignan 
supplementation such as improvement in blood lipid profiles (94, 97), reduction in the 
development of aortic atherosclerosis (313), and delayed onset of type II diabetes (314). 
Furthermore, several studies suggest a protective role for flaxseed lignans against cancers of the 
breast, prostate and colon (315).  
In the flaxseed, SDG exists as an oligomer with ester linkages to 3-hydroxy-3-
methylglutaric acid, cinnamic acid, and with other phenolic glucosides (316). Following oral 
consumption, the glucosidic groups are cleaved from SDG to yield the aglycone form, 
secoisolariciresinol (SECO), in the upper gastronintestinal tract. SECO can be subsequently 
metabolized by the colonic microflora to the mammalian lignans, enterodiol (ED) and 
enterolactone (EL) (287). Although the literature attempts to draw an epidemiological 
association between EL and the positive health effects of flaxseed consumption (82), it still 
remains controversial whether plant derived lignans (i.e. SDG, SECO) and/or the mammalian 
lignans (i.e. EL, ED) mediate the putative health benefits associated with flaxseed lignan 
consumption (296). Hence, knowledge of the biological fate of orally ingested lignans is a 
prerequisite to an understanding of their role in protection against or mitigation of chronic 
diseases. 
A limited number of studies report pharmacokinetic information on flaxseed lignans (317-
319). Oral administration of purified SDG (0.9 mg/kg ) to twelve healthy volunteers showed 
Cmax values of 22.1 and 16.7 ng/mL for enterolignans in plasma at 14.8 and 19.7 h, respectively 
and Area under the curve (AUC) of ED and EL was 292.1 and 525.8 ng.h/mL, respectively 
(320). Single oral dose studies with purified SDG or SECO indicate that urinary excretion of ED 
and EL and their metabolites constitute a minor percentage of the total administered lignan 12-24 
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h post dose with enhanced excretion by 48 h (161). SECO and its metabolites were identified in 
urine and at levels lower than the mammalian lignans, but SDG was not detected (321). 
Furthermore, oral administration of EL resulted in a small recovery of EL in the urine of rats 
(322). With prolonged oral dosing of SDG or SECO, EL and its phase II metabolites become the 
main lignan excreted in the urine (323). Although renal excretion of lignans and lignan 
metabolites occurs to some extent, several studies indicate that fecal excretion is the most 
significant elimination route for both the plant derived and mammalian lignans (324) This may 
suggest poor bioavailability of both the plant derived (particularly SDG) and mammalian lignans 
either due to poor permeation characteristics or extensive first pass metabolism (290).  
Lignans undergo phase II conjugative metabolism (glucuronidation and sulfation) and the 
major circulating forms are the lignan conjugates of glucuronic acid or sulfate which undergo 
enterohepatic recirculation (195). Most in vitro studies with rat and human hepatic microsomes 
demonstrate biotransformation of plant derived and mammalian lignans to a number of aromatic 
and aliphatic oxidative metabolites (325). However, only small amounts of oxidative metabolites 
of lignans were detected in the urine of humans and rats suggesting that cytochrome P450 
mediated metabolism plays a very minor role in lignan metabolism (321). Consequently, 
knowledge of first-pass metabolism by phase II conjugative reactions will be critical to an 
understanding of the biologically active lignan form.  
To mediate their putative biological activity, lignans must first undergo absorption across 
the gastrointestinal barrier and subsequent delivery to the target tissues. Permeation across the 
intestinal epithelial barrier and conjugative metabolism within the intestinal epithelium are two 
important processes that can influence the oral bioavailability of lignans. Preliminary 
information concerning the intestinal permeation and metabolism of lignans can be acquired 
using the Caco-2 cell culture model. Permeability estimates derived from this useful, predictive 
in vitro model of intestinal absorption and metabolism (326) often correlate well with oral drug 
absorption characteristics in humans (50). This in vitro system also has been used to characterize 
the intestinal absorption and metabolism characteristics of other plant polyphenols such as the 
flavonoids and their glycosides (327). Hence, the purpose of this study was to evaluate the 
permeation characteristics of the plant derived lignans, SDG and SECO, and the mammalian 
lignans, EL and ED, and to characterize the extent of phase II conjugative metabolism by the 
Caco-2 absorption model. This information would provide insight into the oral bioavailability of 
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each lignan and the possible bioactive lignan form associated with the positive health benefits of 
flaxseed lignan consumption. 
 
3.3 Materials and Methods  
3.3.1 Chemicals, reagents and Caco-2 Cells 
SDG and SECO (>95% purity) were kind gifts from Agriculture and Agri-Food Canada, 
Saskatoon (Dr. Alister Muir). β-Glucuronidase/sulphatase Type H-5 from Helix pomatia (G-
1512), ED, EL and sodium acetate were purchased from Sigma-Aldrich Canada Ltd. (Oakville, 
ON). Caco-2/TC-7 human colon adenocarcinoma cells were obtained as a kind gift from Dr. 
Wolfgang Koester (Vaccine and Infectious Disease Organization, University of Saskatchewan, 
Canada). Dulbecco’s Modified Eagle’s Medium (DMEM), Transwell® plates, polyethylene 
inserts (6.5 mm diameter, 0.4 µm pore size), and 24-well tissue culture plates were purchased 
from Fisher Scientific (Toronto, ON). Phosphate buffered saline (PBS), fetal bovine serum 
(FBS), trypsin, versene and non-essential amino acids (NEAA) were obtained from Invitrogen 
(Burlington, ON). Umbelliferone (7-Hydroxycoumarin) and riboflavin were purchased from 
Sigma-Aldrich Canada. HPLC grade acetonitrile was purchased from Fisher Scientific. Methanol 
was purchased from Caledon Laboratories (Georgetown, ON). All other chemicals unless 
mentioned were obtained from Sigma-Aldrich Canada. A MilliQ Synthesis Water Purification 
system (Millipore, Bedford, MA) provided purified deionized water. All other chemicals used 
were of analytical grade. A Millicell ERS system for the measurement of transepithelial 
electrical resistance (TEER) values was purchased from Millipore (Billerica, MA).   
 
3.3.2 Cell culture 
 Caco-2 cells derived from human colon adenocarcinoma were used as a model for small 
intestinal mucosal epithelium to investigate the permeation and metabolism of flaxseed (SDG 
and SECO) and mammalian (ED and EL) lignans. Caco-2 cells with passage number 41-54 were 
grown in DMEM containing 10 percent FBS and 1 percent NEAA. Cells were grown at 37°C 
under 95% O2 and 5% CO2. Caco-2 cells were subcultured using 0.25% trypsin in versene for 
cellular detachment and Caco-2 cells (1×105 cells/well) were seeded on polyester membrane 
Transwells (PET) and 24 well tissue culture plates for permeability and phase-II conjugative 
metabolism studies, respectively. Media was replaced in apical and basal compartments of the 
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Transwells (PET) (Corning Life sciences, 24 well format, 6.5 mm diameter, pore size of 0.4 µm 
and pore density of 4×106 pores/cm2, membrane thickness of 1 µm) and 24 well plates three 
times per week. Monolayers were formed on polyester (PET) membrane Transwells.  
Experiments with Caco-2 cells except cytotoxicity assay were conducted after 21 days in culture. 
 
3.3.3 Cytotoxicity assay 
Cytotoxicity of flaxseed (SDG and SECO) and mammalian lignans (ED and EL) in Caco-2 
cells was determined using the sulforhodamine B (SRB) assay (328). Caco-2 cells were grown in 
T-75 flasks using suitable growth media which were replaced three times in a week (growth Area 
of 75cm2, vented caps and straight neck, Fisher scientific (Toronto, ON, Canada)). Trypsin 
(0.25% in versene) and trypan blue dye were used to harvest and count the cells in an 
exponential phase. Complete media (100 µL) containing about 5×103 cells were transferred in 
each well of 96 well plates and were allowed to attach and grow for 24 h. After 24 h, complete 
media (100 µL) containing different lignans (10-500 µM) in HBSS and control (1% DMSO) was 
added to cells containing media and incubated for 72 h. After 72 h, trichloroacetic acid (50 µL of 
50% w/v in water) was added to each well and placed at 4°C for 1 h for fixation of the cells. One 
96 well plate was fixed at start of the experiment to determine the number of cells present in the 
96 well plates at the beginning of the experiment (Tz). Plates were washed with tap water four 
times and allowed to air dry over night. Staining of the cells was done using sulforhodamine 
(0.4% w/v in 1% v/v acetic acid) and washed with acetic acid (1% v/v). Trizma base (200 µL of 
10 mM) was added to dried wells and absorbance was read at 515 nm. The percent growth was 
calculated using equation 3.1 where optical density (OD) indicates absorption. The IC50 was 
derived by fitting four parameter logistic curves (non linear regression analysis) between percent 
cell growth and log concentration using GraphPad Prism 5.0 for windows (GraphPad Software, 
San Diego, California, USA).  
 
%	݈݈ܿ݁	݃ݎ݋ݓݐ݄ ൌ ை஽ೞೌ೘೛೗೐షை஽೅೥ை஽೎೚೙೟ೝ೚೗షை஽೅೥ ൈ 100     Equation 3.1 
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3.3.4 Lignan permeability assay 
A stock solution (10 mM) of SDG was prepared in HBSS and stock solutions (10 mM) of 
SECO, ED and EL were individually prepared using 1 percent DMSO in HBSS for permeability 
studies. Stock solution preparation and dilutions were performed under sterile conditions. On the 
day of the permeability assessment, cells were washed three times with HBSS (100µL) with 10 
mM HEPES buffer, pH 7.4. Monolayers were equilibrated at 37°C for 30 min before 
measurement of TEER values of each well using the Millicell ERS system (329). Working stock 
(100 µM) solutions of SDG, SECO, ED and EL were added separately to apical (200 µL) or 
basolateral (600 µL) compartments of the Transwells, and further incubated at 37°C, 95% O2 and 
5% CO2 for 2 hours. At the end of incubation period, samples were collected from both 
compartments and stored at -20°C until further HPLC analysis. After sample collection, cells 
were again washed three times with HBSS containing 10 mM HEPES (pH 7.4) and equilibrated 
with this solution for 30 minutes before measurement of post assay TEER. Lucifer yellow (a 
marker for paracellular flux) in HBSS was added to the apical compartment of each transwell 
and incubated under the same conditions for 1 hour. Fluorescence levels in the basal 
compartment (Excitation 485 nm and Emission 535 nm) were determined using a Biotek 
Synergy HT microplate reader (Fisher Scientific, Nepean, ON). The lucifer yellow rejection rates 
and post assay TEER values were used as the parameters to ensure monolayer integrity during 
the experiment.  
Apparent Permeability Coefficients (Papp) and Efflux ratios (EFR) were calculated for 
apical to basolateral (A to B) and basolateral to apical (B to A) directions following quantitative 
determination of lignans by HPLC. Calculations are based on the following equations as 
described: 
௔ܲ௣௣ ൌ ௗொௗ௧ ൈ
ଵ
஺೘ ൈ
ଵ
஼బ        Equation 3.2 
 
ܧܨܴ ൌ ௉ೌ೛೛	ሺಳషಲሻ௉ೌ೛೛	ሺಲషಳሻ        Equation 3.3 
 
Where,ௗொௗ௧   = rate of permeation, A୫ = surface area of monolayer, C଴= initial concentration in 
donor compartment.  
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In vivo intestinal permeability in human (Peff,man) was calculated using equation 3.4 (330) 
and fraction of drug absorbed (Fa) was predicted using equation 3.5 (331). 
 
ܮ݋݃൫ ௘ܲ௙௙,௠௔௡൯ ൌ 0.4296 ൈ ݈݋݃൫ ௔ܲ௣௣,஼௔௖௢ିଶ,௣ு଻.ସ൯ െ 0.1434    Equation 3.4 
 
ܨ௔ ൌ 1 െ ൫1 ൅ 0.54 ൈ ௘ܲ௙௙,௠௔௡൯ି଻        Equation 3.5 
 
Where, Papp,Caco-2,pH 7.4  =  apparent permeability in Caco-2 cells at pH 7.4 and Fa is the fraction of 
drug absorbed.  
 
3.3.5 Conjugation of lignans in Caco-2 cells 
After 21 days of culture, Caco-2 cells were washed three times with HBSS containing 10 
mM HEPES buffer, pH 7.4. SDG, SECO, ED or EL stock solutions (10 mM) and working 
solutions (100 µM) were prepared in DMEM. 700 µL of each lignan working stock solution was 
added in triplicate to the 24 well plates and incubated at 37°C, 95% O2 and 5% CO2 for 48 hours. 
Supernatant and cell pellets were collected at 0, 2, 4, 6, 12, 24, and 48 h in triplicate from 24 well 
plates. Supernatant was transferred to 2 mL polypropylene centrifuge tubes. Cold PBS (4°C, 200 
µL) was added to the cell layer and culture plates were subsequently scraped with rubber 
policeman to collect residual cells. Cell suspensions were centrifuged at 76 × g (Eppendorf 
Centrifuge 5804 R, Mississauga, ON) at 4°C for 5 min. Following centrifugation, cells were 
stored at -20°C without disturbing cell pellets until enzymatic hydrolysis. 
A preparation containing both β-glucuronidase and sulfatase from the snail H. Pomatia 
was used for enzymatic hydrolysis of samples after incubating for different time points up to 48 
h. 100 µL of 0.1 M sodium acetate buffer (pH 5.0) containing 0.66 mg of β-glucuronidase and 
sulfatase H-5 was added to 100 µL of sample. Samples were mixed briefly and incubated at 37°C 
for 2 h. Samples were then cooled to room temperature and 200 µL of acetonitrile was added. 
Samples were vortex mixed for 5 min and centrifuged at 2300 × g for 10 min. Supernatant was 
transferred to centrifuge tubes and filtered through 0.2 µm filters and analyzed by HPLC. Results 
are presented as percentage of lignan as free (before enzymatic hydrolysis) and total (after 
enzymatic hydrolysis) relative to zero time control. 
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3.3.6 HPLC analysis 
Samples from the permeability and conjugative metabolism experiments were analyzed 
using an HPLC method as reported (332). Briefly, for SDG, 10 µL of riboflavin (internal 
standard) (25 µg/mL) was added to 100 µL of calibration standards, quality control samples and 
samples from the permeability (both apical and basolateral) and conjugative metabolism assays 
and vortex-mixed. For SECO, ED and EL, 10 µL of umbelliferone (internal standard) (100 
µg/mL) was added to all samples as described for SDG above. Samples (100 µL) were 
transferred to HPLC vials and 50 µL of sample was injected onto the column. Gradient mobile 
phase conditions were used for isolation of SDG separately and for SECO, ED and EL using 
acetonitrile (containing 0.1 % formic acid) and water (containing 0.1 % formic acid) at a flow 
rate of 1 mL/min. An excitation wavelength of 217 nm and an emission wavelength of 677 nm 
was used; the total run time was 25 min. Standard curves were constructed from 0.01 µg/mL to 
10 µg/mL for SECO and ED and 0.05 µg/mL to 10 µg/mL for SDG and EL using weighted 
linear regression (with 1/X2 weighting factor). 
 
3.3.7 Statistical analysis 
 All experiments had a minimum of three independent observations for each test group. 
Data were expressed as mean ± SD where applicable. Comparison of means between two groups 
was performed using independent student’s t-test. Comparison of means between more than two 
groups was performed using one way analysis of variance (ANOVA) along with Dunnett’s post 
hoc test. A Student t-test was used to determine whether slopes and intercepts of the calibration 
curves were significantly different from zero using Prism 4.0 (GraphPad Prism, San Diego, CA, 
USA). The level of significance was set at P<0.05. The graphs were drawn using base package in 
R version 2.13.1 (R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-
0, URL http://www.R-project.org/) (333). 
 
3.4 Results 
3.4.1 Cytotoxicity of lignans to Caco-2 cells 
In order to assess the cytotoxicity potential of flaxseed (SDG and SECO) and mammalian 
lignans (ED and EL) to Caco-2 cells, we incubated these lignans individually with Caco-2 cells 
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up to 72 h. Flaxseed (SDG and SECO) and mammalian lignans (ED and EL) exhibited no 
significant decrease in the number of cells in comparison to the control (1% DMSO). 
 
3.4.2 Transepithelial transport of lignans across a Caco-2 monolayer  
We investigated bidirectional permeation of lignans across the Caco-2 monolayer was 
investigated to determine an apparent permeability constant and efflux ratio (Table 3.1). We first 
tested each lignan for linear transport rates and we determined that transport was linear up to 2 h. 
A preliminary study showed that lignans are stable (> 95 percent) in the test medium added to 
wells without cells and incubated for as long as 48 h. We could not calculate the apical-to-
basolateral and basolateral-to-apical permeation rates for SDG as SDG concentrations were 
below the level of quantitation of the HPLC assay in the respective recipient compartments. 
Efflux ratios of SECO, ED and EL were in the range of 0.8-1.2 (Table 3.1).  
 
Table 3.1: SDG, SECO, ED and EL transport across Caco-2 cell monolayer on Transwell® 
permeable inserts. Apparent permeability coefficients (Papp) from apical-to-basal (A to B) 
and from basal-to-apical (B to A) compartments, efflux ratio (EFR) and predicted fraction 
absorbed (Fa) are reported.   
Compound Papp(A to B) (×10-6) cm/s 
Papp (B to A) 
(×10-6) cm/s EFR ratio
a Predicted Fac 
SDG BLQb BLQb - - 
SECO 8.0± 0.4 9.5±0.4 1.2 0.90 
ED 7.7±0.2 8.9±0.6 1.2 0.90 
EL 13.7±0.2 10.6±0.5 0.8 0.94 
a The efflux ratio is defined as the quotient of the secretory permeability and the absorptive permeability (Papp,B 
to A /Papp,A to B)  
b Below limit of quantification 
c Formulae used in the prediction of Fa are: Fa=1-(1+0.54×Peff,man)-7 and log(Peff,man)=0.4926×log(Papp,Caco-2,pH 7.4)-
0.1434 (330, 331). 
 
3.4.3 Phase II enzyme metabolism of lignans in Caco-2 monolayers 
We assessed the extent of lignan glucuronidation and sulfation of lignans in the Caco-2 
monolayer was assessed for each lignan. Glucuronidase/sulfatase sensitive (phase-II) conjugates 
of flaxseed and mammalian lignans were detected up to 48 h (Figure 3.1). Cellular accumulation 
(intracellular concentration) of flaxseed (SDG & SECO) and mammalian (ED & EL) lignans was 
determined as well as intercellular (supernatant) accumulation. Limited conjugation of SDG was 
observed up to 48 h of incubation with Caco-2 cells, but SECO, ED and EL exhibited significant 
73 
 
conjugation (Figure 3.1). Hydrolysis of cell lysate and supernatant media with β-
glucuronidase/sulfatase enzyme exhibited less than 5% conversion of SDG into SECO and less  
 
 
Figure 3.1: Time course of total (closed circle), free (open circle) and conjugated (triangle) SDG, 
SECO, ED and EL (determined after enzymatic hydrolysis using β-Glucuronidase/sulphatase 
Type H-5 from Helix pomatia) in incubation medium of Caco-2 cells. Cells were incubated in 
triplicate with 100 µM lignans. Mean values with standard deviations are shown. 
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than 3% total conjugation. SECO and ED exhibited 95% and 90% conjugation in 48 h, 
respectively, while EL was completely conjugated within 12 h. The initial rate of conjugation 
was higher for EL as compared with SECO and ED. 
 
3.5 Discussion and conclusion 
Flaxseed contains significant levels of the lignan, SDG, which is known to undergo 
conversion to its aglycone, SECO, and further biotransformation to ED and EL following oral 
consumption. Animal models and human clinical trials using flaxseed lignan products have 
identified blood, urine and tissue levels of SECO, EL, and ED and their phase II metabolites but 
not of SDG. However, no study has specifically evaluated the intestinal permeability and the 
intestinal contribution of the intestine to phase II metabolism of SDG and its metabolites, SECO, 
ED and EL. The Caco-2 cell monolayer is widely used as an intestinal permeability screening 
assay to determine the principal transport mechanisms involved in intestinal absorption as well 
as to evaluate the phase II enzyme metabolism of compounds (334). With the objective to 
determine the effect of intestinal metabolism in the oral bioavailability of compounds, we 
elucidated the intestinal permeability and enterocytic metabolism of purified lignans using Caco-
2 cells in a hope to obtain important information about the bioavailability of these lignans. Our 
data suggest that the principal lignan of flaxseed, SDG, undergoes limited oral absorption, while 
its metabolites, SECO, ED and EL, permeate across the intestinal epithelium and exhibit 
appreciable conjugative metabolism by intestinal cells.  
We were unable to detect transepithelial transfer of SDG was not detected in the Caco-2 
cell monolayer system. Our findings are consistent with other polyphenolic glycosides (335), 
where transport across the intestinal epithelium may be limited by poor passive diffusion 
characteristics or a lack of substrate specificity for the various uptake transporters expressed in 
the intestinal epithelium. In our study, the apparent permeability coefficients of these SECO, ED 
and EL were 0.3-0.5 times of the apparent permeability of metoprolol (29.9±3.2 ×10-6 cm/s), a 
marker compound that separates drugs into high and low permeability class in the 
biopharmaceutical classification system (BCS) (336). With calculated efflux ratios of 0.8-1.2, 
which suggest the involvement of passive diffusion as the principal mechanism responsible for 
the transport of these lignans across the intestinal epithelium (127). Recently published research 
paper on cellular uptake of flaxseed lignans by During et al also suggest simple diffusion as a 
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mechanism of permeation (337).  SECO, ED and EL would be considered as compounds 
exhibiting low to moderate permeability at the intestinal barrier. Nonetheless, the predicted 
fraction of absorbed dose (Fa) of SECO, ED and EL in the intestine by the Compartmental 
Absorption and Transit (CAT) model was more than 90% (Table 3.1). The CAT model 
incorporates intestinal transit time, apparent permeability and radius of the small intestine to 
predict the fraction absorbed and therefore, a comparison based on Fa is more appropriate than 
the apparent permeability coefficients (330, 331). Given Fa values >90% as predicted by the 
CAT model, the SDG metabolites, SECO, ED, and EL, have the potential for complete 
absorption from the gastrointestinal tract.  
 The literature suggests the oral bioavailability of lignans is rather low and lignans are 
largely present as conjugates of glucuronic acid, and to a minor extent, sulfate (176). Oral 
bioavailability is often limited by extensive first pass metabolism by enzymes in the intestine and 
liver. Lignans are known to undergo phase II metabolism in the intestine. Axelson et al detected 
glucuronide conjugates of ED and EL in the portal vein after the oral administration of SDG in 
rats (27) and glucuronide and sulphate conjugates are detected in rhesus monkey and human 
hepatocytes, and in human serum and urine following oral lignan administration (183, 187). In 
our study the extent of glucuronidation of ED and EL in Caco-2 cells compared well with the 
values published by Jansen et al (324). SECO, ED and EL were extensively conjugated after 48 
hours, while SDG remain virtually unmetabolized in the Caco-2 system. The extent of 
conjugation corresponded to the order of their non-polarity (SDG<SECO<ED<EL). Similar 
extent of conjugation has been reported in recently published literature (337). Since metabolic 
enzymes are located intracellularly, compounds must cross the apical membrane of enterocytes 
to undergo phase II metabolism. EL exhibited the highest apparent permeability and predicted 
absorbed fraction, which may explain in part its greater extent of conjugation in the Caco-2 
monolayer. This data is similar to EL uptake and metabolism characteristics reported in HepG2 
liver cancer cell lines (338). Conversely, the poor permeability characteristics of SDG across the 
Caco-2 cell monolayer are consistent with its poor conjugative metabolism. 
Our studies with the Caco-2 cell monolayer indicate SECO, ED and EL undergo passive 
permeation across the small intestinal membrane and extensive intestinal phase II metabolism. 
SDG does not permeate across the monolayer and is not likely to be systemically available 
following oral administration. The ability of the Caco-2 cell monolayer to extensively metabolize 
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SECO, ED and EL indicates a role for the intestine in the presystemic metabolism of these 
lignans. Further studies are required to determine the oral bioavailability and the exact 
contributions of the intestine and liver to presystemic metabolism. Furthermore, glucuronide 
conjugates are pharmacologically inactive with a few exceptions (339), but the compelling 
evidence of health benefits associated with flaxseed lignan consumption coupled with our 
knowledge of their extensive phase II metabolism may warrant an investigation into the possible 
pharmacological activity of these conjugated metabolites. 
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Relation of this manuscript to the thesis: 
In vivo pharmacokinetic investigation of flaxseed lignan is one of the major aims of the thesis. 
This manuscript discusses comparative in vivo pharmacokinetics of flaxseed and mammalian 
lignans in rats. Outcomes of the oral and intravenous single bolus dose pharmacokinetic 
evaluations performed in this chapter is related to the outcomes of the Caco-2 permeation studies 
reported in the previous chapter.    
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CHAPTER 4 
 
Comparative Pharmacokinetics of Purified Flaxseed Lignans in Male Wistar 
Rats 
 
4.1 Abstract 
Flaxseed lignan consumption is associated with various health benefits, but little is known about 
the pharmacokinetics of the different lignans of flaxseed. Data on their bioavailability and 
pharmacokinetics is necessary to better understand their role in the putative health benefits of 
flaxseed lignans. We conducted a comparative pharmacokinetic analysis of the principal lignan 
of flaxseed, secoisolariciresinol diglucoside (SDG), and its primary metabolites, 
secoisolariciresinol (SECO), enterodiol (ED), and enterolactone (EL) in rats. Purified lignans 
were administered to male Wistar rats (250 ± 25 g, 5-7 weeks of age) by intravenous (IV) bolus 
injection (N=6) or by oral gavage (p.o.) (N=6). Serial blood samples were collected and serum 
was analysed using HPLC with fluorescence detection. Percent serum protein binding was 
determined by ultrafiltration. Pharmacokinetic parameters were calculated using non-
compartmental methods. In general, flaxseed lignans demonstrate high systemic clearance, large 
volume of distributions and short half-lives. The pharmacokinetic parameters of flaxseed lignans 
exhibited the following order: systemic clearance (SDG<SECO<ED), volume of distribution 
(SDG<SECO<ED) and half-life (SDG<ED<SECO) Oral bioavailability was 0%, 25%, and <1% 
for SDG, SECO, and ED, respectively. Serum protein binding was 0%, 67%, 93%, and 98% for 
SDG, SECO, ED, and EL, respectively. Administration of EL at 1 mg/kg (IV) and 10 mg/kg 
(p.o.) killed rats within a few hours of administration precluding a pharmacokinetic analysis of 
this lignan. Limited serum concentration data suggested very rapid distribution of EL into the 
tissues prior to its acute fatal toxicity. The cause of acute toxicity requires further investigation.  
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4.2 Introduction  
Flaxseed, a widely used natural product, is marketed in different forms including whole 
flaxseed, defatted flaxseed, flaxseed meal or oil, and as a flaxseed lignan enriched complex. 
Flaxseed consumption is associated with a number of putative health benefits such as diabetes, 
cardiovascular disease and cancer (4, 106, 340), and flaxseed lignans are believed to contribute 
to these beneficial effects through diverse mechanisms. Secoisolarisiresinol diglucoside (SDG) is 
the major lignan of flax and is present in flaxseed as an oligomer of SDG molecules complexed 
with hydroxymethylglutaric acid (HMGA). The SDG polymer acts as a source of production of 
other lignans in the gut lumen (30). Following oral consumption, the complex is believed to 
undergo hydrolysis with subsequent deglycosylation of SDG to form secoisolariciresinol (SECO) 
(37). Unabsorbed SECO can undergo further metabolism by the colonic microflora to produce 
the mammalian lignans, enterodiol (ED) and enterolactone (EL) (Figure 4.1).  
Evidence from preclinical and clinical studies indicate SDG and/or its metabolites have 
protective effects against chronic disease such as cancer, cardiovascular disease, and 
inflammation (81, 341, 342). Epidemiological studies also suggest an association of these health 
effects with serum EL concentrations. Many of these studies report no genotoxicity, hematology 
or behavioral changes following oral consumption of flaxseed or flaxseed products (116-118); 
but other studies have reported some adverse reactions in special populations such as pregnant 
and lactating females (114, 115, 199). In general, there is a significant body of data on flax safety 
and efficacy derived from animal and human studies, however, there is limited pharmacokinetic 
data on SDG and its metabolites and the potential for drug interactions has not been adequately 
investigated. Since safety and efficacy often correlate with systemic concentrations, 
characterization of the absorption, distribution, metabolism and excretion is necessary for any 
prospective evaluation of safety and efficacy of flaxseed lignan products. 
Some pharmacokinetic (PK) data is available on flaxseed lignans. Much of the reported PK 
information follows from nutritional intervention studies where different sources of flaxseed 
(flaxseeds, whole flaxseed, ground flaxseed etc) were administered in vivo such that a clear  
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Figure 4.1: Pathways for the conversion of plant lignan SDG-HMG polymer to mammalian 
lignan (EL). The SDG-HMG complex undergoes hydrolysis into its monomer units, 3-HMG and 
SDG and intestinal enzymes cleave the glucose moieties from SDG to convert it to its aglycone 
form, Secoisolariciresinol (SECO). SECO can undergo further metabolism to the Enterodiol 
(ED), Metaresinol (MAT) and Larisiresinol (LAR) and to Enterolactone (EL) by intestinal 
microflora. These biosynthetic pathways were elucidated using human fecal innoculum (adapted 
from (36, 38)).  
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understanding of the exact lignan dose was not possible. However, such studies indicate flaxseed 
lignans distribute mainly in the liver, prostate, kidney and intestine (158). These lignans undergo 
significant first pass metabolism (mainly glucuronide and sulfate conjugates along with a minor 
amount of cytochrome P450 enzyme mediated metabolism) and enterohepatic recirculation (176, 
177, 183). Flaxseed lignans are excreted mainly as glucuronidated an sulfated enterolignan 
conjugates via the urine, feces and bile along with minor amounts of lignan aglycones (193, 
194). Following an oral administration of radiolabeled SDG (3H-SDG, 3.7kBq/g body weight) to 
female rats, 77% of urine radioactivity was attributed to SECO, ED and EL and their conjugates, 
but no measurable SDG was identified in plasma or urine samples (343). One human clinical 
study reported the pharmacokinetics of ED and EL after administration of purified SDG (1.31 
µmol/body weight) to healthy volunteers (157). The clinical study supported the in vivo 
conversion of SDG principally into ED and EL but did not provide comparative pharmacokinetic 
parameters of purified lignans. In our current study, we examined the comparative 
pharmacokinetics of purified flaxseed lignans following intravenous and oral bolus 
administration in male Wistar rats. Such information will guide more focused investigations into 
relevant absorption and disposition characteristics of flaxseed lignans and into the mechanisms 
of lignan action and potential toxicity. Evaluation of preclinical safety and efficacy is an 
important step towards application of accepted principles that permit the safe and effective use of 
this natural product. 
 
4.3 Material and methods 
4.3.1 Chemicals and reagents 
Secoisolariciresinol diglucoside (SDG) and secoisolariciresinol (SECO) (>95% purity) 
were kind gifts from Agriculture and Agri-Food Canada, Saskatoon (Dr. Alister Muir).  HPLC 
grade acetonitrile was purchased from Fisher scientific (Toronto, ON, Canada). Silastic tubing 
was purchased from VWR (Mississauga, ON, Canada). Diethyl ether was purchased from EMD 
Chemicals Limited (Gibbstown, NJ). Methanol was purchased from Caledon Laboratories 
(Georgetown, ON). Enterodiol (ED) and enterolactone (EL) (as supplied from the manufacturer) 
, umbelliferone (7-Hydroxycoumarin), riboflavin, PEG 300, ethanol, tween 80, benzyl alcohol 
and all other chemicals unless otherwise indicated were purchased from Sigma-Aldrich 
(Oakville, ON, Canada). Amicon Centrifree micropartition cartridges containing ultracel 
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regenerated cellulose was purchased from Millipore (Billerica, MA, USA).  MilliQ water at 18.2 
MΩ resistance was obtained from a MilliQ water purification system (Millipore, MA, USA). All 
other chemicals used were analytical grade.   
 
4.3.2 Single oral and intravenous bolus dose pharmacokinetics 
Male Wistar rats (N=6) with a mean weight of 225±25 g were obtained from the Animal 
Resources Center, University of Saskatchewan. Rats were housed in a temperature and humidity 
controlled facility (22°C  2°C) on a 12-hour light:dark cycle (0700 h – 1900 h) and had free 
access to standard rodent diet and tap water. One day before dose administration, rats were 
randomized into the oral or intravenous administration routes, and silastic cannulas (internal 
diameter and outer diameter, 0.63 mm and 1.19 mm, respectively) (VWR, Mississauga, ON, 
Canada) were surgically implanted under isoflurane anaesthesia into the right jugular and left 
femoral veins for the intravenous bolus dosing study, whereas only the right jugular vein was 
cannulated for the oral bolus dosing study. Flaxseed lignans SDG, SECO, ED and EL, were 
administered orally to overnight fasted rats as a suspension in a vehicle containing the 
formulation excipients, PEG 300, ethanol, Tween 80, benzyl alcohol and saline, in different 
proportions depending upon the lignan (dose volume <0.5 mL). SDG was dissolved in 100% 
saline. SECO was dissolved in a mixture of PEG 300 (65%), Tween 80 (8%), benzyl alcohol 
(3%) and ethanol (24%). For ED and EL, PEG 300 (20%), ethanol (10%) and Tween 80 (15%) 
were used in saline as a vehicle. The oral dose of SDG, SECO, ED and EL was 40, 40, 10 and 10 
mg/kg, respectively. Blood samples were collected at 0 (pre-dose), 5, 10, 15, 20, 30, 45 min, and 
at 1, 2, 4, 6, 8, 12 and 24 h post dosing. SDG, SECO, ED and EL were dosed intravenously via 
the femoral cannula at 20, 20, 5 and 1 mg/kg, respectively. Blood samples were collected from 
the jugular cannula at 0 (pre-dose), 5, 10, 15, 20, 30, 45 min, and at 1, 2, 4, 6, 8, 12 and 24 h post 
dosing. Samples were left to coagulate for 40 min at room temperature and centrifuged at 2000 × 
g for 5 min to separate serum. Serum was transferred to microcentrifuge tubes and stored at -
80°C until analysis. Lignans were quantified using a HPLC-fluorescence (high pressure liquid 
chromatography-fluorescence) method (332). All procedures pertaining to animal handling and 
sample collection were approved by the University of Saskatchewan’s Animal Research Ethics 
Board, and adhered to the Canadian Council on Animal Care guidelines for humane animal use. 
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Pharmacokinetic (PK) parameters were estimated using WinNonLin 4.1 (Pharsight, St. 
Louis, MO) and expressed as mean±SD. The AUC0-∞ values were calculated by the trapezoidal 
rule-extrapolation method. Non-compartmental methods estimated the systemic clearance (ClS), 
apparent volume of distribution (Vd), half-life (t1/2), bioavailability (F), maximum plasma 
concentration (Cmax), and time to Cmax (Tmax). The graphs were drawn using base package in R 
version 2.13.1 (R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, 
URL http://www.R-project.org/) (333). 
 
4.3.3 Serum protein binding studies 
SDG, SECO, ED and EL were tested for their serum protein binding capacity using 
Amicon Centrifree micropartition cartridges containing ultracel regenerated cellulose (14 mm, 
30 kD molecular weight cut-off) (Millipore, Billerica, MA, USA). Blood was collected from 
anaesthetized (isoflurane) male Wistar rats (250±25 g) by cardiac puncture and allowed to clot 
for 30 min at room temperature. Subsequently, blank serum was collected by centrifugation at 
3000 × g for 5 min. An aliquot of 100 µL of lignan stock solutions (500 µg/mL) was added into 
900 µL of blank serum to obtain 50 µg/mL of lignans in serum and equilibrated at 37°C for 20 
min. After equilibration, the serum samples were transferred onto the micropartition kit 
membranes and centrifuged using a fixed angle (25°) rotor (TA-14-50) in a Beckman Coulter 
Allegra 25R centrifuge (Beckman Coulter, Mississauga, ON, Canada) for eight minutes at 
1000×g. About 70 µL of filtrate was collected and analysed using HPLC-Fluorescence method 
(332). 
 
4.3.4 High performance liquid chromatography conditions 
Lignan concentrations in serum were determined using a previously developed and 
validated HPLC-fluorescence (high pressure liquid chromatography-fluorescence) method (332). 
Briefly, the HPLC (Agilent Technologies, Mississauga, ON) system consisted of a Series 1200 
quaternary pump with online degasser, autosampler, and fluorescence detector. Processed 
samples (50 µL) were injected onto a Waters Symmetry C18 column (4.6 × 150 mm, 5 µm) 
maintained at room temperature. The mobile phase consisting of water with 0.1 percent formic 
acid (component A) and acetonitrile with 0.1 percent formic acid (component B) in different 
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ratios and the analytes were eluted under gradient mode delivered at a flow rate of 1 mL/min.  
Excitation and emission wavelengths were set at 277 nm and 617 nm, respectively.  
Stock solutions (1 mg/mL) of the lignans, internal standards (umbelliferone and riboflavin) 
and quality control samples were prepared by initial dissolution in methanol followed by dilution 
with mobile phase (70 percent component A:30 percent component B for SECO, ED, EL and 
umbelliferone; 80 percent component A:20 percent component B for SDG and riboflavin) and 
storage at -20±5°C. Working solutions of the lignans (0.1 µg/mL – 100 µg/mL) were prepared 
by serial dilution of the stock solution with mobile phase while working solutions of the internal 
standard were prepared by a single dilution of the stock solution to a concentration of 100 
µg/mL.  
Calibration curve and quality control samples were prepared on each day of analysis by 
adding 10 µL of individual working solutions to 90 µL of pooled rat blank serum with vortex-
mixing for 30 seconds. For SECO, ED and EL, 10 µL of umbelliferone (internal standard) 
solution (100 µg/mL) was added to 100 µL of calibration standards, QC samples, or rat serum 
samples and vortex-mixed for 10 sec. To all samples, 4 mL of diethyl ether was added, vortex-
mixed for 10 minutes, centrifuged at 4°C at 780 × g and the aqueous layer was snap frozen with 
liquid nitrogen and the organic layer was transferred to glass tubes and evaporated to dryness 
under vacuum at 40°C in an evaporator (Centrivap Concentrator, Labconco Corporation, Kansas, 
MO). The residue was reconstituted in 100 µL of mobile phase, vortex-mixed for 2 minutes and 
transferred to HPLC vials. For SDG, 10 µL of riboflavin (internal standard) solution (25 µg/mL) 
was added to 100 µL of calibration standards, QC samples, or rat serum samples and briefly 
vortex-mixed. Samples were transferred to centrifuge filters (Modified PES 10K, 500 µL, VWR 
International, Mississauga, ON) and centrifuged at 13,300 × g for 30 min. The filtrate was 
transferred to HPLC vials. The intra- and inter-day precision and accuracy was within 10% and 
all QC samples for a given run were within 10% of their nominal value.  
 
4.3.5 Red blood cell partitioning 
Fresh blood was collected from male Wistar rats by cardiac puncture using isoflurane 
anesthesia. Enterolactone (EL) (1 mg/mL) solution was added to the three different blood 
aliquots separately to make the final concentration of EL as 5µg/mL. All blood aliquots were 
incubated at 37°C and 80 rpm. Blood samples were collected intermittently at different time 
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points at 5, 10, 15, 30, 60, 90 and 120 min. Duplicate samples were centrifuged at 2000 × g for 5 
min and stored at -80°C until analysis while the third aliquot was stored as such for analysis. All 
the samples were analyzed using high performance liquid chromatography – fluorescence 
method as described above (332).   
 
4.4 Results 
4.4.1 Single oral and intravenous bolus dose pharmacokinetic studies 
Since a comparative pharmacokinetic characterisation of pure flaxseed lignans in rats was 
not previously evaluated, we conducted single dose oral and intravenous pharmacokinetic studies 
in male Wistar rats (N=6). The mean intravenous and oral bolus serum concentration versus time 
profiles for SDG, SECO and ED are presented in Figure 4.2. While the concentration of SDG in 
serum samples following oral administration was below the limit of quantification, SDG levels 
following intravenous dosing were detectable up to 4 h. SECO in intravenous and oral serum 
samples was detected up to 8 h and 4 h, respectively. The oral PK profile of SECO exhibited a 
bimodal profile with very rapid absorption such that Cmax was achieved at 5 min.  Quantifiable 
levels of ED were obtained up to 4 h postdose following both oral and intravenous 
administration. Natural log serum concentration versus time profiles of SDG, SECO and ED (not 
shown) suggest two-compartment model characteristics. Intravenous and oral administration of 
EL at a dose of 1 mg/kg and 10 mg/kg, respectively, were fatal to rats within 2 hours of 
administration. In general, the rats were sluggish after administration of the EL and the death 
was preceded by tremors, clawing, pawing, burying and jumping. In contrast to our findings, In 
2011, Damdimopoulou et al published the serum levels of conjugated and total EL (7.5 ± 1.6  
mol/L at 0.5 h post dose) when EL (10mg/kg) was (most likely synthesized in their own lab) 
administered intraperitonially to gonadectomized C57Bl female mice (344) which could  raises 
the question on EL synthesis method.Intravenous and oral pharmacokinetic parameters 
calculated using a noncompartmental approach by WinNonLin 4.1 is presented in Table 4.1 and 
4.2, respectively. SDG exhibited the lowest apparent volume of distribution, systemic clearance 
and half-life. SECO and ED exhibited large apparent volumes of distribution, but SECO’s 
systemic clearance was lower which attributed to its longer half-life relative to ED (Table 4.1). 
SECO exhibited the highest oral bioavailability at ~25% in rats, while SDG and ED showed poor 
oral bioavailability (Table 4.2).  
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Table 4.1: Mean (±SD) pharmacokinetic parameter estimates calculated by a noncompartmental 
pharmacokinetic (PK) analysis using WinNonLin 4.1 following an intravenous bolus 
administration of SDG, SECO, ED and ELa (20, 20 and 5 and 1 mg/mL) in male Wistar rats 
(N=6). 
Pharmacokinetic 
parametersb 
SDG 
(20 mg/kg) 
SECO 
(20 mg/kg) 
ED 
(5 mg/kg) 
k (h-1) 1.49 ± 0.52 0.19 ± 0.07 0.52 ± 0.24 
T1/2 (h) 0.52 ± 0.17 4.0 ± 1.5 1.8 ± 1.2 
AUC (0-∞)(h.μg.mL-1) 22.1 ± 12.51 2.59 ± 0.35 0.22 ± 0.04 
ClS (Lh-1kg-1) 1.11 ± 0.46 7.82 ± 1.11 23.1 ± 4.51 
Vd (Lkg-1) 0.76 ± 0.29 44.1 ± 12.2 54.2 ± 27.5 
aEL was administered at 1 mg/mL intravenously, but rats died within 2 hours of administration 
bk = Elimination rate constant; T1/2 = Half-life; AUC (0-∞) = Area under the serum concentration 
versus time curve; ClS = Systemic clearance; Vd = Apparent Volume of distribution.  
 
Table 4.2:  Mean (±SD) pharmacokinetic parameter estimates calculated by a noncompartmental 
pharmacokinetic (PK) analysis Using WinNonLin 4.1 following a single oral dose administration  
of SDG, SECO, ED and ELa (40, 40 and 10 and 10 mg/mL) in male Wistar rats (N=6)  
Pharmacokinetic  
parametersb 
   SDGc 
(40 mg/kg) 
  SECO 
(40 mg/kg) 
     ED 
(10 mg/kg) 
k (h-1)      -- 0.29 ± 0.14 0.47 ± 0.15 
T1/2 (h)      -- 2.96 ± 1.8 2.35 ± 1.5 
AUC (0-∞)(h.μg.mL-1)      -- 1.28 ± 0.47 0.002 ± 0.04 
Cmax (µg.mL-1)      -- 0.53 ± 0.48 0.028 ± 2.52 
Tmax (h)      -- 0.58 ± 0.46 0.23 ± 0.03 
F (%)      -- 24.7 <1 
aEL was administered at 1 mg/mL intravenously, but rats died within 2 hours of administration 
bk = Elimination rate constant; T1/2 = Half-life; AUC (0-∞) = Area under the serum concentration 
versus time curve; Cmax = Maximum serum concentration; Tmax = Time at which the 
concentration of lignans reaches Cmax  
cThe concentration of SDG was below limit of quantification (50 ng/mL).  
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Figure 4.2: Mean serum concentration (+SD) versus time profiles of SDG, SECO and ED upon 
oral and intravenous administration to male Wistar rats (N=6); the oral doses of SDG, SECO, ED 
and EL were 40, 40, 10 and 10 mg/kg, respectively, and intravenous doses were 20, 20, 5 and 1 
mg/kg, respectively. Following oral administration, SDG was not detectable by HPLC; EL was 
fatal to rats following both oral and intravenous administration. 
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4.4.2 Serum protein binding studies and red blood cell partitioning (Enterolactone) 
Since only the unbound form of a molecule is free to exert an effect, the extent to which 
lignans bind to serum protein was determined in rat serum using ultrafiltration. Percent serum 
protein binding data for flaxseed (SDG and SECO) and associated mammalian lignans is shown 
in Table 4.3. SDG was not bound to serum protein and SECO, ED, and EL showed increasing 
serum protein binding characteristics in ascending order (Table 4.3). Red blood cell partitioning 
study indicated that EL did not accumulate in red blood cells (ratio of blood concentration to 
plasma concentration ≈1).  
 
Table 4.3: Percentage rat serum protein binding (N=3) for SDG, SECO, ED and EL separately at 
50 µg/mL using Amicon Centrifree micropartition cartridges containing ultracel regenerated 
cellulose (14 mm, 30 kD). 
 SDG SECO ED EL 
% binding Not bound 67 93 98 
 
 
4.5 Discussion and conclusion 
Flaxseed lignans are gaining research interest due to their putative health benefits in a 
number of chronic diseases such as cancer, cardiovascular disease and diabetes (4, 49, 109). To 
promote the safe use of this natural product in human populations, investigations into the 
relevant absorption and disposition characteristics of flaxseed lignans and their mechanism of 
action and potential toxicity are necessary. As an important step towards an understanding of 
their preclinical safety we evaluated the oral and intravenous pharmacokinetic characteristics of 
purified flaxseed lignans in the rat, which is an often-used animal model for such investigations. 
Most of the pharmacokinetic data reported in the literature has been collected after 
administration of flaxseed products, which contain multiple constituents that might substantially 
modulate the pharmacokinetic parameters of lignans. The pharmacokinetics of ED and EL after 
per oral administration of purified SDG (1.31 µmol/body weight) in healthy human subjects 
(157) and in rats (343) has been reported, but to our knowledge there are no other 
pharmacokinetics studies on the administration of purified SECO, ED or EL.  
In our study flaxseed lignans exhibited low to no absolute oral bioavailability in male 
Wistar rats. Poor oral bioavailability may be attributed to poor intestinal permeability or high 
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first pass metabolism. For SDG, serum concentrations after oral administration were below the 
limit of quantification. In a previous study in our laboratory (manuscript submitted), an apparent 
permeability value for SDG in a Caco-2 cell monolayer system (an in vitro model of oral 
absorption) (345), could not be calculated as we failed to detect the transepithelial flux of SDG 
across the Caco-2 cell monolayer. This was not unexpected given its polar nature (clog P = -
1.338), as a result of the presence of two glucose moieties, and lack of reported specificity for 
uptake transporters that might be present in the Caco-2 cell monolayer. Furthermore, phase II 
enzyme metabolism of SDG in the Caco-2 cell monolayer was less than 3% indicating that SDG 
does not undergo significant intestinal wall conjugation. Lack of transport across the Caco-2 cell 
monolayer and minimal phase II enzyme metabolism suggests poor permeation characteristics 
will limit the oral absorption of SDG. This is consistent with the lack of oral bioavailability in 
the male Wistar rats in our study suggesting SDG is unlikely to be the bioactive lignan form, and 
that the health benefits are likely associated with SDG metabolites.  
The aglycone form of SDG, SECO, demonstrated moderate bioavailability (~25%) while 
the bioavailability of SECO’s metabolite, ED, was less than 1%. Despite greater apparent 
permeability values in the Caco-2 cell monolayer (manuscript submitted), ED’s lower oral 
bioavailability may be due to more extensive first pass metabolism. The Caco-2 cell monolayer 
showed more efficient metabolism of ED relative to SECO (manuscript submitted). Jansen et al. 
also found extensive glucuronidation and sulfation of ED and EL after in vitro incubation of ED 
and EL in HT-29 and Caco-2 cell lines (176). The ability of the gastrointestintal mucosa to 
contribute significantly to presystemic metabolism is also supported by the finding that ED and 
EL were largely found as glucuronic acid and sulfate conjugates in the portal vein of the rats 
following an oral flaxseed lignan administration (27). No study has specifically evaluated the 
contribution of the liver to presystemic metabolism and the oral bioavailability of flaxseed 
lignans. However, its contribution is supported by in vitro liver microsomal studies where both 
phase II enzyme conjugates and aromatic hydroxylated metabolites of ED and EL have been 
reported in rat, pig, rhesus monkey and human liver microsomes (56, 183-186). The extent to 
which liver metabolism affects the presystemic metabolism and disposition of lignans in rats 
remains to be studied.  
Oral bolus administration of SECO demonstrated bimodal serum concentration versus time 
profiles in all rats investigated in our study. This was not observed following intravenous 
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administration. A bimodal serum concentration versus time curve usually arises as a result of 
enterohepatic recirculation or absorption from two different sites or absorption windows. Since 
the time of appearance of the second peak in the serum concentration-time profile was shorter 
than rat gastric emptying time (~60 min) (346), it is unlikely that the bimodal profiles are due to 
enterohepatic recirculation. We fitted a two-compartment model with absorption from different 
sites in WinNonLin but the model was unidentifiable due to over-parameterization and lack of 
sufficient time points during the ascendency of the second serum concentration peak. Further 
studies with a greater number of serial blood samples in the early portion of the serum 
concentration-time profile are necessary to unambiguously determine whether two absorption 
sites are possible.  
The flaxseed lignans demonstrated rapid elimination characteristics in the rat. As expected, 
the systemic clearance increased with decreasing polarity of lignans (SDG is the most polar and 
ED is the least polar). A meta-analysis of 47,018 Pfizer compounds showed that an increase in 
log P values (to a certain limiting value) corresponds to an increase in membrane permeability 
and liver microsomal clearance (347), as an increase in permeability would increase exposure to 
metabolic enzymes. The systemic clearance values of the flaxseed lignans showed a similar trend 
with increasing log P values (SDG<SECO<ED). Interestingly, the systemic clearance of SECO 
and ED exceeded the blood flow rate to rat liver (13.8 mL/min) (348). The well-stirred model of 
hepatic clearance predicts that the hepatic clearance cannot exceed hepatic blood flow (i.e. 
hepatic blood flow is the limiting value of hepatic clearance) (349). Since systemic clearance is 
the sum of all clearance mechanisms contributing to the elimination of a compound, additional 
nonhepatic mechanisms of elimination are likely involved in the systemic clearance of SECO 
and ED in the rat.These high systemic clearance values also further support a significant role of 
the intestine in not only presystemic metabolism but overall disposition of the lignans in the rat. 
The intestine’s involvement in lignan disposition may explain the predominance of the fecal 
excretory route in lignan elimination as reported in the literature (188). In this study, Bach 
Knudsen et al administered wheat and rye to the pigs and observed the formation of SECO, 
MAT, ED and EL in feces and 20-25% of these compounds were excreted intact on either diet. 
As with systemic clearance, the apparent volume of distribution and extent of serum 
protein binding of the flaxseed lignans increased with decreasing polarity (SDG<SECO<ED). 
Although SDG did not bind serum protein, its poor permeability characteristics would likely 
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limit its tissue distribution relative to SECO and ED. Both SECO and ED had very large 
apparent volume of distribution values indicating extensive distribution into peripheral organs, a 
finding consistent with the literature (158, 159). ED showed extensive serum protein binding 
characteristics and very large volume of distribution. Tissue partitioning is a significant factor 
determining the volume of distribution and these data suggest ED has a high affinity for tissue 
binding sites relative to its affinity for serum protein binding. Several studies have suggested the 
accumulation of ED and EL in certain tissues such as the liver, prostate and breast (158), which 
is consistent with the distribution characteristics of ED identified in our study.  
The half-life of flaxseed lignans is rather short in rats. SDG had the shortest half-life, 
followed by ED and SECO. Since half-life is a hybrid function of the volume of distribution and 
systemic clearance, SDG’s lower volume of distribution relative to the other lignans contributed 
to its shorter half-life. Despite similar apparent volume of distribution values, ED’s higher 
systemic clearance contributed to its shorter half-life relative to SECO. Although we could not 
evaluate EL, Kuijsten et al reported a longer half-life for EL in comparison to ED when pure 
SDG (1.31 µmol/kg body wt) was administered as a single oral dose to healthy human beings 
(157).  
Although the sequential conversion of SDG into SECO, SECO into ED and then into EL is 
widely reported in the literature but we did not observe these metabolites after administration of 
purified parent lignans (157). SECO, ED and EL was expected to appear in the systemic 
circulation after oral administration of SDG; ED and EL was expected to be detected in the 
systemic circulation after oral administration of SECO; EL was expected to be detected in 
systemic circulation after oral administration of ED but we did not detect these expected 
metabolites in all these three situations. The most likely explanation is that the systemic 
concentrations of these metabolites were below our limit of detection. The systemic 
concentrations of these metabolites depend upon the rate and extent of conversion of these 
lignans as well as the rate and extent of their absorption. Possibly, the conversion rate is low and 
generates small amount of metabolites, which do not produce systemic concentrations large 
enough to be detected by our analytical method. Currently, the rates of these bioconversions are 
unknown and the study of these conversion rates might explain our observations. 
The pharmacokinetic parameters of EL could not be established because EL was fatal to 
rats (death within 1-2 hours post-administration) when administered at 1 mg/kg (IV) and 10 
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mg/kg (p.o.). Interestingly, EL was not detected in serum samples collected prior to death 
following either intravenous or oral administration. A red blood cell partitioning study suggested 
that EL did not accumulate into red blood cells and therefore does not explain the undetectable 
levels of EL. Possibly, EL underwent very rapid and extensive distribution into the tissues and 
our current HPLC-fluorescence method lacked sufficient analytical sensitivity to detect low EL 
serum levels that may result from a very high apparent volume of distribution., A more sensitive 
analytical method, such as LC-MS/MS, is required to confirm these assertions. Nonetheless, EL 
may accumulate in a vital organ(s) leading to organ dysfunction and rapid death. Just prior to 
death rats exhibited symptoms such as tremor, pawing and burying. These symptoms of toxicity 
were observed in rats after administration of bifenthrin, a pesticide that acts on the central and 
peripheral nervous systems (350). One study reported (159) very low lignan concentrations in the 
brain, which might suggest that EL or a toxic metabolite of EL acted on the peripheral nervous 
system (or some other critical organ system) to cause toxicity. The exact cause of death remains 
unknown and requires further investigation.   
One of the potential problems with this study is the concentrations used. No allowance has 
been made for the dilution effect that would occur during the normal bioconversion of SDG to 
SECO to ED to EL. Since this process is a biological one and likely does not occur instantly, the 
effective concentration of ED and EL in the mammalian system could easily be more than an 
order of magnitude lower that the concentration of SDG or SECO given. 
In conclusion, the lignans are characterized by high systemic clearance and apparent 
volume of distribution values and short half-lives. SDG did not undergo significant absorption 
and thus is not likely to be directly responsible for the putative health benefits of flaxseed lignan 
consumption. SECO was the most bioavailable and ED showed the greatest systemic clearance, 
apparent volume of distribution and extent of serum protein binding of the lignans studied. The 
high systemic clearance values suggest a significant involvement of nonhepatic clearance 
mechanisms, and the extensive distribution characteristics indicate a high affinity of the lignans 
for extravascular tissues. Surprisingly, oral (10 mg/kg) and intravenous (1 mg/kg) administration 
of purified EL caused death within 2 hours of administration, although the cause of this acute 
toxicity remains unknown. Our general pharmacokinetic characterization of the lignans 
administered in their respective purified forms is consistent with the reported literature involving 
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administration of flaxseed lignans in complex mixtures, but many questions remain regarding the 
absorption and disposition of this interesting class of compounds.  
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Relation of this manuscript to the thesis: 
Second aim of the thesis is a pharmacodynamic investigation of flaxseed lignans in chronic 
disease states that the literature suggests lignans show benefit. This manuscript summarises our 
efforts at investigating effects flaxseed lignan administration in blunting of postprandial blood 
glucose levels in type II diabetes. Postprandial elevation in blood glucose was recently identified 
as an independent risk factor for cardiovascular disease in diabetic patients. The pharmacokinetic 
information gleaned from the previous chapters was instrumental in the study design identified in 
this manuscript. 
  
95 
 
CHAPTER 5 
 
Effects of Flaxseed Administration on Postprandial Blood Glucose Levels in 
Type II Diabetic Rats: Pilot Studies 
5.1 Abstract 
Postprandial hyperglycemia is considered an independent risk factor for cardiovascular disease 
(CVD). Flaxseed lignans have positive modulating effects on fasting blood glucose and known 
health benefits in CVD, but no study has evaluated the effect of flaxseed lignans on postprandial 
hyperglycemia. Therefore, we hypothesized that the flaxseed lignans decrease postprandial 
hyperglycemia following a high glycemic index meal. Two different parallel design placebo 
controlled pilot studies in healthy and type II diabetic male Wistar rats (diabetes induced by a 
single intraperitoneal injection of streptozotocin, 60 mg/kg) were conducted to investigate the 
effects of the purified flaxseed lignan, secoisolariciresinol diglucoside (SDG), and flaxseed 
lignan enriched complex (FLC), respectively, on postprandial blood glucose levels. SDG (40 
mg/kg) was orally administered once as an acute administration to male Wistar rats (N=2) and 
FLC (containing ~38% SDG; dose = ~ 40 mg/kg and 80 mg/kg SDG) was administered once 
daily for 4 weeks as chronic administration to type II diabetic male Wistar rats (N=2). Oral 
glucose tolerance test (OGTT) was performed at 0, 2 and 12 hours after the administration of 
SDG or on the 28th day of FLC administration The oral glycemic tolerance test (OGTT) 
consisted of a glucose solution (2 g/kg in 0.5 mL sterile water) administered by oral gavage. 
Blood samples were collected by saphenous venepuncture at 0, 15, 30, 45, 60, 90, 120, 150 and 
180 minutes following the glucose administration and analyzed for blood glucose levels using an 
Accucheck glucometer. Evaluation of the differences in the magnitude of the blood glucose 
levels and area under the blood glucose concentration versus time profile did not show any 
significant differences between control and lignan treated rats in either healthy or type II diabetic 
rats. These pilot studies suggest the flaxseed lignan, SDG, does not influence postprandial 
hyperglycemia in healthy rats and in streptozotocin-induced diabetic rats.  
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5.2 Introduction  
Diabetes mellitus is considered a major risk factor for cardiovascular disease (CVD) (295). 
Diabetes mellitus is characterized by insufficient insulin secretion (type I) and/or insufficient 
utilization of glucose (type II) by skeletal muscles with reduced glycogen synthesis resulting in 
abnormally high blood glucose levels or hyperglycemia (299). CVD accounts for almost 75% of 
mortality in subjects with type II diabetes. Various prospective studies suggest the association 
between high blood glucose levels in diabetic patients and increased risk of microvascular 
(retinopathy, neuropathy and nephropathy) and macrovascular (atherosclerosis) complications 
(351-353). Consequently, intense research continues on the treatment and/or prevention of 
diabetes, micro- and macrovascular complications, and cardiovascular disease. Recently, 
postprandial hyperglycemia was proposed as a diagnostic criterion along with impaired fasting 
glucose levels in diabetes mellitus (354, 355). 
Postprandial hyperglycemia, the exaggerated rise in blood glucose levels following a meal, 
has been identified as a major independent cardiovascular risk factor in diabetic patients (302, 
356). Recent reports indicate that prolonged and repeated exposure to postprandial 
hyperglycemia principally contributes to the development of atherosclerosis, even in individuals 
with normal fasting blood glucose levels (357). The major mechanisms involved in the 
development of hyperglycemia and CVD include endothelial dysfunction, inflammation, and 
oxidative stress (291), which lead to the vascular alterations, micro- and macrovascular 
complications in diabetic patients (303). Additionally, the literature indicates increasing support 
for the interrelationship between lipid and glucose homeostasis, possibly via the bile acid 
activated nuclear hormone receptor pathways (358). Therefore, various therapeutic agents acting 
on these pathways may simultaneously address hyperglycemia and dyslipidemia with type II 
diabetes (359). 
Diabetic patients are encouraged to make lifestyle adjustments, including dietary 
management and exercise, to control high blood glucose levels. In addition to such measures, 
many pharmaceutical products are available for the treatment of type I and type II diabetes. Oral 
hypoglycemic agents combined with slow and fast release insulin therapies, particularly at the 
later stage of disease, are the usual treatment for diabetic patients (298). Natural products have 
gained popularity as alternatives to the management of diabetes and in the promotion of general 
health and wellness (292). Flaxseed lignans are natural health products known to have putative 
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health benefits in cancer, cardiovascular disease and hyperlipidemia. Flaxseed lignans decrease 
plasma cholesterol and glucose concentrations in a dose dependent manner (93), and may 
enhance the management of diabetes possibly via inflammatory pathways. Along with reduction 
in atherosclerosis, recent preclinical and clinical studies support the beneficial effects of flaxseed 
lignans in reducing type II diabetes (13, 93, 106, 314). Prasad et al reported the delay (80%) in 
onset of diabetes when SDG (40 mg/kg/d) was administered to rats (314). Fukumistu reported 
that high fat diet containing 1% SDG resulted in decreased insulin concentrations in mice (112). 
In two different clinical studies, Pan et al reported reduced HbA1c levels and suppressed levels 
of C-reactive protein (CRP) in type II diabetic patients when 360 mg/g flaxseed lignan capsules 
were administered to type II diabetic patients. No change in other diabetic biomarkers such as 
interleukin-6 (IL-6) and retinol binding protein-4 (RBP-4) were observed (13, 106). Similar 
reductions in CRP levels were observed when 500 mg/day flaxseed lignan complex was 
administered to healthy participants with hypercholesteremia (95). Zhang et al also reported a 
25% reduction in fasting blood glucose levels when BeneFlax (~38% SDG) at a dose of 600 
mg/day SDG was administered to hypercholesterolemic patients (93). Additionally, a small 
number of studies suggest flaxseed lignans may reduce postprandial hyperglycemic responses 
(292). However, no study has specifically evaluated the dose-dependent effect of flaxseed 
lignans in blunting postprandial hyperglycemic levels following a high glycemic index meal. 
Therefore, we investigated the effect of acute and chronic administration of SDG and flaxseed 
lignan complex (FLC) (~38% SDG), respectively, in blunting postprandial blood glucose levels 
in healthy and type II diabetic male Wistar rats. 
 
5.3 Material and methods 
5.3.1 Materials 
Secoisolariciresinol diglucoside (SDG) (>95% purity) was a kind gift from Agriculture and 
Agri-Food Canada, Saskatoon (Dr. Alister Muir). Flaxseed lignan complex (~ 38% SDG) was a 
kind gift from Archer Daniels Midland (ADM) (Deactur, Illinois, USA).  Streptozotocin, glucose 
and carboxymethyl cellulose (CMC) were purchased from Sigma (Oakville, ON, Canada). 
MilliQ water at 18.2 MΩ resistances was obtained from a MilliQ water purification system 
(Millipore, MA, USA). Blood glucose meters called Accucheck compact plus models were kind 
gifts from Roche Diagnostics (Laval, QB, USA).   
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5.3.2 Methods 
This work was approved by the University of Saskatchewan’s Animal Research Ethics 
Board, and adhered to the Canadian Council on Animal Care guidelines for humane animal use. 
Male Wistar rats were obtained from the Animal Resources Centre, University of Saskatchewan. 
A parallel design, placebo controlled pilot study was conducted to evaluate the effect of SDG in 
blunting postprandial hyperglycemia in fasted (~12 h) healthy male Wistar rats (300 ± 50 g) 
(N=2). While 0.5 mL water was administered to control group (N=2), treatment groups (N=2) 
received pure SDG (40 mg/kg in 0.5 mL water) by oral gavage. Oral glucose tolerance test 
(OGTT) was performed in three treatment groups at 0, 2, and 12 hours after administration of 
SDG. For the OGTT, 2 g/kg glucose solution in 0.5 mL water administered as an oral gavage and 
blood samples were collected by saphenous venepuncture at 0, 15, 30, 45, 60, 90, 120, 150 and 
180 minutes following the glucose solution administration and analyzed for blood glucose levels 
using Accucheck glucometer. Evaluation of the differences in the magnitude of the blood 
glucose levels and area under the concentration versus time profile of blood glucose were 
conducted. The importance of this pilot study lies in the need to optimize time of the SDG dose 
relative to the high glucose solution in blunting postprandial hyperglycemia.  
Further, a parallel design, placebo controlled pilot study was conducted to examine the 
influence of chronic administration of FLC in blunting postprandial hyperglycemia in type II 
diabetic male Wistar rats (N=2). Type II diabetes was induced by the use of streptozotocin (60 
mg/kg, intraperitoneally) to rats (200 ± 25 g) and diabetes was assessed by measuring blood 
glucose levels (>10 mmol/L) using commercial Accucheck glucometer. Streptozotocin, a toxin 
isolated from the bacteria Streptomycetes achromogens, is often used to develop various diabetic 
models as this toxin completely destroys pancreatic β cells (360). Every day at the same time for 
four weeks, FLC (a suspension with 0.25 % carboxymethyl cellulose (CMC)) was administered 
by oral gavage at two different doses (equivalent to 40 mg/kg SDG and 80 mg/kg SDG) to 
treatment groups while control group received 0.5 mL of 0.25% CMC solution in water. Each 
day the weights of rats were taken and doses were adjusted accordingly.  On the 28th day, rats 
were fasted for 12 h and OGTT was performed at 0, 2, and 12 hours after the administration of 
FLC. Blood samples were collected by saphenous venepuncture at 0, 15, 30, 45, 60, 90, 120, 150 
and 180 minutes following the glucose meal and analyzed for blood glucose levels using 
Accucheck glucometer. The area under the blood glucose concentration versus time curve was 
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calculated by the linear trapezoidal method truncated at the last blood glucose concentration 
determination.  
 
5.4 Results 
Pure SDG (40 mg/kg) or FLC (~38% SDG ) (Dose ~ 40 mg/kg and 80 mg/kg SDG) were 
administered orally to normal healthy male Wistar rats and type II diabetic rats, respectively, to 
determine the effect of flaxseed lignans in blunting postprandial blood glucose levels. Figure 5.1 
shows the results of mean postprandial blood glucose levels in healthy male Wistar rats after 
acute administration of pure SDG (40 mg/kg) simultaneously, 2 h and 12 h before administration 
of a high glycemic index meal (2 g/kg glucose solution in water).  The results indicate no 
obvious change in postprandial blood glucose concentrations or area under the curve (Figure 5.1) 
with a single dose SDG administration either simultaneously (Group A), 2 h (Group B) or 12h 
(Group C) before an oral glucose challenge. Therefore, another parallel design, placebo 
controlled pilot study was conducted to study the effects of 4 week chronic daily administration 
of FLC (~ 40 mg/kg and 80 mg/kg SDG) in diabetic male Wistar rats. Figure 5.2 shows the 
results of postprandial blood glucose levels in diabetic rats when FLC (~80 mg/kg of SDG) was 
administered to type II diabetic rats groups (N=2) simultaneously, after 2 and after 12 h before 
administration of a high glycemic index meal (2 g/kg glucose solution in water). In type II 
diabetic rats, no change in postprandial blood glucose levels or area under the glucose 
concentration curve (Figure 5.3) was observed. With chronic administration of FLC (~ 40 mg/kg 
and 80 mg/kg SDG), a decrease in body weight gain was observed (Figure 5.4), suggesting 
hypolipidemic effects of these lignans as reported earlier by our lab in hyperlipidemic rats (97). 
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Figure 5.1: Mean postprandial blood glucose levels (mmol/L) at different times in healthy male 
Wistar rats (N=2) after oral glucose tolerance test (OGTT) (glucose administration 2 g/kg, p.o.). 
SDG was administered at 40 mg/kg p.o. and OGTT was conducted at 0 h (Group A), 2 h (Group 
B) and 12 h (Group C) after SDG administration. Placebo groups (N=2) consist of healthy male 
Wistar rats with vehicle administration (without SDG administration).   
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Figure 5.2: Mean postprandial blood glucose levels (mmol/L) in type II diabetic male Wistar rats 
(N=2) after OGTT (glucose administration 2 g/kg, p.o.). Flaxseed lignan complex (FLC) was 
administered at two doses (equivalent to 40 mg/kg and 80 mg/kg of secoisolariciresinol 
diglucoside (SDG) p.o.) for 28 days to streptozotocin induced diabetic rats. OGTT was 
conducted on the 28th day at 0 h (Group A), 2 h (Group B) and 12 h (Group C) after the last dose 
of FLC. Placebo groups (N=2) consist of diabetic male Wistar rats with vehicle administration 
(without FLC administration).    
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Figure 5.3: Mean area under the glucose concentration time curve (mmol/L × min) in male 
Wistar rats (N=2) after the oral glucose tolerance test (OGTT) (glucose administration 2 g/kg, 
p.o.). A single dose of secoisolariciresinol diglucoside (SDG) (40 mg/kg, p.o.) was administered 
to healthy male Wiatar rats while Flaxseed lignan complex (FLC) at two doses (equivalent to 40 
mg/kg and 80 mg/kg of SDG, p.o.) was administered to streptozotocin induced diabetic male 
Wistar rats. OGTT was performed on the 1st day (SDG, single dose) and 28th day (FLC, chronic 
dose) at 0 h (Group A), 2 h (Group B) and 12 h (Group C) after the last dose of SDG or FLC.  
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Figure 5.4: Average observed weight (points) and LOESS (line) of the rats (N=2) on different 
days (28 days) of Flaxseed lignan complex (FLC) administration at the doses equivalent to of 0, 
40 and 80 mg/kg of secoisolariciresinol diglucoside (SDG) in streptozotocin induced male 
diabetic Wistar rats.  
 
 
5.5 Discussion 
Postprandial hyperglycemia i.e. elevated blood glucose levels after a meal, is recently 
recognized as a risk factor for CVD (355) and evidence suggest that flaxseed lignan and flaxseed 
lignan extract consumption shows benefits in type II diabetes (13, 48, 106). Studies that suggest 
the effect of flaxseed in hyperglycemia are based on biomarker studies and no study has directly 
measured postprandial blood glucose concentrations (13, 106). The literature suggests that 
enterolactone (EL), a mammalian lignan formed in the gastrointestinal tract following flaxseed 
lignan consumption, may act as a putative bioactive lignan form based on various in vitro and 
preclinical pharmacodynamic studies (76, 80, 361). Since the appearance of EL in the systemic 
circulation after SDG administration is delayed (39), the blunting effect of SDG may be 
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associated with a time delay to allow conversion of SDG to EL. Therefore in my pilot study I 
investigated the effect of SDG or FLC in blunting postprandial hyperglycemia. In my study 
design the time of OGTT was varied with respect to SDG or FLC administration to capture any 
delayed effect that might be required.   Therefore, we hypothesized that SDG or FLC can blunt 
postprandial blood glucose levels in streptozotocin induced type II diabetic male Wistar rats.  
Acute (pure SDG, 40 mg/kg) and chronic administration (FLC, ~ 40 and 80 mg/kg SDG) 
resulted in no significant changes in postprandial blood glucose levels in healthy and type II 
diabetic male Wistar rats (N=2), respectively. I administered FLC at two different doses (FLC, ~ 
40 and 80 mg/kg SDG) to investigate the dose dependent effect of FLC on postprandial glucose 
levels. No change in blood glucose levels might be explained due to various reasons. Firstly, type 
II diabetes was induced by administration of streptozotocin (60mg/kg, intraperitoneally) and this 
may not be a suitable model for assessment of postprandial hyperglycemia. Streptozotocin is a 
plant toxin that destroys pancreatic β cells and may be a more suitable model for type I diabetes 
(360, 362). Use of other type II diabetes models such as long-term high fat diet induced diabetes 
model, Zucker fa/fa rats, or ob/ob mouse may offer different outcomes (363) because these 
models maintain high levels of insulin and insulin resistance (362). Other factors such as animal 
strain, animal gender and animal species might also have affected the outcome (362).   
Literature support for modulation of blood glucose levels largely arise from studies that 
measured changes in various biomarkers such as C-reactive protein (CRP), retinol binding 
protein-4(RBP-4), and HbA1c (glycosylated haemoglobin) in type II  diabetic patients (13, 106) 
administered chronically flaxseed lignan supplements at different doses (106). None of these 
reports measured blood glucose levels directly except Zhang et al (93) where they obserbed 25% 
reduction in fasting blood glucose levels in hypercholesterolemic patients. Modulation of 
biomarkers may not always translate into effect and thus changes observed in biomarkers may 
not translate into positive modulation of the actual disease condition. Since changes in the 
postprandial blood glucose levels is the ultimate outcome, my data might suggest that SDG or 
FLC are not effective in the blunting of postprandial hyperglycemia. Nonetheless, further 
investigation using alternative models of type II diabetes or metabolic syndrome is necessary to 
support this assertion. 
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5.6 Conclusion 
Acute (SDG, 40 mg/kg) and chronic (FLC, ~ 40 mg/kg and 80 mg/kg SDG) administration 
of flaxseed lignans do not decrease postprandial blood glucose levels in healthy and 
streptozotocin-induced diabetic rats. The study was a preliminary study and not sufficiently 
statistically powered. Further studies with different diabetic models may give a different 
outcome.  
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Relation of this manuscript to the thesis: 
In addition to diabetes, flaxseed lignans have shown benefit in prostate cancer. The mechanism 
through which lignans modulate prostate cancer progression is not known. Delineating the 
mechanism of action is essential to understand the pharmacodynamics of lignans as a therapeutic 
moiety. This manuscript describes our effort in delineating mechanisms of actions of flaxseed 
lignans in prostate cancer. This manuscript extends our evaluations of the pharmacodynamics of 
flaxseed lignans, which complements the pharmacokinetic evaluations conducted in the previous 
chapters of this thesis.   
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6.1 Abstract 
Flaxseed and associated mammalian lignans are suggested to have pharmacodynamic actions in 
various disease areas including breast and prostate cancer, cardiovascular disease and diabetes. 
There are several suggested mechanism(s) of action for these pharmacodynamic activities. 
Sesame lignans are structurally similar to flaxseed lignans and we expected flaxseed lignans to 
exhibit similar mechanism of action as that of sesame lignans. Sesame lignans are reported to 
alter fatty acid metabolism and, therefore, we tested the transcriptional and translational changes 
in various targets such as acetyl CoA carboxylase-1 (ACC-1), fatty acid synthase (FAS), steroid 
regulatory element binding protein-1C (SREBP-1C) and carnitine palmitoyl transferase-1 (CPT-
1)) of fatty acid metabolism after treatment with enterolactone (EL) in prostate cancer (PC-3 
cells) and prostate normal (RWPE-1) cell lines. EL caused selective cytotoxicity and exhibited a 
concentration- and time-dependent inhibition of FAS in prostate cancer cells but not in normal 
prostate cells. These studies suggest EL exhibits anti-proliferative activity in prostate cancer cells 
by inhibiting the fatty acid synthesis pathway.  
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6.2 Introduction 
Prostate cancer is one of the leading causes of male death in North America and current 
treatments remain inadequate to effectively manage this disease (364). Identification of novel 
targets and discovery of new therapeutic moieties will likely improve treatment outcomes and 
one such target could be modulation of fatty acid metabolism. The literature suggests that 
prostate cancer cells use fatty acid metabolism to meet their bioenergetic and biosynthetic 
requirements for the rapid growth rather than aerobic glycolysis (213) while normal prostate 
cells depend on glucose as energy source. This property separates prostate cancer cells from 
other cancer types as well as normal prostate cells and may be modulated to inhibit prostate 
cancer cell growth without affecting normal cells (365).  
Fatty acid homeostasis plays a central regulatory role in cell signalling, membrane fluidity 
and energy processing. Fatty acid homeostasis depends upon the fine balance between fatty acid 
synthesis and oxidation and involves a number of different enzymes and transcription factors that 
regulate anabolic and catabolic pathways in fatty acid metabolism. Fatty acid synthesis occurs by 
a series of steps mainly in liver, muscle and adipose tissues. Several proteins including fatty acid 
synthase (FAS), acetyl CoA carboxylase (ACC), sterol regulatory element binding protein-1C 
(SREBP-1C) and carnitine palmitoyl transferase-1 (CPT-1) play key roles in the regulation of 
fatty acid metabolism (236). Modulation of these proteins may offer a mechanism to control 
prostate cancer cell growth (221, 366).   
FAS is a key enzyme responsible for fatty acid synthesis and its induction or inhibition is 
likely to result in the increase or decrease in fatty acids, respectively. FAS is over expressed in 
prostate cancer cells to meet the bioenergetic requirements of prostate cancer cells and the level 
of FAS expression is used to grade the severity of prostate cancer (217, 221). Since prostate 
cancer cells depend on fatty acid as an energy source, FAS inhibition may affect the viability and 
growth of prostate cancer cells (246). Similarly, inhibition of acetyl CoA carboxylase (ACC), 
which converts acetyl CoA to malonyl CoA to initiate fatty acid synthesis (237), or CPT-1, 
which is responsible for the transport of long chain fatty acids into the mitochondria to initiate 
fatty acid oxidation (248), may alter prostate cancer cell energy homeostasis to influence cell 
viability and growth (221). SREBP-1C, a transcription factor, regulates the expression of FAS 
and other proteins involved in fatty acid synthesis (230, 367). Therefore, SREBP-1C may be an 
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upstream target whose inhibition may result in a decrease in fatty acid levels and subsequent loss 
of prostate cancer cell viability.  
Epidemiologically, dietary flaxseed lignan consumption is associated with a decreased 
incidence of prostate cancer (82, 368). Morton et al in 1997 demonstrated that higher levels of 
enterolactone were positively associated with reduced risk of prostate cancer especially in Asian 
men (82). Similarly, in a Swedish clinical trial, intermediate serum levels of EL were positively 
associated with reduced risk of prostate cancer (369). This association has been attributed to 
circulating levels of the lignan, enterolactone (EL), a metabolite of the plant lignan, 
secoisolariciresinol diglucoside, following metabolic conversion by the gut microflora (81, 82, 
368).  Clinical and pre-clinical investigations provide further support for flaxseed and EL’s role 
in prostate cancer.  In a clinical study, administration of flaxseed (30g/day) along with low fat 
diet (≤20% of kcal) for 6 months to prostate cancer patients caused decrease in prostate specific 
antigen (PSA) serum levels and decreased the proliferation rate of benign epithelium. (370). In a 
preclinical study dietary supplementation of 5% flaxseed to transgenic adenocarcinoma mouse 
prostate (TRAMP) model inhibited the growth of prostate neoplasia (361).  Furthermore, EL was 
found to be cytotoxic against prostate cancer cell lines such as PC-3, DU-145 and LNCaP cell 
lines (80).  
Interestingly, some of the polyphenols, sesame lignans and flavonoids, which are 
structurally similar to flaxseed lignans are reported to alter fatty acid metabolism. Many 
flavonoids such as quercetin, apigenin and taxifolin, cause the inhibition of FAS as a mechanism 
of their antitumor activities (251). Sesame lignans including episesamin, sesamolin and sesamin 
altered the fatty acid metabolic enzymes at transcriptional and translational levels (249). These 
lignans show similar efficacy in decreasing the activity of FAS and SREBP-1c; however, 
sesamolin shows higher induction potential for fatty acid oxidation targets than sesamin due to 
greater bioavailability and higher tissue and serum levels of this metabolite (250). Furthermore, 
sesame lignans (structurally similar to flaxseed lignan) exhibited an antiproliferative effect on 
prostate cancer cells by inhibition of fatty acid metabolism and the biotransformation of sesame 
lignan also produces enterolignan (29), which may be responsible for the inhibition of fatty acid 
metabolism. Therefore, we hypothesized that flaxseed lignans inhibit fatty acid synthesis and/or 
oxidation as a mechanism of its antiproliferative activity in prostate cancer cells. In this report, 
we present the changes in mRNA expression and protein expression levels of four key proteins 
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involved in fatty acid metabolism (FAS, ACC-1, SREBP-1C and CPT-1) in prostate cancer and 
prostate normal cell lines. 
 
6.3 Material and methods  
6.3.1 Materials 
Secoisolariciresinol diglucoside (SDG) and secoisolariciresinol (SECO) (>95% purity) 
were kind gifts from Agriculture and Agri-Food Canada, Saskatoon (Dr. Alister Muir). 
Phosphate buffered saline (PBS) pH 7.8, versene, trypsin (2.5%), and keratinised–serum free 
media (K-SFM) were obtained from Invitrogen Inc. (Burlington, ON, Canada). Fetal bovine 
serum (FBS), T-75 Flasks, 24- and 96-well tissue culture plates, and horse serum were purchased 
from Fisher scientific (Toronto, ON, Canada). Ham's F12 (F-12K), Eagle’s Minimum Essential 
Medium (EMEM), and Dulbecco's Modified Eagle's Medium (DMEM) were purchased from 
ATCC (American Type Culture Collection, Rockville, USA). Enterodiol (ED), enterolactone 
(EL), penicillin-streptomycin antibiotic solution, potassium chloride (KCl), 
ethylenediaminetetraacetic acid (EDTA), magnesium chloride (MgCl2), sucrose (BDH), bovine 
serum albumin (BSA), ethylene glycol tetraacetic acid (EGTA), palmitoyl CoA, 5,5'-dithio-
bis(2-nitrobenzoic acid) (DTNB), Bradford reagent, L-carnitine, human epidermal growth factor 
(HEGF), cholera toxin, bovine insulin, hydrocortisone and all other chemicals unless otherwise 
indicated were purchased from Sigma (Oakville, ON, Canada). MilliQ water at 18.2 MΩ 
resistance was obtained from a MilliQ water purification system (Millipore, MA, USA).  All 
other chemicals were of analytical grade. 
 
6.3.2 Cell culture 
HepG2, MCF-7, MCF-12A, RWPE-1 and PC-3 cell lines were procured from ATCC 
(American Type Culture Collection, Rockville, USA). All the cell lines were subcultured as per 
ATCC procedures. HepG2, PC-3, and MCF-7 were subcultured using Eagle’s Minimum 
Essential medium (EMEM), Ham's F12 medium and EMEM containing 0.01 mg/mL bovine 
insulin, respectively. All these media were supplemented with Fetal Bovine Serum (FBS) and 
penicillin and streptomycin antibiotic solution (1% v/v). RWPE-1 was subcultured using 
Keratinocyte Serum Free Medium (K-SFM) supplemented with Bovine Pituitary Extract (BPE) 
0.05 mg/mL, epidermal growth factor (EGF) 5 ng/mL, MCF-12A was subcultured using 1:1 ratio 
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of Dulbecco's Modified Eagle's medium and Ham's F12 medium supplemented with 5% horse 
serum, 20 ng/mL human epidermal growth factor (HEGF), 100 ng/mL cholera toxin, 0.01 
mg/mL bovine insulin and 500 ng/mL hydrocortisone. The media for RWPE-1 and MCF-12A 
were also supplemented with 1% v/v penicillin streptomycin antibiotic solution. All the cells 
were grown in an atmosphere of 95% O2 and 5% CO2 with 95% humidity.  
 
6.3.3 Cytotoxicity assay 
Cytotoxicity of flaxseed (SDG and SECO) and mammalian lignans (ED and EL) were 
determined using sulforhodamine B (SRB) (328). Cells were grown in T-75 flasks (growth Area 
of 75 cm2, vented caps and straight neck, Fisher scientific (Toronto, ON, Canada)) and growth 
media were replaced three times in a week. Cells were harvested in exponential phase using 
trypsin (0.25% in versene) and counted using trypan blue dye. Complete media (100 µL) 
containing about 5×103 cells were poured in 96 well plates and were allowed to attach and grow 
for 24 h. After 24 h, complete media (100 µL) containing different lignans and control (1% 
DMSO) was added to cells containing media and incubated for 72 h. After 72 h, trichloroacetic 
acid (50 µL of 50% w/v in water) was added to each well and placed at 4°C for 1 h for fixation 
of the cells. One 96 well plate was fixed at the start of experiment to determine the initial number 
of cells in 96 well plates at start of experiment (Tz). Plates were washed with tap water four 
times and allowed to air dry over night. Staining of the cells was done using sulforhodamine 
(0.4% w/v in 1% v/v acetic acid) and washed with acetic acid (1% v/v). Trizma base (200 µL of 
10 mM) was added to dried wells and absorbance (OD) was read at 515 nm. The percent growth 
was calculated using equation 6.1. The IC50 was derived by fitting four parameter logistic curves 
(non linear regression analysis) between percent cell growth and log concentration using 
GraphPad Prism 5.0 for windows (GraphPad Software, San Diego, California, USA).  
 
% cell growth=
ODsample-ODTz
ODcontrol-ODTz
×100   Equation 6.1 
 
 
 
 
112 
 
6.3.4 Quantitative reverse transcription-polymerase chain reaction (QRT-PCR) 
Purified total mRNA was extracted according to manufacturer’s protocol using a RNeasy 
Mini kit (Qiagen Inc., Mississuaga, ON). Optical density (OD) at 260 nm and OD ratio 260/280 
nm was used as parameters to determine quantity and purity, respectively, of extracted mRNA 
using a Nanoview spectrophotometer (GE Healthcare, Baie d’Urfe, Quebec, Canada).  A known 
quantity of purified mRNA was used to synthesize cDNA according to the manufacturer’s 
protocol using a QuantiTect Reverse Transcription kit (Qiagen Inc., Mississuaga, ON).  
Specific primers of various gene sequences were designed using Primer3 software 
(Whitehead Institute for Medical Research, Primer 3). Validation of these forward and reverse 
primers was performed for  specificity of amplification, amplification efficiency over a 
concentration range and consistency with amplification efficiency of a housekeeping gene. Real 
time reverse transcription PCR involved Power SYBR Green PCR master mix (Applied 
Biosystems, Streetsville, ON) and an Applied Biosystems 7300 Real-Time PCR system (Applied 
Biosystems, Streetsville, ON). The PCR reaction was set up in three stages. Activation of 
samples was done at 94°C for 15 min. Exponential amplification of 40 cycles was done using 
three different temperature and time conditions such as denaturing at 94°C for 15 seconds, 
annealing at 60°C for 30 seconds and primer extension at 60°C for 30 seconds. The melt curve 
analysis was done by heating at 65°C-95°C at 0.5°C/second. ΔΔCT method was used to 
determine the fold change in mRNA expression levels.  
 
6.3.5 Validation of primers 
Melt curve analysis and single band of suitable size range on 2% agarose gel 
electrophoresis was used to determine the amplification specificity of the primers. Amplification 
efficiency ranges from 1.9 to 2.1 using three different log concentrations was selected as a 
criteria to validate the primers including the housekeeping gene. Similarity in amplification 
efficiency of the gene of interest and the housekeeping gene was determined by using the ΔΔCT 
method. The slope of less than 0.1 when ΔCT (the difference between target gene CT and 
housekeeping gene CT) was plotted against log concentration of RNA ensured similar efficiency. 
Primers showing specific amplification and similarity in amplification efficiency with the 
housekeeping gene were selected (Table 6.1). β-Actin was selected as the housekeeping gene 
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based on minimum variation in untreated and treated samples and similar amplification 
efficiency treated and untreated samples.  
 
Table 6.1 Validated forward and reverse primers for the mRNA expression analysis of various 
enzymes and transcription factors of fatty acid metabolism by QRT-PCR using SYBR green. 
Enzyme or 
Transcription 
Factor 
Forward primer Reverse primer 
FAS TCGTGGGCTACAGCATGGT GCCCTCTGAAGTCGAAGAAGAA
ACC-1 AGGGTGCGTTTCAATCAGATGCT AGGTTGGGCCAAGGGAGATGGT
SREBP-1C GTGGAGGGAACACAGACG TGCTCTGGAAAGGTGAGC 
CPT-I CTGTGGAGTCCCCTTTCC TAGCCGTCATCAGCAACC 
β-Actin ATGTCACGCACGATTTCC TTGCTATCCAGGCTGTGC 
 
 
6.3.6 ELISA for FAS 
Cells (1 × 105) were plated on polystyrene T-75 flasks and allowed to grow for 60-70% 
confluency before treatment with 25, 50 and 75 µM of EL and 1% DMSO (control) for 6, 12 and 
24 hours. Supernatants were collected and analyzed for FAS protein using an ELISA Kit for 
human fatty acid synthase (Uscn Life Science Inc, China), according to manufacturer’s 
instructions. 
 
6.3.7 CPT-I activity assay 
Cells, as grown above, were treated with 25, 50 and 75 µM of EL and 1% DMSO (control) 
for 6, 12 and 24 hours. Cells were washed with phosphate buffered saline (pH 7.4) and harvested 
using rubber policeman. Cell pellets containing about 1×108 cells were obtained after 
centrifugation at 1000×g for 15 minutes at 4°C. Cell pellets were homogenized in 
homogenization buffer IX (contains HEPES, MgCl2, EDTA, pH 7.4) containing 10 µL of 
protease inhibitor cocktail (Sigma, Oakville, ON) using a hand held homogenizer for 20 sec (5 
sec for 4 times). 20 µL of the reaction buffer and 50 µL of cell homogenate was added to each 
well of a 96 well plate. 10 µL of malonyl CoA (200 µM) was added to the inhibitor wells. 110 
µL of water was added to normal wells and 100 µL of water was added to the inhibitor wells. 
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Wells were centrifuged at 4000 rpm for 1 min to remove any air bubble. The plate was incubated 
at 37°C for 5 min. CPT levels were analysed using a UV-Spectrophotometric technique at 412 
nm. 20 µL of L-carnitine (10X) solution was added to each well and analysis was done at 412 
nm after 2, 5, 10, 20 and 30 min after addition of L-carnitine. The protein content was 
determined using the Bradford assay.  
 
6.3.8 Statistical analysis 
The significant changes in mRNA and protein expression were tested by one way ANOVA 
with Dunnett’s multiple comparison post-hoc tests using GraphPad Prism 5.0 (GraphPad 
software, San Diego, USA). 
 
6.4 Results 
 
6.4.1 Cytotoxicity assay 
IC50 values for SDG, SECO, ED and EL were determined in five different cell lines to 
identify the optimum concentration for the treatment of cells (Table 6.2).  SDG and SECO 
exhibited no cytotoxicity in either cancer or normal immortalized cell lines at concentrations 
exceeding 1000 µM. ED (1000 µM) exhibited cytotoxicity only against breast cancer cells and 
EL has cytotoxicity potential in breast and prostate cancer cells, but not in normal cells. 
Concentration of EL (25, 50 and 75 µM) used in the expression analysis of PC-3 and RWPE-1 
cells is based on the IC50 values calculated using cytotoxicity assay. 
  
Table 6.2: The IC50 values of plant lignans secoisolariciresinol diglucoside (SDG), 
secoisolariciresinol (SECO) and associated mammalian lignans, enterodiol (ED) and 
enterolactone (EL) in breast cancer (MCF-7), breast normal (MCF-12A), prostate cancer (PC-3), 
prostate normal (RWPE-1) and hepatic cancer (HEPG-2) cell lines. Cytotoxicity was assessed 
using the sulforhodamine B (SRB) assay (N=3). 
Flaxseed Lignans 
*IC50 (µM) 
PC-3 MCF-7 RWPE-1 MCF-12A 
HepG2 
SDG >1000 >1000 >1000 >1000 >1000 
SECO >1000 >1000 >1000 >1000 >1000 
ED >1000 690 >1000 >1000 971 
EL 57.0 72.8 >1000 >1000 92.7 
*IC50: The concentration that results in half of the maximum observed inhibitory effect on cell 
proliferation;  
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6.4.2 Quantitative reverse transcription-polymerase chain reaction (QRT-PCR) 
In order to determine the effect of EL on mRNA expression of fatty acid metabolism 
pathways in the prostate cancer cell line, PC-3, and prostate normal cell line, RWPE-1, mRNA 
expression analysis was conducted using quantitative RT-PCR. Figure 6.1 shows the fold change 
in mRNA expression relative to control following EL exposure of PC-3 and RWPE-1 cell lines. 
In PC-3 a concentration dependent decrease in the expression levels of ACC-1 with an increase 
in incubation time is observed whereas little variation is noted in RWPE-1 cells. EL 
downregulates FAS (65% at 75 µM after 12 h) transcription in concentration- and time-
dependent manner in PC-3; however, no such trend was observed in RWPE-1. The maximum 
inhibition of mRNA expression of FAS and ACC-1 was observed at 75 µM (highest 
concentration tested) after 12 h of incubation with EL. The percent inhibition at 24 h was lower 
than 12h.  mRNA levels of FAS were decreased with increasing EL concentrations at 12 and 24 
h. FAS mRNA levels did not change with EL exposure to RWPE-1 cells. mRNA levels of 
SREBP-1C and CPT-I in PC-3 do not show any consistent concentration- and time-dependent 
trends in comparison to RWPE-1 cells (Figure 6.1).  
 
6.4.3 FAS ELISA and CPT-I activity assay 
The ELISA for the presence of FAS in cell supernatant was performed using a 
commercially available kit to determine the effect of enterolactone (EL) on protein expression. 
EL significantly (p<0.001) decreased FAS expression in PC-3 cells, however; levels of FAS 
were below the limit of detection (0.312 ng/mL) in RWPE-1 cells in both control and EL treated 
wells. FAS inhibition in PC-3 cells ranged from 101% (75 µM, 6 h) to 21% (75 µM, 12 h). A 
concentration-dependent inhibition of FAS was observed with maximum inhibition at 12 h at 75 
µM whereas levels of FAS approached the normal levels at 24 h in comparison to 12 h at all 
three concentration levels (Figure 6.2). EL had no effect on CPT-I levels in PC-3 cells and 
RWPE-1 cells (Figure 6.3). 
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Figure 6.1: Change in mRNA expression levels of various enzymes and transcription factors with 
respect to time, involved in fatty acid synthesis and oxidation in PC-3 and RWPE-1 cell lines 
after treatment with 25, 50 and 75 µM of EL for 6, 12 and 24 h with respect to control (1% 
DMSO) in respective media. 
 
6.5 Discussion and conclusion 
Consumption of various lignans such as sesame, flaxseed and associated mammalian 
lignans are positively associated with decrease in prostate and breast cancer (82, 371, 372); 
however, the bioactive lignan form and mechanism of action remain unknown. Several clinical 
studies and in vitro investigations suggested EL as the lignan likely mediating the positive effects 
in breast and prostate cancer (80, 82).  In our cytotoxicity assay against breast cancer and 
prostate cancer cell lines, EL caused cytotoxicity only in prostate and breast cancer cell lines at 
an IC50 value physiologically achievable. The IC50 values of the other flaxseed lignans, SDG, 
SECO and ED in both breast and prostate cancer cell lines were too high to be physiologically 
achievable. The IC50 of EL was 57 and 72.8 µM against PC-3 and MCF-7 cells, respectively, 
using sulforhodamine B assay. Lin et al reported similar IC50 values against PC-3 cell lines and 
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additionally EL showed anti-proliferative activity against other prostate cancer cell lines 
including DU145 and LNCaP cell lines (80). In our study, EL demonstrated >50 times selectivity 
for prostate cancer cells over normal prostate cells. Thus, we selected enterolactone to identify 
the mechanism of cytotoxicity in prostate cancer cell lines (limited financial resources precluded 
evaluation in breast cancer cell lines). Since sesame lignans, which are structurally similar to 
flaxseed lignans, inhibit prostate cancer cell through modulation of fatty acid metabolism (212, 
373) and sesame lignans also form enterolactone upon biotransformation in the gut (29), we 
hypothesized that EL alters the expression of FAS, SREB-1C, CPT-1, and/or ACC as key 
proteins involved in fatty acid metabolism in prostate cancer cells.   
EL caused decreased expression of FAS in a concentration and time dependent manner 
with maximum reductions observed at 12h after initial exposure. EL had no effect on ACC, 
CPT-1, and SREBP-1C expression. The effect on FAS mRNA expression correlated with protein 
expression. Others have observed a dose dependent inhibition of FAS mRNA expression in rat 
hepatocytes after administration of sesame lignans as a dietary source to the rats with modulation 
of SREBP-1C and other proteins involved in fatty acid metabolism (211, 212, 250, 373). No 
statistically significant changes in FAS mRNA and protein was observed at 6 h of exposure; 
however reductions in FAS mRNA and protein expression levels was significant at 12 and 24 h 
exposure. We noted recovery in expression at 24 h, which may due to degradation of EL with 
time such that mRNA and protein expression increased due to decreased concentration of EL. 
We have noted instability of EL at room temperature in serum samples (332), but we did not 
measure the concentration of EL in cell culture medium to rule this out. Alternatively, the 
decreased FAS mRNA levels may send a feedback signal to increase the synthesis of 
transcription factors that promotes FAS mRNA expression.   
Our pilot study provides some supportive evidence that EL is a FAS inhibitor and further 
studies are required. Whether inhibition of FAS alone will result in the decreased proliferation of 
prostate cancer cells is another unanswered question. Further studies are needed to determine 
EL’s mechanism of cytotoxicity and whether this cytotoxicity in prostate cancer cells is due to 
inhibition of fatty acid synthase.  
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Figure 6.2: Expression of FAS as percent of control (1% DMSO) using FAS ELISA Kit for 
human fatty acid synthase (Uscn Life Science Inc, China), in PC-3 cell supernatant after 
treatment with 25, 50 and 75 µM of EL and 1% DMSO (control) in respective media for 6, 12 
and 24 hours. FAS expression in PC-3 cells significantly (p<0.05) decreased at all concentrations 
(maximum at 75 µM at 12 h). Statistical analysis was performed using one way ANOVA with 
Dunnett’s multiple comparison post-hoc test.  
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Figure 6.3: Protein normalized expression of CPT-I as percent of control (1% DMSO) using 
spectrophotometric method in PC-3 and RWPE-1 after treatment with 25, 50 and 75 µM of EL 
and 1% DMSO (control) in respective media for 6, 12 and 24 hours. There is no significant 
change (p>0.05) in protein expression of CPT-I in PC-3 and RWPE-1 cells. Statistical analysis 
was performed using one way ANOVA with Dunnett’s multiple comparison post-hoc test . 
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CHAPTER 7 
 
General Discussion 
 
7.1 Discussion 
Natural Health Products (NHPs) are consumed worldwide with 65-80% of world 
population and two thirds of the Canadian population using NHPs as a part of their healthy living 
styles (258, 267). Natural products regulation in Canada is an evolving regulatory area and the 
new amendments in the regulatory laws aim to provide accessibility of Canadians to NHPs while 
reducing their inappropriate usage. The NHPD regulates NHPs in Canada (265) and under the 
current regulations, flaxseed can be marketed as a food, a functional food or NHPs based on the 
product representations and claims. In Canada, NHPD approval of a therapeutic claim is based 
on the evaluation of a data package that should include preclinical and clinical (phase III) trials 
demonstrating safety and efficacy, along with any epidemiological data. The chemopreventive or 
therapeutic claims of flaxseed lignans, one of the major active constituents of flaxseed, will 
require such safety and efficacy evaluations (252, 265). 
Knowledge of the pharmacokinetics of flaxseed lignans is important to understand their 
safety and the potential exposure dose necessary for therapeutic effectiveness. The flaxseed 
lignan, SDG, is transformed into SECO and subsequently into the mammalian lignans, ED and 
EL, in the gastrointestinal tract. This conversion is considered essential for various biological 
activities shown by these lignans, but the bioactive form among these lignans is not known. We 
expected that a comparative pharmacokinetic characterization of individual purified lignans may 
provide suggestive evidence about the potential bioactive lignan.  
In vitro and in vivo pharmacokinetic studies on these purified lignans were conducted in 
order to gain a better understanding of their absorption and disposition characteristics. In vitro 
evaluations included assessment of permeability and metabolism in Caco-2 and in vivo 
evaluations involved oral and intravenous oral bolus dosing in male Wistar rats. We hoped to 
glean information that will help us to design prospective safety and efficacy studies.    
To perform these in vitro and in vivo pharmacokinetic studies, we required a validated, 
accurate, precise and specific bioanalytical method to quantify flaxseed and associated 
mammalian lignans. Therefore, we developed and validated a HPLC-fluorescence method in rat 
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serum as per USFDA guidelines (332). Fluorescence was chosen as a method of detection over 
UV due to increased sensitivity and specificity of the fluorescence method. LC-MS/MS method 
of detection would improve sensitivity and selectivity; however, an LC-MS/MS instrument was 
not available in our facility.  HPLC-fluorescence method provides an analytical method for labs 
with limited or no accessibility to LC-MS/MS. Given the wide difference in the polarity of SDG 
with other three lignans (SECO, ED and EL), the analysis of SDG could not be 
chromatographically separated using a gradient suitable for the other lignans.  A separate mobile 
phase gradient condition was established for SDG as well as a different method of extraction. 
Different mobile phase conditions and extraction methods increased time and cost of sample 
processing and analysis ,but it did allow for methods that passed all the validation criteria except 
for bench top stability of EL. EL was not stable in serum for 6 hours at room temperature but did 
not show any signs of degradation when stored on ice for 6 hours (332). We did not investigate 
EL’s lack of stability in serum but we surmised that the lactone ring of EL opens at higher 
temperature in the serum. Lactone ring opening explains the plasma degradation of 
camptothecin, a cytotoxic natural product and contains a lactone ring (374, 375). Further 
investigation is required to determine EL’s lack of stability in serum.   
One of our first in vitro evaluations to understand the absorption characteristics of lignans 
involved a permeability assessment using the Caco-2 polarized monolayer. SDG, SECO, ED and 
EL showed low apparent permeabilities in the Caco-2 cell monolayer. Differentiated Caco-2 
cells functionally and morphologically resemble small intestinal enterocytes and permeation 
across the Caco-2 cells is well correlated with in vivo absorption in human (127). The 
concentration of lignans used in the permeability experiments were high (100 µM) because we 
assumed that the exposure of enterocytes will be higher after oral administration and no 
cytotoxicity was observed at these concentrations in the Caco-2 cell system. SDG demonstrated 
poor permeability across Caco-2. Although a positive permeability marker substrate, metoprolol, 
was not simultaneously conducted with the lignan permeability assessments in Caco-2, the 
apparent permeability values of SECO, ED and EL were below the reported apparent 
permeability of metoprolol (30 cm/sec). Metoprolol Caco-2 permeability is a cut off that divides 
different classes of Biopharmaceutical Classification System (BCS) (336). The BCS 
classification system divides drugs into four classes (class I: high solubility and high 
permeability; class-II: low solubility and high permeability; class III: high solubility and low 
122 
 
permeability; class IV: low solubility and low permeability) based on solubility and permeability 
of the drugs (376) . In general, the permeability of lignans increased with an increase in 
lipophilicity. The large molecular size and very high polarity explains the poor permeability of 
SDG. Molecules with similar characteristics demonstrate low oral bioavailability (377), which 
suggests SDG may also have poor oral bioavailability.  The failure to detect SDG following an 
oral dose in male Wistar rats confirms the lack of oral bioavailability of SDG. These data suggest 
SDG is unlikely the bioactive lignan mediating the putative health benefits of oral flaxseed 
lignan consumption. 
Additionally, our Caco-2 transport studies suggest that lignans undergo passive diffusion, 
and carrier-mediated influx or efflux processes are not likely involved in their transport across 
the polarized epithelium of the gastrointestinal mucosa. The efflux ratio (EFR), a ratio of 
apparent permeabilities of basal-to-apical to apical-to-basal compartments, where ratios lower 
than 0.8 suggest active influx while ratios greater than 1.2 suggest active efflux (127, 330), were 
between 0.8 and 1.2, suggesting that passive diffusion governs the transport of these lignans. 
Similar to our results, these lignans showed passive diffusion mediated uptake in Caco-2 in a 
recently published report (337).   
In addition to permeability across the gastrointestinal mucosa, oral bioavailability is 
determined by the extent of first-pass metabolism. The delineation of first pass metabolism of an 
orally administered therapeutic agent is critical in any pharmacokinetic understanding because 
high first-pass metabolism may lead to low oral bioavailability. Before reaching the systemic 
circulation, an orally administered compound first encounters the intestine and liver where 
significant presystemic metabolism can occur. Phase II conjugative metabolites of ED and EL 
were observed in the portal vein of rats on a flaxseed diet suggesting that lignans undergo phase 
II enzyme metabolism in the intestine (27). Jansen et al (176) also reported the phase II enzyme 
metabolism of ED and EL in Caco-2 cells. No information on the intestinal metabolism of SDG 
and SECO is available. Therefore, we conducted a comparative metabolic study of SDG, SECO, 
ED and EL in Caco-2 cells.  Our method of determination of extent of conjugation was indirect; 
we subtracted concentrations of unconjugated lignans from total concentration, which was 
determined by hydrolysis of glucuronides with glucuronidase/sulphatase enzyme from Helix 
pomatia. Although the deconjugation enzyme isolated from Helix pomatia lacks specificity, we 
manipulated the experimental conditions to promote glucuronidase activity.  After 48 hours of 
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incubation of lignans with Caco-2, the total concentrations (conjugated and unconjugated) 
obtained by 2 h hydrolysis with glucurnoidase resulted in concentrations similar to initial lignan 
concentrations. This suggests that Caco-2 primarily produces glucuronide conjugates of the 
SECO, ED, and EL.  
The contribution of liver has also been reported in the literature. Jacobs and Metzler (185) 
identified oxidative metabolites of ED and EL in rat, pig and human liver microsomes while 
Niemeyer et al (184) identified these metabolites in rat bile and urine while Dean et al (183) 
studied the metabolism of EL in rhesus monkeys.  All these studies aimed at metabolite 
identification and did not report the extent of metabolite formation. Lack of data on the extent of 
phase I and II metabolism in liver does not allow us to predict the effect of liver metabolism on 
oral bioavailability of lignans. Nonetheless, liver metabolism of lignans will contribute to 
reductions in the oral bioavailability of lignans. 
In our conjugative metabolism studies of lignans in Caco-2, the total concentrations 
(hydrolyzed) and the concentrations of unconjugated (non-hydrolyzed) SDG were similar 
suggesting that SDG does not undergo glucuronidation in Caco-2 cells. Interestingly, Obermeyer  
(35) suggested that glucuronidase converts SDG to its aglycone SECO, yet we observed no 
significant decrease in the concentration of SDG after  48 h exposure to β-glucuronidase 
treatment. This observation led us to a follow-up investigation on the deglycosylating effect of β-
glucuronidase on SDG. Less than 5% of SDG was converted to SECO when SDG was incubated 
with β-glucuronoidase. Our results clearly contradict Obermeyer’s findings; however, his 
findings can be critiqued based on two arguments. First, in that study a flaxseed homogenate 
(slurry) was incubated for 24 hours with β-glucuronidase at 37°C. Carbohydrates and proteins 
present in the flaxseed slurry create an ideal condition for the growth of opportunistic bacteria 
(378). Possibly, these opportunistic bacteria would have metabolized flaxseed lignan complex to 
form SECO. The authors do not justify incubating for 24 h when β-glucuronidase enzyme may 
not be active after a few hours of incubation under in vitro conditions. Secondly, Obermeyer 
used an enzyme concentration 37 times higher than the concentration used in our experimental 
conditions (35). Obermeyer used 5000 units/mL of β-glucuronidase in the incubation while we 
used 135 units/mL of β-glucuronidase (35). Thirdly, the amount of SDG used in the incubation 
could be different and amount of substrate (SDG) can affect the formation of metabolites 
(SECO). Unfortunately, the amount of SDG used in Obermeyer’s experiment is unknown. 
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Arguably, the fourth reason could be the differences in β-glucuronidase enzyme used and if we 
believe this argument, our results should be more reliable. Since, the source of enzyme was same 
(Sigma) only batch-to-batch variation can lead to the differences in enzymatic activity. Since the 
quality control measures at Sigma are expected to improve in 17 years, the experimental results 
with later batch should be more reliable. 
The in vitro Caco-2 experiments suggested that the lignans may exhibit low bioavailability 
following oral administration. To confirm, we preceded with in vivo oral and intravenous bolus 
studies. We selected rat as our preclinical species because rat is a preferred species for many 
preclinical safety and efficacy evaluations. Much of the available literature reports the 
pharmacokinetics of lignans following administration of various flaxseed products, but not the 
purified lignan forms. Such studies are confounded by a lack of understanding of lignan content 
in the flaxseed product and an ability to know the dose of lignan administered. As well, flaxseed 
products contain many different constituents, which may interact with the lignans resulting in 
altered oral pharmacokinetic characteristics relative to the purified lignan. Furthermore, without 
an intravascular administration an understanding of the key dispositional characteristics (i.e. 
volume of distribution, systemic clearance) is not possible. Kuijsten et al (157) administered a 
small dose of purified SDG orally to healthy subjects while Rickard and Thompson (343) 
administered purified SDG orally to rats. Damdimopoulou et al (344) administered EL to C57B1 
reporter mice and determined the plasma concentration of EL and EL-glucuronides. None of 
these studies reported comparative pharmacokinetics after the oral and intravenous 
administration of purified lignans. Thus, we conducted comparative pharmacokinetics of lignans 
in rats.  
Flaxseed lignans show poor or low oral bioavailabilities in male Wistar rats. Our studies 
and literature evidence of low permeability and high intestinal metabolism of these lignans may 
explain the low oral bioavailability. Among the four lignans, SDG exhibited the lowest oral 
bioavailability as the serum concentrations after oral administration of SDG at a dose of 40 
mg/kg were below our limit of quantification. Likely, high polarity of SDG (clogP=-1.338) and 
large molecular size (MW= 686.71) may explain the low oral bioavailability. Since SDG is not 
the bioavailable form among these four lignans, SDG may not be the bioactive form and it must 
undergo biotransformation to show bioactivity. The literature also hypothesizes that SDG 
metabolites are responsible for its biological activity (29, 40). The deglycosylated form of SDG, 
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SECO, shows moderate oral bioavailability (25%), while ED shows less than 1% oral 
bioavailability. In Caco-2 studies, the Papp value of ED exceeded SECO and also showed a 
greater rate of glucuronidation than SECO. Jansen et al also observed extensive conjugation of 
ED and EL in HT-29 and Caco-2 cells (176). The extensive metabolism of lignans is further 
supported by a study by Axelson and Setchell (193), who observed that majority of ED and EL 
in the portal vein in rat was present as glucuronide and sulfate conjugates. These data suggest 
that despite the better permeability characteristics, ED likely undergoes more extensive 
metabolism during its transit from the gastrointestinal tract to the systemic circulation. Although 
the literature supports the contribution of liver in first pass metabolism of lignan, the exact 
contribution is not known. Similarly, tea catechins undergo extensive phase II metabolism as 
well as degradation in the presence of intestinal microorganisms and thus exhibits low oral 
bioavailability in humans (377, 379). 
  An interesting observation following from the oral administration of SECO was its 
bimodal concentration time profile. All rats exhibited this “double peak” phenomenon. Usually, 
bimodal concentration versus time profiles arise due to enterohepatic recirculation or absorption 
from two different sites. However, the Cmax of the first peak at 5 minutes post administration and 
appearance of the Cmax of the second peak at a time shorter than a rat’s gastric emptying time 
(346) suggests the appearance of bimodal peak may not be attributed to enterohepatic 
recirculation. Alternatively, the absorption of SECO may be occurring from two different 
absorption sites. I fitted a mathematical model for absorption from two different sites to SECO 
oral concentration profile but the parameters could not be estimated due to the small number of 
observations defining each peak. Further study will be needed to understand the absorption 
characteristics of SECO.  
Flaxseed lignans are rapidly eliminated in rat and the systemic clearance values of SDG, 
SECO and ED seemed to relate to the polarity of the lignan; the more polar the lignan the lower 
its systemic clearance value. A meta-analysis on a large number of compounds shows that 
increase in permeability is positively correlated with liver microsomal clearance (380). Likely, 
the increase in permeability increases the transport across the cell membrane and the 
accessibility of intracellular metabolic enzymes increases, which leads to high liver microsomal 
clearances. Similarly, lignans increasing permeability is probably increasing their clearances. 
Interestingly, the systemic clearance values of SECO and ED exceeded the hepatic blood flow 
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rate. According to mass balance principles, systemic clearance is a product of blood flow rate to 
the eliminating organ and the extraction ratio (i.e. the efficiency with which the eliminating 
organ removes a compound from a volume of blood traversing through the eliminating organ.) 
With an extraction ratio of one, the systemic clearance cannot exceed the blood flow rate to the 
eliminating organ. When specifically applied to the liver, hepatic clearance cannot exceed the 
hepatic blood flow rate (349). Consequently, non-hepatic elimination mechanisms must 
additionally contribute to the systemic clearance of these lignans in rats. Other routes of 
elimination may be excretion in urine (193) and feces (188) or extrahepatic phase II metabolism. 
Similar to systemic clearance, serum protein binding and volume of distribution also 
increased with a decrease in polarity (SDG<SECO<ED). SDG shows the lowest volume of 
distribution and, likely, the low lipophilicity and large molecular size of SDG limits its 
peripheral distribution. Lipophilicity and plasma protein binding are major factors in the 
determination of volume of distribution (381). Despite having a high fraction unbound, SDG 
exhibited a low volume of distribution because its hydrophilicity may have limited its 
partitioning into peripheral tissues. On the other hand, SECO and ED exhibited large volumes of 
distribution indicating higher distribution into peripheral tissues, which is supported by the 
literature (158, 159). The volume of distribution of ED was unexpectedly large given the high 
plasma protein binding of ED. Apparently, ED has very high tissue partitioning and tissue 
binding (fb,T)  characteristics because tissue partitioning and the fu,p/fu,T are the major determinant 
of volume of distribution. Several tissue distribution studies (158) have suggested presence of 
ED in different tissues supporting the fact that ED has high tissue partitioning characteristics. 
Since half-life is dependent on volume of distribution and clearance, expectedly, half-life 
was short in rats. Among SDG, SECO and ED, half-life of SDG was shortest while SECO had 
the longest half-life. Despite having similar volumes of distribution, SECO had longer half-life 
due to lower systemic clearance. Although we could not determine the pharmacokinetics of EL 
in our study, Kuijsten et al reported half-lives of ED and EL in human after per oral 
administration of SDG. Half-life of EL (~12.6 h) was longer than that of ED (~4.4 h). Also, the 
half-lives of lignans were not administration route dependent eliminating the possibility of flip-
flop kinetics.  
The pharmacokinetics of EL could not be established because the rats died within a few 
hours of administration (1 mg/kg, iv; 10 mg/kg, p.o.). Interestingly, in a study reported in the 
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literature, a 2 mg oral administration of EL to female Wistar rats did not result in death or 
toxicity (184). In a clinical study (157), EL was also detected in the plasma after administration 
of SDG to healthy volunteers and no toxicity was reported. The difference in outcomes may be 
the result of different sources of EL or gender/species specific toxicity. Sources of EL used in 
different studies were not the same and likely, impurities could have led to toxicity. 
The concentrations of EL in the serum samples collected before the death of animals were 
below limit of quantification. In order to eliminate any possibility of entrapment of EL into RBC 
that may explain lower concentrations in the serum, we conducted an RBC partitioning study. 
The RBC to plasma partition ratio was almost equal to one indicating that RBC entrapment is not 
a cause of lower serum concentrations. Therefore, lower serum concentrations suggest rapid 
distribution of EL into other organs.  
Several speculations can be made to explain the mechanism of toxicity; however, more 
studies are needed to identify the actual reason for the toxicity of EL.  Firstly, rapid distribution 
of EL into a sensitive peripheral tissue may result in acute toxicity and rapid death of the rats. 
Alternatively, EL undergoes extensive metabolism and the metabolite is highly toxic. A third 
possibility is that the EC50 and LD50 of EL are very low and the concentration of EL exceeded 
LD50 at the administered doses. In all three cases, certainly some vital organ is affected to show 
acute toxicity. The rats exhibited signs of tremor, jumping and pawing. The pesticide, befenthrin, 
showed similar symptoms in rats when administered at higher doses. This chemical acts on the 
central and peripheral nervous systems (350). Similarly, the central and/or peripheral nervous 
systems may be the target of EL’s acute toxicity. In a tissue distribution study (159, 160), the 
concentration of EL in the brain suggests that it may be acting on nervous system. However, 
further investigations are needed to support any of these arguments.   
In general, the lignan metabolites of SDG exhibit high volumes of distribution, high 
systemic clearance values, and short half-lives. Since SDG does not undergo significant 
absorption, it is less likely to be the bioactive form that mediates the health benefits of flaxseed. 
SECO shows the highest oral bioavailability while ED exhibits the highest systemic clearance. 
The systemic clearance value of SECO exceeds hepatic blood flow suggesting a role for non-
hepatic elimination mechanisms. EL showed toxicity at the tested doses (10 mg/kg p.o. and 
1mg/kg i.v.) and requires further investigation to determine the reasons for toxicity.  
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7.2 Pharmacodynamic studies 
Flaxseed has benefit in several diseases including diabetes, cancer and cardiovascular 
disease (81, 314, 340) and the lignans may mediate these beneficial effects. Recently, 
postprandial hyperglycemia was identified as an independent risk factor for cardiovascular 
disease (302). Although various preclinical and clinical reports suggest that flaxseed lignans 
have anti-diabetic effects (13, 106, 107), no study had evaluated the effects of lignans on 
postprandial hyperglycemia. To evaluate the effect of lignans on postprandial hyperglycemia we 
proposed the administration of lignans in streptozotocin induced diabetic rats. Acute and chronic 
dosing pilot studies were proposed using SDG and the commercially available lignan product, 
BeneFlax (38% flaxseed lignan complex), respectively. Neither acute (SDG) nor chronic 
administration (once daily for 28 days of Beneflax) caused a blunting of postprandial 
hyperglycemia in normal and streptozotocin-induced hyperglycemic male Wistar rats. Adjusting 
the time of SDG or BeneFlax administration with the oral glucose tolerance test (OGTT) 
(simultaneous, 2 h and 12 h prior to the OGTT) to consider the need to allow for the conversion 
of SDG to ED and EL in the colon had no influence on postprandial hyperglycemia. The lack of 
efficacy may be due to the short duration of administration or the diabetic model used in our 
study. Probably, a longer administration and different diabetic models such as high fat diet 
induced hyperglycemia or Zucker fa/fa rats may have given a different result. It may be possible 
that the results obtained by other labs that suggest SDG shows benefit in postprandial 
hyperglycemia is not therapeutically significant because none of the studies in the literature 
measured the postprandial hyperglycemia blunting effect of SDG (13, 93, 106). Arguably, this 
may be a case of failure of translation of biomarker changes into symptomatic relief of disease. 
We did not pursue this further and may be studied in detail later in our lab.    
One of the directions of flaxseed lignan research in our lab was to identify the 
mechanism(s) of action of flaxseed lignans. Flaxseed lignans show beneficial effects in breast 
and prostate cancers (1, 81). Prostate and breast cancer cells use fatty acid as their major energy 
source rather than glucose (221). Inhibition of fatty acid synthesis and oxidation results in death 
of prostate and breast cancer cell lines (217, 382). Fatty acid metabolism is also very important 
in diabetes and cardiovascular disease and may be a central link between the different 
pharmacodynamic activities shown by lignans. Sesame lignans, which are structurally very 
similar to flaxseed lignans, modulate fatty acid metabolism (250). Thus, we proposed that 
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flaxseed lignans modulates fatty acid metabolism to exhibit its antiproliferative effect in prostate 
cancer.  
In order to find working concentrations of lignans, we determined their IC50 against breast 
and cancer cell lines using sulforhodamine B (SRB) assay (328). Sulforhodamine B assay was 
preferred over the MTT assay because MTT assay may be influenced by polyphenols while SRB 
assay is not (383). The IC50 of SDG, SECO and ED was very high (~1000 µM) and may not be 
feasible to achieve such concentration in the tumour under physiological conditions. Only EL 
showed IC50 values that may be achieved physiologically. Therefore, EL may be the only form 
among tested lignans that could show antiproliferative activity in prostate and breast cancer cells. 
Several studies have also suggested EL as the bioactive form of lignan (16). Thus, we selected 
EL for further evaluations. In my work, I tested the effect of EL in prostate cancer cells while 
work on breast cancer cell lines is ongoing in our lab.   
Fatty acid synthesis and oxidation helps to maintain fatty acid homeostasis and alterations 
in these pathways may disturb fatty acid homeostasis. Prostate cancer cells use fatty acid as the 
energy source whereas normal cells do not (221). Thus, disturbance of fatty acid homeostasis 
may lead to selective toxicity to cancerous cells without affecting normal cells (218). Following 
exposure to EL, the mRNA expression of ACC-1 and FAS, two major enzymes of fatty acid 
synthetic pathway, showed a concentration- and time-dependent decrease in mRNA expression 
in PC-3 cells. On the other hand, mRNA expressions of CPT-1, the enzyme that facilitates the 
transport of acetyl CoA into mitochondria for β-oxidation and mRNA expression of SREBP-1C, 
a transcription factor that regulates fatty acid synthesis (230, 231, 367) failed to exhibit 
concentration or time dependent changes. The changes in mRNA expression levels of these 
biomarkers were not significant in the RWPE-1 (normal prostate cells) cell line. Maximum 
inhibition of FAS and ACC-1was observed at 75 µM after 12h of incubation. The maximum 
inhibition observed at 12 h approached control levels at 24 h suggesting that the inhibition of 
FAS and ACC-1 is reversible. We previously reported that EL was not stable at room 
temperature in serum (332). Consequently, the return to control levels may be due to a 
degradation of EL in the cell culture plate wells. We did not test the concentrations of EL in the 
incubation medium nor did we add EL to the plate wells to determine whether FAS expression 
remained low relative to control.  
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We selected one target each from fatty acid synthesis and oxidation pathway to determine 
changes in protein expression levels or enzyme activities. Similar to mRNA expression results, 
EL inhibited FAS in a concentration- and time-dependent manner. The concordance between 
FAS mRNA and protein expression expression suggests EL modulates FAS in prostate cancer 
cell lines by transcriptional inhibition. Several transcriptional factors regulate transcription of 
genes and the delayed effect of EL (no significant effect at 6h post-treatment with EL) suggests 
that it may be inhibiting synthesis of some transcriptional factors. We investigated one of the 
transcription factors, SREBP-1C, which generally requires post-transcriptional modifications to 
obtain the transcriptionally active nuclear form (384).  Apparently, EL does not inhibit SREBP-
1C in prostate cancer or prostate normal cell lines. The levels of FAS protein expression were 
below the limit of quantification in RWPE-1 cells because FAS is not elevated in normal cell 
lines (218). EL did not significantly change CPT-1 activity in PC-3 and RWPE-1 cells in a dose-
dependent manner. These results support the claim that EL inhibits fatty acid synthesis to show 
antiproliferative activity of prostate cancer cells, but does not affect fatty acid oxidation. 
Changes in mRNA expression levels and protein expression of other targets such as transcription 
factors in prostate cancer cells may also have impact on fatty acid metabolism and requires 
further investigations. 
 
7.3 Challenges and limitations of the studies 
My current work encountered several challenges and has many limitations. The first and 
foremost challenge was to develop a sensitive bioanalytical method. A change in the detection 
technique to fluorescence increased the sensitivity of the method but lacked sufficient analytical 
sensitivity for a complete pharmacokinetic characterization of the lignans. A better detection 
technique such MS/MS would improve detection sensitivity, but this was not availabile during 
my studies. The second challenge was the availability of purified plant lignans and mammalian 
lignans. Plant lignan purification methods are very costly and cumbersome. Therefore, resource 
availability was a major issue in most of the experimental designs. Thirdly, we tested the effect 
of the mammalian lignan, EL, on a limited number of enzymes of fatty acid metabolism 
pathways.  Inclusion of other important enzymes and transcriptional regulators would have 
helped to put the pharmacodynamic studies into better perspective. Lastly, the administration of 
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EL was fatal to rats and I was not able to proceed with further evaluations due to animal welfare 
concerns. 
 
7.4 Conclusion 
My current research work provides important insight into intravenous and oral 
pharmacokinetics of purified flaxseed lignan and associated mammalian lignans, which are 
critical in understanding their safety and efficacy. My research work indicates that SDG may not 
be the bioactive form and EL may be a lignan form with antiproliferative activity in prostate 
cancer. We reported the comparative phase-II conjugative metabolism in Caco-2 cells and 
pharmacokinetic characteristics of these lignans in male Wistar rats. For the first time, we are 
reporting the toxicity of EL. Pharmacodynamic studies suggest that enterolactone inhibits fatty 
acid synthesis to show antiproliferative action in prostate cancer cells and does not show such 
effect in prostate normal cell lines. However, further studies are needed to validate this 
conclusion.  
 
7.5 Future directions 
The primary objective of our pharmacokinetic investigations on purified flaxseed lignans is 
to improve our understanding of lignan safety and efficacy. Single dose pharmacokinetics of 
these lignans in rats is an important first step, but our next step towards the development of these 
lignans is multiple dose pharmacokinetic and phamracodynamic investigations on efficacy and 
safety of these lignans. Since we could conclude that SDG is not the bioavailable form and less 
likely to be responsible for bioactivity, further investigations on the safety and efficacy of 
purified lignans should involve principally SECO, ED and EL.  
 
7.5.1 Anti-tumour effect of lignans in prostate cancer 
While the benefits of flaxseed supplementation in prostate cancer are supported by 
different clinical study outcomes (81, 83, 84), efficacy of purified flaxseed lignan remains 
unknown in preclinical species. Although in vitro cytotoxicity assays reported efficacy of lignans 
(80) in prostate cancer cell lines but to the best of our knowledge, the efficacy in preclinical 
prostate cancer model is not established. Administration of 7-hydroxymetairesinol, a precursor of 
EL, decreased the growth of prostate tumor in LNCaP human prostate cancer xenografts in 
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athymic mice (86) but efficacy of EL, SECO and ED remains to be proven. A study involving 
the effect of administration of purified lignans (SECO, ED and EL) in prostate tumor 
xenografted athymic nude mice is necessary to provide supportive evidence of lignan efficacy in 
prostate cancer. A significant reduction in the tumor size in comparison to vehicle controlled 
group will be considered effective. If the lignans are found to show significant anti-cancer 
activity a series of studies as proposed in ensuing sections will be conducted; however, if the 
lignans are found ineffective the studies described below would not be warranted. 
 
7.5.2 Multiple dose pharmacokinetic studies in rat 
Multiple dose pharmacokinetic studies determine the steady state pharmacokinetic 
parameters. Since multiple doses of SECO, ED and EL will be administered, steady state 
pharmacokinetics (Css, Cmax, Cmin) will affect the efficacy and safety. Currently, we do not know 
steady state pharmacokinetics of SECO, ED and EL in rats. SECO, ED and EL will be 
administered at multiple occasions and blood samples will be collected over the duration of the 
experiment to determine steady state pharmacokinetic parameters of SECO, ED and EL. The 
concentration in the plasma will be determined and pharmacokinetic parameters will be obtained 
by non-compartmental analysis. 
 
7.5.3 Tissue distribution of SECO, ED and EL in rats 
The site of action of lignans is likely to be located in peripheral tissue and the 
concentration of free lignans at the site of action will determine the pharmacological response. 
The tissue distribution data can also be used to explain toxicity studies. Animals will be dosed 
with SECO, ED and EL and blood samples, urine and feces of animal will be collected. Animals 
will be sacrificed at the end of the study and different organs will be isolated, homogenized and 
concentrations determined. The concentrations may be below limit of quantification which may 
be resolved by the use of radiolabelled lignans and determining the radioactivity in different 
organs.  
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7.5.4 Pharmacokinetics studies in larger animals 
Pharmacokinetic data in larger animals are required for allometric scaling. 
Pharmacokinetic studies will be conducted in rabbits and dogs and the clearance and volume of 
distribution will be extrapolated allometrically to predict first-in-human dose.  
 
7.5.5 Dose range finding study in rats 
Dose range finding (DRF) study establishes dose response curve to determine appropriate 
dose levels and develop strategies for toxicology studies. The efficacy and toxicity of therapeutic 
moieties are dose dependent and knowing the no effect level dose (NEL), effective dose range, 
dose with no observed adverse effect level (NOAEL) and maximum tolerated dose (MTD) are 
very critical in the assessment of safety and deciding first-in-human dose. Although, the history 
of human consumption of flaxseed is long, administration of purified lignans requires assessment 
to understand their safety.   
A dose range finding study will be conducted in two phases. In the first phase, a single 
escalating dose of SECO, ED and EL will be administered orally to rats. In second phase, a fixed 
dose of SECO, ED and EL will be administered on multiple occasions. Change in the biomarkers 
of prostate cancer such as PSA, free androgen index, IL-8, TNF-α etc. will be used as metrics for 
their efficacy. The fixed dose for second phase will be determined based on the first phase of 
DRF study and pharmacokinetics. At the end of the study, animals will be sacrificed and their 
organs collected and any abnormal histopathological changes will be investigated. NEL (no 
effect level), NOAEL (no observed adverse effect level) and MTD (maximum tolerated dose) 
will be determined. If the proposed dose range is not appropriate for the determinations of NEL, 
NOAEL and MTD, a different dose range will be investigated. In case the administration of 
highest proposed dose is not feasible, highest feasible dose will be the highest used dose in the 
study. Different dosage regimens may be used to increase the tolerability of SECO, ED and EL.  
 
7.5.6 General preliminary acute and chronic toxicity (non-GLP) studies in rats 
Preliminary acute and chronic toxicity studies determine the safety, identify potential organ 
toxicity, and provide guidance for the design of regulatory (GLP) toxicity studies, which are 
required for approval of the clinical trials. These preliminary non-GLP studies will provide a 
go/no-go decision on lignans. We will use three doses (low, intermediate and high dose) of 
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SECO, ED and EL and administer once daily to rats orally for 30 days. These three doses will be 
selected based on dose range finding study. Low dose will be in the NEL range while high dose 
will be above NOAEL but below MTD to determine target organ for toxicity. Scheduled blood 
sampling and weighings will be conducted as well as routine inspections by veterinary staff will 
be performed. Blood samples will be used to measure cytokine levels and immune response 
against SECO, ED and EL. At the end of the study, animals will be euthanized and subjected for 
necropsy. Highest dose used in the preliminary toxicity may be limited by maximum tolerated 
dose, maximum feasible dose, saturation of exposure and 50 fold margin of exposure. The 
interim results of toxicity study and dose range finding study may lead to change in the strategy 
of toxicological studies.  
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